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  Abstract 
Abstract 
  
 A chicken anaemia virus (CAV) protein, Apoptin, has been shown to induce 
specific killing targeted at human transformed cells, leaving non-transformed cells 
unaffected. Investigation has revealed that Apoptin is phosphorylated on a threonine 
residue in transformed cells, suggesting a role for kinase activation in Apoptin 
cytotoxicity.  
 
 The aim of this study was to identify the kinase or kinases involved in Apoptin 
cytotoxicity using a serine/threonine kinase siRNA library. In addition, we have recently 
identified that Apoptin interacts and is phosphorylated by Protein Kinase C (PKC). Also, 
a potential role for cyclic Guanosine Monophosphate dependent protein kinase (PKG) 
in the regulation of Apoptin has been investigated. PKC/PKG expression was 
investigated in cell lines in relation to Apoptin sensitivity. Subsequent modification of 
PKC/PKG kinase expression was investigated and its effects on Apoptin sensitivity. 
Further to these studies, a recently discovered human derived gyrovirus producing a 
protein with homology to CAV Apoptin was investigated.   
 
 The results indicated that in HCT116 colon cancer cells Apoptin cytotoxicity was 
not related to the kinase activity of the siRNA library targets. PKCβ1 was confirmed to 
be important in sensitivity to Apoptin in multiple myeloma cell lines, however, this 
importance in Apoptin-induced cell death in head and neck cancer is currently unclear. 
PKG expression was found to be higher in normal cells compared to transformed cells. 
In contrast, PKC expression was shown to be higher in transformed cells when 
compared to normal cells. Apoptin phosphorylation experiments proved to be 
inconclusive with regards to kinase expression. Physical interaction between Apoptin, 
PKC and PKG was detected by immunoprecipitation, however, evidence of functional 
effects based solely on these interactions was not found. The results indicate that PKG 
and PKC expression is potentially linked to Apoptin function in the cell lines tested. In 
addition, a newly discovered Human gyrovirus (HGyV) Apoptin was shown to have a 
similar cellular localisation to CAV Apoptin, and was also found to be toxic to 
transformed cells, though more indiscriminately than CAV Apoptin.    
 
 In conclusion, the results presented here in this study propose a novel role for 
PKG and PKC in the tumour specific activation of Apoptin in normal and transformed 
cells. In the absence of PKG, transformed cells activate Apoptin through PKC leading 
2 
  Abstract 
to nuclear localisation and apoptosis. PKG expression in normal cells appears to block 
this process, resulting in cytoplasmic localisation of Apoptin and abrogation of Apoptin 
induced cell death. Additionally, the novel viral protein human gyrovirus Apoptin has 
been shown to behave in a similar manner to CAV Apoptin, providing a further tumour 
specific protein for future study. The information obtained during this study will 
therefore be important in the development of therapeutic strategies for not only 
determining sensitivity to Apoptin of certain tumours but also for the sensitisation of 
tumour cells to Apoptin.      
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Cancer is a disease that can be categorised as a genetic disorder caused by 
mutations either inherited or induced by external factors. Accumulation of mutations 
leads to changes in cellular signalling and function, changing the characteristics of the 
cell. In time, these changes can lead to cells that are no longer sensitive to normal 
homeostatic regulation by the local cellular environment and even by the whole 
organism (Sarasin, 2003). Many studies have reported that cancer formation is 
dependent on multiple steps or changes occurring in the cell and surrounding tissues 
(Doll and Peto, 1978; Peto et al., 2000; Peto et al., 1975). In support of this hypothesis, 
Hanahan and Weinberg proposed a set of requirements, in 2000 and again in 2011, 
which seems to apply to the development of all cancers, called the hallmarks of cancer.  
 
Initially, in 2000, the study comprised of 6 individual steps in the development of 
cancer (Hanahan and Weinberg, 2000), and these included the initiation of 
angiogenesis, the resistance to cell death, the sustainment of proliferative signalling, 
the evasion of growth suppressors, the activation of invasion and metastasis and the 
enabling of replicative immortality. At the time of writing in 2000, these 6 steps were the 
known developmental factors in cancer formation. By 2011, further advances had seen 
the addition of two more potential hallmarks of cancer development; (Hanahan and 
Weinberg, 2011) reprogramming of energy metabolism and the evasion of immune 
destruction.  
 
The effects these processes have on the cell environment and body as a whole 
is to disrupt the normal function of tissue homeostasis, which is dependent on the exact 
balance of cell proliferation, cell death and a combination of positive and negative 




  Chapter 1: Introduction 
1.1.1 Tumour therapy and targets for cancer treatment  
 
Cancer therapy aims to remove cancer cells from the body to prevent further 
tumour growth. Due to the non-specific nature of current treatment strategies, such as 
chemotherapy and radiotherapy, unwanted side effects are inevitable. It is because of 
these side effects that it is very important to develop more specific therapies for cancer 
treatment that target only tumour cells within the patient. 
 
 In order to develop less intrusive methods of treatment with higher efficiency 
and specificity for cancer, the mechanisms of cancer at the molecular level should be 
investigated and exploited. For example, the hallmarks of cancer, explained above, 
describe characteristics applicable to all forms of cancer; in depth study and 
exploitation of characteristics not present in normal cells could provide potentially 
tumour specific therapeutic approaches. Many studies have shown that anticancer 
drugs, in particular, induce apoptosis by varying methods such as activation of 
caspases, alterations in mitochondrial integrity and function, activation of death 
inducing ligand or receptor systems and the stabilisation of p53 in sensitive cells 
(Blagosklonny, 2002; Fulda et al., 1998). All of these processes contribute to similar 
fates for the tumour cell, for example, changes in chromatin condensation and 
endonucleolytic cleavage of DNA, indicators of apoptosis. The evidence suggests that 
different anticancer agents, interacting with different targets in the cell, all depend on a 
tumour cell’s ability to initiate programmed cell death for their cytotoxic function 
(Hickman, 1992; Hickman et al., 1992).  
 
 Changes in the function of certain apoptotic pathways may attribute to the 
cause of some cancers and could be responsible for increased resistance to cell death 
(Hanahan and Weinberg, 2011). Increasing the understanding of apoptosis and its 
function in cancers could therefore lead to methods of sensitising tumours to current 
therapies and even lead to the production of novel anticancer treatments. In the next 
section an overview of the current understanding of the apoptosis pathways will be 






  Chapter 1: Introduction 
1.2  Apoptosis 
 
Apoptosis, or programmed cell death, is a normal mechanism that occurs in 
healthy tissues during many different processes in the body, including embryonic 
development, tissue growth and cellular homeostasis. This mechanism is essential in 
the efficient development of the human body from early growth to ageing and as a tool 
for maintenance of the correct population size for cells in organs all over the body. In 
addition to these functions, apoptosis also acts as a defence mechanism against 
disease or external damaging agents and is also involved in immune reactions 
removing dead and unwanted cells from the population. Apoptosis can be triggered by 
a variety of stimuli, both physiological and pathological; however, the same stimulus 
may not induce the same apoptotic response in different cells (Norbury and Hickson, 
2001). As mentioned previously, the acquisition of mechanisms to evade apoptosis is 
one of the hallmarks of cancer, with both the gain of function of anti-apoptotic and the 
loss of function of pro-apoptotic signalling contributing to the cancer phenotype and 
tumourigenesis (Hanahan and Weinberg, 2000). Defective apoptotic mechanisms allow 
genetically unstable cancer cells to evade destruction and confer resistance to 
chemotherapy (Cummings et al., 2004; Schmitt, 2003).  
 
Using a combination of light and electron microscopy techniques, the physical 
changes associated with apoptosis have been described, such as cell shrinkage and 
chromatin condensation resulting in pyknosis which occur during the early stages 
(Hacker, 2000; Kerr et al., 1972). Extensive membrane blebbing follows and nuclear 
fragmentation, known as karyorrhexis, which leads to the separation of cell fragments 
into apoptotic bodies, a process referred to as budding. These bodies contain 
cytoplasm, tightly packed organelles and may or may not contain nuclear fragments. 
The integrity of the organelles and the apoptotic bodies themselves are maintained, 
thus avoiding damage to surrounding cells and tissues by the release of harmful 
breakdown products such as cytokines. Ultimately, the apoptotic bodies are 
phagocytosed by macrophages, parenchymal cells or neoplastic cells and degraded 
within phagolysosomes (Kurosaka et al., 2003; Savill and Fadok, 2000).  
 
Current research shows that there are two main signalling pathways that lead to 
apoptosis; the extrinsic pathway, modulated by the death receptor, and the intrinsic 
pathway, also known as the mitochondrial pathway. DNA damage mainly induces 
apoptosis via the intrinsic pathway while extracellular signals such as signals from the 
16 
  Chapter 1: Introduction 
cytotoxic cells of the immune system, drive apoptosis through the extrinsic pathway. 
Induction of either pathway ultimately results in caspase activation, with each caspase 
potentially activating other procaspases, allowing initiation of a protease cascade 
(MacFarlane, 2009). Such a cascade, where one caspase activates other caspases, 
leads to rapid cell death via the amplification of the apoptotic signalling pathway.  
 
There are 11 members of the caspase gene family found in humans and at 
least 7 of these are important in apoptosis (Riedl and Shi, 2004). Of these 7 apoptotic 
caspases there are two distinct groups, the initiator caspases and the effector 
caspases. The initiator caspases comprise of -2, -8, -9 and -10, and the effector 
caspases include -3, -6 and -7 (Rai et al., 2005).  
 
1.2.1 The extrinsic apoptotic pathway 
 
The extrinsic signalling pathways that initiate apoptosis involve transmembrane 
receptor-mediated interactions through death receptors from the tumour necrosis factor 
(TNF) receptor family of genes (Locksley et al., 2001). Currently, the most well 
described ligands and corresponding death receptors include FasL/FasR, TNF-
α/TNFR1, Apo3L/DR3, TRAIL-R1/DR4 and TRAIL-R2/DR5 (Rubio-Moscardo et al., 
2005; Suliman et al., 2001). The defining sequences that occur during the extrinsic 
pathway are best described by the FasL/FasR and TNF-α/TNFR1 models. Binding of 
the Fas ligand to the Fas receptor results in binding of the adaptor protein Fas-
associated death domain, FADD, and the binding of the TNF ligand to the TNF 
receptor results in the binding of the adaptor protein TNFR1-associated death domain, 
TRADD, with the recruitment of FADD and the death domain kinase receptor 
interacting protein (RIP) (Grimm et al., 1996; Wajant, 2002). FADD subsequently 
interacts with procaspases-8 via dimerisation of the death effector domain and forms a 
death inducing signalling complex, called DISC, which results in the activation of 
caspase-8 (Kischkel et al., 1995). Caspase-8 activation signals the execution phase of 
apoptosis, however, this can be inhibited by a protein called c-FLIP which bind to 
caspase-8 and FADD and render them ineffective (Kataoka et al., 1998). The extrinsic 
apoptotic pathway has also been shown to be linked to the intrinsic pathway via BID 
cleavage to truncated BID by caspase-8, this leads to outer membrane 
permeabilisation in mitochondria (Li et al., 1998).   
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1.2.2 The intrinsic apoptotic pathway 
 
The intrinsic apoptotic pathway is mediated by the mitochondria and is triggered 
by signals that occur intracellularly. The control and regulation of this pathway occurs 
through the Bcl-2 family of proteins (Cory and Adams, 2002). The Bcl-2 family can be 
divided into two distinct classes, the pro-apoptotic members and the anti-apoptotic 
members. The pro-apoptotic Bcl-2 members include Bax, Bak, Bok, Bid, Bad, Bim, Bik, 
Bmf, Hrk, Noxa and Puma and the anti-apoptotic members include Bcl-2, Bcl-xL, Bcl-w, 
A1 and Mcl1 (Cory and Adams, 2002). The main mechanism of action of the Bcl-2 
proteins is the regulation of cytochrome c release from the mitochondria by regulation 
of the mitochondrial membrane permeability (Hunter et al., 2007). Cytochrome c binds 
to and activates Apaf-1 which recruits procaspase-9 forming the apoptosome (Hill et 
al., 2004). The activation of caspase-9 leads to downstream effector caspase activation 
resulting in the activation of caspase-3 which induces apoptosis (Hu et al., 1999). 
Inhibitors of apoptosis (IAPs) inhibit the activation of caspases involved in the intrinsic 
apoptotic pathway such as caspase-3, -7 and -9 (Roy et al., 1997). In order to 
counteract the inhibition of apoptosis induced by IAPs, mitochondria can release 
Smac/DIABLO which directly abrogate the function of IAPs, allowing caspase activation 
to continue unabated (Ekert et al., 2001).  
 
1.2.3 The execution pathway 
 
 Both the extrinsic and intrinsic apoptotic pathways culminate in one final 
pathway considered the final stage of apoptosis, the execution pathway. Execution 
caspases activate cytoplasmic endonuclease, degrading nuclear proteins, while 
proteases degrade cytoskeletal proteins. Cleavage of various substrates including 
cytokeratins, poly (ADP-ribose) polymerase (PARP) and the plasma membrane 
cytoskeletal protein, α-foldrin, are performed by the executioner caspases (caspase-3, -
6 and -7) (Slee et al., 2001). These processes contribute to and result in the 
biochemical and morphological changes observed during apoptosis. The phagocytic 
uptake of cells is thought to occur before the final, irreversible DNA fragmentation 
phase involved in apoptosis. Phospholipid asymmetry and the externalisation of 
phosphatidylserine on the surface of apoptotic cells and their fragmented bodies is the 
hallmark of apoptotic phagocytosis. Phosphatidylserine’s appearance on the outer 
surface of apoptotic cells facilitates non-inflammatory phagocytic recognition allowing 
for early and efficient uptake with minimal inflammatory response (Fadok et al., 2001).                               
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Figure 1.1 Diagram of the extrinsic and intrinsic apoptotic pathways. The intrinsic pathway begins 
with DNA damage and subsequent cytochrome c and Smac release from mitochondria. What follows is 
the recruitment of Apaf1 by cytochrome c which forms the apoptosome with caspase-9, leading to a 
cascade of caspase activation and, ultimately, apoptosis. Smac binds to the inhibitor of apoptosis 
proteins (IAPS) abrogating their inhibition of the effector caspases. The extrinsic pathway begins with 
the activation of the cell surface death receptors which leads to Fas-associated death domain (FADD) 
and the death inducing signalling complex (DISC) binding to activate caspase-8 (at this point, caspase-
8 can cleave Bid into t-Bid, thus initiating the intrinsic pathway). This induces a cascade of caspase 
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1.3  Tumour specific agents 
 
 As explained in section 1.1.1, tumour specific therapies are very interesting 
prospects in the treatment of cancers. This section will summarise a number of proteins 
that specifically kill tumour cells, in particular, originating from cellular or viral sources 
that have been reported to induce tumour specific apoptosis. These include HAMLET, 
TRAIL, MDA7, E4orf4 and Apoptin, the focus of this study which will be given a more 
in-depth review in section 1.3.5. 
 
1.3.1 TNF-related apoptosis inducing ligand (TRAIL) 
 
 TRAIL is a member of the TNF family of cytokines, with the ability to trigger 
apoptosis in various tumour cells by activating certain death receptors. To date, five 
human TRAIL receptors, or death receptors (DR), have been identified including 
TRAIL-R1 (DR 4), TRAIL-R2 (DR5), the decoy receptors TRAIL-R3 (DcR1) and TRAIL-
R4 (DcR2), and osteoprotegerin (OPG) (Zhao et al., 2012). TRAIL-R1 and TRAIL-R2 
are transmembrane receptors that contain cytoplasmic death domains which act as 
agonistic receptors of TRAIL. In contrast, TRAIL-R3 and TRAIL-R4 are also 
transmembrane receptors, but they lack cytoplasmic tails and therefore act as 
antagonistic receptors of TRAIL. Whether or not OPG is an antagonist for TRAIL is still 
under investigation due to its low affinity for TRAIL at 37°C (Truneh et al., 2000). Both 
TRAIL-R1 and TRAIL-R2 are expressed in most human tissues and have minimal 
cytotoxic effects in normal cells (Chaudhari et al., 2006). TRAIL selectively induces 
apoptosis in transformed and tumour cells, but does not have this effect in normal cells, 
making it an interesting agent for cancer specific therapies (Ashkenazi, 2008; Steele et 
al., 2006; Stieglmaier et al., 2008).  
 
 TRAIL induces cell death mainly through the extrinsic pathway, by interacting 
with TRAIL-R1 and TRAIL-R2 causing conformational changes in these receptors 
(Scaffidi et al., 1998). This leads to the recruitment of FADD and the formation of DISC, 
the recruitment of caspase-8 or -10 follows which leads to the activation of caspase-3, -
6 and -7 and subsequent cleavage of associated death substrates (Gonzalvez and 
Ashkenazi, 2010; Kischkel et al., 2000). TRAIL can also induce apoptosis through the 
intrinsic apoptotic pathway which begins after caspase-8 mediated cleavage of Bid into 
the proapoptotic truncated Bid (tBid) (Li et al., 1998). This truncated form of Bid 
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translocates to the outer membrane of the mitochondria where it activates Bax and Bak 
leading to mitochondrial membrane permeabilisation and subsequent cytochrome c 
release, which also serves to amplify the extrinsic pathway apoptotic signal (Wu, 2009). 
In addition, several pro-survival signalling cascades are known to be stimulated by 
TRAIL such as IKK, Akt and JNK (Abdulghani and El-Deiry, 2010).  
 
1.3.2 Human alpha-lactalbumin made lethal to tumour cells (HAMLET) 
 
 First described in 1995, HAMLET is a protein discovered serendipitously during 
the study of the effects of human milk on bacteria (Hakansson et al., 1995). HAMLET is 
a structural derivative of α-lactalbumin, one of the main proteins found in human milk, 
and it is this derivative that harbours tumour-selective capabilities (Hallgren et al., 
2008).   
 
 The process by which HAMLET induces apoptosis in tumour cells is through 
efficient uptake through direct contact with the plasma membrane, whereby it 
accumulates in the organelles of the cell; the nuclei, mitochondria, endoplasmic 
reticulum and proteasomes (Hallgren et al., 2008). The apoptosis inducing function of 
HAMLET requires the unfolding of α-lactalbumin and the presence of the C18:1 fatty 
acid as a required cofactor (Mok et al., 2007). In the tumour nuclei, HAMLET binds to 
histones and disrupts the function of chromatin, particularly affecting the organisation of 
chromatin within the tumour nuclei leading to loss of transcription and nuclear 
condensation (Permyakov et al., 2005). In vitro, HAMLET has been shown to bind 
strongly to histones and impair their deposition on DNA (Duringer et al., 2003). In 
mitochondria, HAMLET causes the release of cytochrome c, through membrane 
permeabilisation, which results in the activation of the caspase pathways (Kohler et al., 
2001). HAMLET can also induce apoptosis in a p53, Bcl-2 and caspase-independent 
manner in tumour cells (Hallgren et al., 2006). Further to HAMLET’s convincing 
apoptosis capabilities, there is evidence that HAMLET can also induce autophagy in 
tumour cells (Aits et al., 2009), a lysosomal catabolic pathway that recycles cellular 
molecules (Scarlatti et al., 2009).        
 
 Through clinical trials, HAMLET has successfully proven its selective apoptosis 
inducing capabilities. Two clinical trials showed that HAMLET was active against skin 
papillomas and bladder cancer, with no recorded side effects on the adjacent healthy 
tissues. Of the skin papilloma study, almost all of the papillomas were eradicated from 
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patients (Gustafsson et al., 2004) and of the bladder cancer study 8 of the 9 treated 
patients presented significant reductions in bladder tumours (Mossberg et al., 2010). In 
contrast, however, one study reports that HAMLET can indeed induce apoptosis in 
normal primary cells, even to a greater extent than some tumour cell lines (Brinkmann 
et al., 2011). From HAMLET’s convincing clinical trials through to its molecular effects 
in tumour cells, the evidence points to HAMLET as a promising anti-cancer therapeutic 
with desired tumour specific characteristics. However, as seems to be the case with 
most tumour specific cytotoxic proteins, the evidence can indicate conflicting functions, 
suggesting that more study is required to fully understand these proteins.   
   
1.3.3 Melanoma differentiation-associated gene- 7 (Mda-7)  
 
     Mda-7 (also known as interleukin 24) is a cytokine which has been shown to 
induce tumour specific caspase dependent apoptosis in a wide range of cells, including 
melanoma, glioblastoma, osteosarcoma, breast cancer, cervix, lung, colon, 
nasopharynx, ovary and prostate (Dash et al., 2010; Fisher et al., 2007). Normal cells, 
for example, melanocytes, astrocytes, fibroblasts, mesothelial and epithelial cells are 
reported to show minimal effects upon overexpression of Mda-7, suggesting tumour-
selective properties (Chada et al., 2004; Dash et al., 2010). In breast cancer cells in 
particular, Mda-7 has been shown to induce apoptosis by downregulation of Bcl-2 and 
Akt (Bocangel et al., 2006). Bcl-2 importance in Mda-7 apoptotic function was also 
shown by overexpression studies that abrogated Mda-7 induced apoptosis upon 
increased expression of Bcl-2 (Su et al., 2006). Cancer specific apoptosis induced by 
Mda-7 has also been shown to occur through activation of the FasL/TRAIL pathways 
(Ekmekcioglu et al., 2008). Clinical trials have shown that Mda-7 is well tolerated and 
demonstrates significant tumour specific clinical activity (Eager et al., 2008; Emdad et 
al., 2009; Lebedeva et al., 2007).  
 
1.3.4 E4 open reading frame 4 (E4orf4) 
 
 The E4orf4 adenovirus derived protein selectively kills tumour cells regardless 
of p53 status (Lavoie et al., 2000), which suggests that this protein may kill tumour cells 
that have resisted other conventional therapies (Fuster et al., 2007). A small 
polypeptide, consisting of 114 residues which shares no extensive sequence homology 
with any known protein, the product of E4orf4 adenovirus, is reported to induce tumour-
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selective apoptosis in its host cell (Kleinberger, 2000). This product is very stable and 
is shown to persist at high levels even late into infection (Boivin et al., 1999). However, 
for normal viral replication, the E4orf4 product is not essential and an exact role for this 
product in the lytic infection of the E4orf4 adenovirus is not clearly understood (Lavoie 
et al., 2010).  
 
 The apoptotic pathways activated by E4orf4 are diverse and include p53-
independent (Shtrichman and Kleinberger, 1998) and caspase independent cell death 
(Lavoie et al., 1998). Recently, it has also been shown that mitochondrial release of 
cytochrome c is not required for E4orf4 induced apoptosis (Li et al., 2009). 
Phosphorylation of the E4orf4 product is modulated by the Src-family kinases and it 
has been shown that the E4orf4 product interacts with protein phosphatase 2A (PP2A) 
(Lavoie et al., 2010). Studies suggest that the interaction of the E4orf4 protein product 
with the Src-family kinases and PP2A result in its apoptotic action (Marcellus et al., 
2000; Shtrichman et al., 1999). E4orf4 appears to activate apoptosis through 
alternative death pathways as it does not require classical caspase pathways and 




 Apoptin was discovered during the study of the first known gyrovirus, chicken 
anaemia virus (CAV), a virus that has been reported to induce apoptosis in chicken 
thymocytes and lymphoblastoid cells (Noteborn et al., 1994), hence the name chicken 
anaemia virus. Three proteins are encoded by CAV; VP1 (a capsid protein), VP2 (a 
scaffold protein and protein phosphatase) and VP3 (Backendorf et al., 2008b). VP3 is 
the most interesting protein produced by CAV as it possesses the same apoptotic 
ability as the virus (Noteborn et al., 1991; Zhuang et al., 1995b) and because of this it 
was renamed Apoptin (Backendorf et al., 2008b).  
 
 At 121 amino acids in length, Apoptin is a protein rich in prolines, serines, 
threonines and basic amino acids (Noteborn et al., 1991). In addition to its apoptotic 
ability in chicken thymocytes and lymphoblastoid cells, Apoptin has been shown to 
have tumour specific cytotoxicity in human tissues and cells, for example primary 
fibroblasts, keratinocytes, smooth muscle cells, T-cells and endothelial cells are not 
killed by Apoptin (Backendorf et al., 2008b; Danen-Van Oorschot et al., 1997; Guelen 
et al., 2004; Zhang et al., 2003; Zhuang et al., 1995b). Although Apoptin has been 
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shown to not induce apoptosis in a variety of normal cells, the transformation of such 
cells using SV40 Large T antigen does create cells that are sensitive to Apoptin 
induced cell death (Danen-Van Oorschot et al., 1997).  
 
 Recent studies have revealed the discovery of a new gyrovirus found in 
humans called human Gyrovirus (HGyV) and, interestingly, this virus also encodes a 
protein with sequence homology to CAV Apoptin (Sauvage et al., 2011). This protein 
will be reviewed in further detail in section 1.3.5.6.  
 
1.3.5.1 The tumour specific characteristics of Apoptin 
 
      Further understanding of Apoptin’s tumour specific function is required to 
potentially exploit its characteristics in a clinical setting, and in order to do this, the 
structural and molecular properties of the protein were initially investigated. Studies 
revealed that Apoptin contains a bipartite nuclear localisation signal formed of nuclear 
localisation signal 1 and nuclear localisation signal 2 (NLS1 and NLS2) at amino acids 
82-88 and 111-121(Figure 1.2), respectively (Danen-Van Oorschot et al., 2003). In 
addition, Apoptin contains a hydrophobic sequence that resembles a nuclear export 
signal (NES) (Figure 1.2), which suggests that the protein has the ability to shuttle 
between the nucleus and the cytoplasm of cells (Noteborn et al., 1991). The studies 
showed that both NLS1 and NLS2 could function independently of each other, 
however, both regions were required for efficient nuclear localisation (Danen-Van 
Oorschot et al., 2003). In addition, Apoptin possesses a Leucine Rich Sequence (LRS) 
at its N-terminal end (Figure 1.2) important for the protein’s binding ability not only to 
other proteins such as promyelocytic leukaemia (PML) protein, but to other Apoptin 
molecules facilitating its multimerisation and aggregation (Argiris et al., 2011). This 
sequence was initially thought to be a second NES; however a more recent study has 
shown that this LRS actually contributes to nuclear accumulation of Apoptin such that 
in its absence a marked reduction in tumour specific Apoptin nuclear localisation is 
observed (Oro and Jans, 2004; Poon et al., 2005; Wadia et al., 2004).       
 
 A reported characteristic of Apoptin’s behaviour in cells is its ability to form 
complexes with other proteins and subsequently interact with DNA via the LRS 
(Leliveld et al., 2003). For example, in tumour or transformed cells, Apoptin localises to 
the nucleus where it colocalises mostly with heterochromatin and nucleoli and induces 
apoptosis (Leliveld et al., 2003; Zhang et al., 2003). Apoptin is also observed to localise 
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to PML bodies in the nucleus of tumour cells and this behaviour is reported to be 
dependent on the LRS (Poon et al., 2005). In normal cells, however, Apoptin does not 
localise to the nucleus and remains in the cytoplasm, where it is physically unstable. It 
then disperses into fine particles and accumulates slowly into larger aggregates, at 
which point it moves to the plasma membrane and no traces remain in the cell (Zhang 
et al., 2003). The difference in apoptotic function in tumour and normal cells correlates 
with the observed changes in cellular localisation, because of this it was hypothesised 
that nuclear localisation was essential for Apoptin induced apoptosis. Upon forced 
nuclear expression of Apoptin in normal cells, however, it was shown that cell death 
was not induced, this suggested that Apoptin induced apoptosis required more than 
just nuclear localisation for its function (Danen-Van Oorschot et al., 2003).  
 
 Studies on Apoptin also revealed another interesting characteristic that would 
benefit future understanding of the protein. Phosphorylation occurs on Apoptin in 
tumour cells and not in normal cells on a specific residue, Threonine 108 (T108), 
however, the kinase responsible is currently unknown (Rohn et al., 2002). Further 
supporting this, a gain of function point mutation study of the Apoptin T108 residue by 
substituting it for glutamic acid, found that Apoptin was able to enter the nucleus of 
normal cells and induce apoptosis (Backendorf et al., 2008b; Rohn et al., 2002). Thus 
suggesting that phosphorylation of T108 is very important in the nuclear localisation of 
Apoptin and the activation of Apoptin induced apoptosis. The variation and number of 
tumour and transformed cells that are killed by Apoptin suggests that these cells 
perhaps share similar characteristics that are exploited by Apoptin to induce apoptosis 
and that this cell death may follow the same route of activation in these cells. Because 
of this, and the potential importance of phosphorylation for Apoptin’s function, it is 
important to further understand and identify a potential tumour specific kinase involved 
in Apoptin induced apoptosis. Such a finding could lead to the development of new 
cancer therapeutics that exploit Apoptin’s exciting properties.  
 
LRS NLS2NLS1 NES
1 33 46 82 88 97 105 111 121
P
T108
Figure 1.2 Diagram of Apoptin’s structure. The nuclear localisation signals 1 and 2 (NLS1 and 
NLS2) are highlighted in green, the nuclear export signal (NES) is highlighted in blue and the leucine 
rich sequence (LRS) is highlighted in orange. The Threonine 108 (T108) phosphorylation site is 
indicated by the red circle. This figure was modified from another study (Los et al., 2009). 
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1.3.5.2 Mechanisms of Apoptin mediated cell death   
 
 Apoptin mediated apoptosis appears to involve the mitochondrial death 
pathway and has been shown to coincide with the release of cytochrome c, a key step 
in the intrinsic apoptotic pathway (Danen-van Oorschot et al., 2000). Activation of 
caspase-3, a key downstream effector caspase, is also observed during Apoptin 
mediated cell death. In addition, a deficiency in Apaf1, a target of cytochrome c, 
strongly protects tumour cells from Apoptin induced apoptosis (Burek et al., 2006). It 
has also been shown that Apoptin induced cell death does not occur through the 
extrinsic pathway. For example, cells deficient in FADD or caspase-8, upstream targets 
of the extrinsic pathway, were shown to be just as sensitive to Apoptin mediated cell 
death as their parental clones (Maddika et al., 2005). Further work showed that both 
caspase-8 and also caspase-1 were not involved in Apoptin cell death as inhibitors of 
these cysteine proteases did not affect cells sensitivity to Apoptin cytotoxicity (Danen-
van Oorschot et al., 2000).  
 
 Intriguingly, the role of anti-apoptotic Bcl-2 in Apoptin’s function is still not 
completely clear, studies have shown some contrasting findings. In one study, Apoptin 
function was found to be independent of Bcl-2 in human osteosarcoma Saos-2 and 
U2OS cells (Zhuang et al., 1995a). Another study found that the Bcl-2 protein 
accelerated Apoptin induced cell death (Danen-Van Oorschot et al., 1999). In contrast 
to the above findings, one study showed that Apoptin induced cell death was inhibited 
by the overexpression of both Bcl-2 and Bcl-xL in human breast cancer MCF-7 and 
human medullablastoma D283 cells (Burek et al., 2006). These contrasts in the study 
of Apoptin cytotoxicity relative to Bcl-2 activity may be explained by inherent 
differences in specific tumour cells and, more precisely, the cellular factors that control 
and regulate Bcl-2 and its anti-apoptotic function.  
 
 Another Bcl-2 protein, BAX (a pro-apoptotic member of the Bcl-2 family), was 
shown to sensitise cells to Apoptin induced apoptosis, cells found to lack BAX 
expression were strongly protected (Burek et al., 2006). Together, the data described 
here suggests that Apoptin induced cell death is mediated by the Bcl-2 family, involves 
the activation of caspases and mitochondrial release of cytochrome c via the intrinsic 
apoptotic pathway. Nur77, a nuclear orphan receptor and a member of the steroid 
receptor family, perhaps sheds some light on the controversies surrounding Bcl-2 and 
Apoptin mediated cell death. It has been reported that Nur77 can change the function 
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of Bcl-2 from an anti-apoptotic to a pro-apoptotic molecule leading to the activation of 
the mitochondrial death pathway (Lin et al., 2004a). The varying levels of Nur77 found 
in different cell types could, therefore, explain the differing effects of Bcl-2 on Apoptin 
induced cell death. In addition, translocation of Nur77 from the nucleus to the 
cytoplasm in MCF7 cells has been shown to be triggered by Apoptin and siRNA 
knockdown of Nur77 protected MCF7 cells from Apoptin mediated apoptosis (Maddika 
et al., 2005).  
 
1.3.5.3 Molecules that interact with Apoptin 
 
 Several cellular proteins have been described that interact with or bind to 
Apoptin and affect its cellular localisation and its subsequent apoptosis inducing ability. 
Peptidyl-prolyl isomerase-like 3 (Ppil3), which belongs to the cyclophilin family, has 
been reported to interact with Apoptin. The members of this family play a role in 
mitochondrial maintenance, cell cycle control and apoptosis, processes linked to 
Apoptin induced cell death. Knockdown of Ppil3 by siRNA was shown to lead to the 
translocation of Apoptin from the cytoplasm into the nucleus, while expression of the 
protein caused Apoptin to migrate to the cytoplasm in tumour cells (Huo et al., 2008). 
Another reported binding partner for Apoptin is Hippi, a protein that interacts with and is 
an apoptosis co-mediator of huntington-interacting protein 1 (Hip 1). In normal cells, 
Apoptin and Hippi colocalise in the cytoplasm, but in tumour cells, Apoptin localises to 
the nucleus leaving Hippi in the cytoplasm (Cheng et al., 2003).This suggests that Ppil3 
and Hippi may play a role in the cytoplasmic localisation of Apoptin in normal cells.  
 
 Other proteins that have been shown to interact with Apoptin include Nmi (N-
Myc interaction protein, which binds to DNA) (Backendorf et al., 2008b) and E1B-
21kDa (the small adenovirus 5 E1B protein of 21kDa which inhibits Apoptin induced 
cell death) (Zhuang et al., 1995a). More recently, Gallus heat shock cognate protein 70 
(Hsc70) was reported to associate with Apoptin (Chen et al., 2011b). Knockdown of 
Hsc70 resulted in inhibition of Akt phosphorylation by Apoptin, suggesting that Hsc70 
may be essential in the phosphorylation of Akt induced by Apoptin (Chen et al., 2011a).  
 
 APC1, a subunit of the anaphase-promoting complex/cyclosome (APC/C), has 
been shown to associate with Apoptin. This interaction results in the inhibition of 
APC/C ubiquitin ligase function causing G2/M arrest and apoptosis in p53-null 
transformed cells (Teodoro et al., 2004b). This interaction is present in tumour cells but 
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not in normal cells, suggesting another possible tumour selective mechanism of 
Apoptin function. Apoptin expression in transformed cells can also initiate the formation 
of promyelocytic leukaemia (PML) bodies and the recruitment of APC/C to these 
nuclear structures (Heilman et al., 2006; Janssen et al., 2007).  
 
 Apoptin can also interact with a pro-apoptotic protein called death effector 
domain-associated factor (DEDAF). This protein has been found to associate with 
death effector domain (DED)-containing pro-apoptotic proteins and colocalises with 
Apoptin in the nucleus of cancer and transformed cells, but not in primary fibroblasts or 
mesenchymal cells (Danen-van Oorschot et al., 2004). Co-expression of DEDAF and 
Apoptin was shown to increase the rate of apoptosis when compared to either protein 
expressed alone (Danen-van Oorschot et al., 2004). It has also been reported that 
Apoptin colocalises with FADD and Bcl-10, a caspase recruitment domain-containing 
protein, in cytoplasmic structures called death effector filaments (Guelen et al., 2004).  
 
1.3.5.4 Phosphorylation of Apoptin and the importance of threonine 108  
 
 As described previously, the process by which Apoptin selectively targets 
tumour cells for destruction is currently unknown. Phosphorylation on Threonine 108 
(T108), however, appears to play a role in the cellular localisation of Apoptin, but the 
kinase responsible has yet to be identified (Rohn et al., 2002). Mapping the structure 
and sequence of Apoptin revealed that T108 is adjacent to the nuclear export signal 
(NES) implying that phosphorylation of T108 seems to induce tumour specific 
localisation of Apoptin through the inactivation of the NES (Rohn et al., 2002). 
However, one study reported that T108 phosphorylation does not play as big a role in 
Apoptin’s pro-apoptotic function as was previously thought (Lee et al., 2007). However, 
there is a cluster of Threonine residues (aa 106-108) within the Apoptin sequence that 
could still facilitate the phosphorylation of Apoptin in the presence of T108 mutation. In 
support of this theory, one study showed that mutation of T108 was not sufficient to 
abrogate Apoptin’s apoptotic function; both T108 and T107 were required to be 
mutated to completely abolish Apoptin induced cell death (Rohn et al., 2005).  
 
 The importance of Apoptin phosphorylation in its tumour specific function has 
made the search for an Apoptin kinase a priority in understanding the protein’s activity 
in tumour cells. Previous work had identified the cyclin-dependent kinase, CDK2, as a 
potential Apoptin kinase required for Apoptin induced apoptosis. In PC3 and MCF7 cell 
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lines, Apoptin was shown to interact with phosphatidylinositol 3-kinase (PI3-kinase) 
which leads to activation and nuclear localisation of Akt (Maddika et al., 2008). In the 
nucleus, Akt then activates CDK2 by direct phosphorylation and, in addition, 
phosphorylation induced degradation of p27Kip1 by the proteasome-dependent pathway 
(Maddika et al., 2008). Dominant-negative mutants of PI3-kinase and Akt, as well as 
inhibitors of these molecules, reduced CDK2 activation and also inhibited Apoptin 
induced apoptosis. Additionally, CDK2-deficient fibroblasts and CDK2 knockdown cells 
displayed reduced sensitivity to Apoptin induced cell death (Maddika et al., 2009).  
 
 Recent work by our group has identified an isoform of the protein kinase C 
(PKC) family of kinases as a potential Apoptin kinase. The study suggests that PKCβ 
regulates the translocalisation of Apoptin into the nucleus and induces apoptosis in 
human multiple myeloma (MM) cell lines (Jiang et al., 2010a). Affymetrix microarray 
analysis revealed that PKCβ was a potential Apoptin kinase candidate. In support of 
this, in vitro immunoprecipitation studies found that PKCβ was responsible for Apoptin 
phosphorylation (Jiang et al., 2010a). Subsequent PKCβ knockdown, using shRNA 
techniques, showed a significant decrease in Apoptin phosphorylation. Apoptin induced 
apoptosis was shown to occur through the upregulation of PKCβ, the activation of 
caspase-9 and caspase-3, cleavage of the PKCδ catalytic domain and downregulation 
of the proto-oncogene tyrosine-protein kinase MER (MERTK) (Jiang et al., 2010a). In 
contrast to previous Apoptin kinase work, this study also demonstrated that Apoptin 
induced apoptosis was activated through the downregulation of Akt.  
 
 Additionally, recent studies have found that Apoptin localisation is dependent on 
DNA damage response (DDR) signalling, for example, induction of DDR signalling in 
normal primary cells resulted in nuclear localisation and apoptosis. In contrast, 
inhibition of DDR signalling through RNA interference of DDR factors such as DNA-
dependent protein kinase (DNA-PK) resulted in cytoplasmic localisation of Apoptin in 
transformed cells. In addition, Apoptin was observed to inhibit the formation of DNA 
damage foci in normal cells, suggesting a novel mechanism of DDR inhibition during 
viral infection (Kucharski et al., 2011). 
     
1.3.5.5 The clinical potential of Apoptin  
 
 Apoptin’s ability to induce apoptosis specifically in tumour cells has been shown 
in several studies and, in addition to this, a number of in vivo studies have been 
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published that provide intriguing insights into Apoptin’s potential in the clinical 
environment. Several preclinical studies have also shown that Apoptin can improve the 
efficacy of existing therapies, highlighting another potential therapeutic role for Apoptin.  
 
 In vivo studies using HepG2 cells xenografted into nude mice demonstrated 
that only a single injection of adenoviral Apoptin intratumourally resulted in a significant 
reduction in tumour mass. This observation also coincided with no serious side effects 
when the Apoptin virus was delivered intravenously, subcutaneously or via 
intraperitoneal injection in healthy rats (Pietersen et al., 1999). A further xenograft 
study in immune-deficient mice using human hepatoma cells revealed that multiple 
injections of adenoviral Apoptin decreased tumour mass in addition to prolonging 
survival in 60% of mice treated (van der Eb et al., 2002). Interestingly, after 6 months, 
30% of the treated mice remained tumour free.  
 
 Another Apoptin expressing virus that has been used in in vivo studies is 
baculovirus which was shown to induce apoptosis in H22 murine hepatoma cells 
grafted into C57BL/6 mice. The reported effects of intratumoural delivery of this virus 
were significant suppression of tumour growth and a significant increase in length of 
survival of the mice carrying tumours in comparison to those treated with a control virus 
expressing EGFP (Pan et al., 2010).  
 
 Further in vivo studies in mice used a cancer specific promoter, called human 
telomerase reverse transcriptase promoter (hTERT). This promoter was combined with 
Apoptin in an adenoviral vector to form Ad-hTERT-E1a-Apoptin to produce E1a-
Apoptin that was driven by the hTERT promoter. Intratumoural injection of this 
adenovirus in C57BL/6 mice with B16 xenografted cells resulted in the reduction of 
tumour mass and an increase in animal survival (Li et al., 2010). A similar study also 
showed similar results in gastric carcinoma in nude mice that had established primary 
tumours; however, improvements in tumour burden and mouse survival were seen in 
both intratumoural injection and systemic delivery of Ad-hTERT-E1a-Apoptin (Liu et al., 
2012).  
 
 As previously mentioned, Apoptin has shown potential in combination therapy 
with other more conventional anti-cancer treatments. For example, radiotherapy has 
been shown to have enhanced efficacy upon combination treatment with Apoptin. 
Using radioresistant SQD9 human head and neck squamous carcinoma cells, 
concurrent treatment with irradiation and exposure to Apoptin produced cytochrome c 
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release and cleavage of caspase-3. Irradiation alone, however, did not induce the 
same apoptosis associated events in SQD9 cells (Schoop et al., 2010). Further to this, 
delivery of the TRAIL and VP3 genes (pBud-TRAIL-VP3) to gastric cancer cells by 
attenuated Salmonella typhimurium was shown to significantly diminish the size and 
growth of SGC-7901 xenografts in nude mice (Cao et al., 2010).  
 
 A combination of delivery mechanisms for Apoptin has also been tested in vivo 
using a lentiviral construct to deliver secretable TAT-Apoptin. The addition of a 
secretory signal peptide was made to transacting activator of transcription (TAT)-
Apoptin to produce a virus capable of secreting Apoptin from its infected hosts and 
using the TAT delivery system to deliver Apoptin to neighbouring cells. Results using 
TAT-GFP as a control showed that the TAT-Apoptin virus, delivered systemically, 
eradicated the hepatocellular carcinoma xenograft tumours in the nude mice, while the 
xenografts that received the TAT-GFP control continued to grow (Ma et al., 2012). This 
treatment was also shown to have a low cytotoxicity in the animals used.  
 
 Other approaches to Apoptin delivery have also been studied and show great 
promise. One of these methods of delivery, mentioned briefly above, is the TAT or 
transacting activator of transcription. This method of protein transduction is most 
commonly used and comprises of a positively charged domain found in the HIV-1 
trans-activator protein TAT called the TAT protein transduction domain (TAT-PTD) (Ho 
et al., 2001). TAT-Apoptin has been shown to be efficiently transduced into both normal 
and tumour cell lines, where the normal cells (1BR3 and 6659 fibroblasts) were not 
killed, but the tumour cells (Saos-2 and HSC-3) were sensitive and became apoptotic 
(Guelen et al., 2004). Protein transduction domain 4 (PTD4), a domain similar to TAT 
with minor modifications, has also been shown to efficiently deliver proteins across 
plasma membranes and significantly inhibit tumour growth in vivo when tagged to 
Apoptin (PTD4-Apoptin) (Sun et al., 2009). Using combination treatment with PTD4-
Apoptin and dacarbazine in C57BL/6 mice bearing subcutaneous B16-F1 melanoma 
tumours produced a synergistic anti-tumour effect (Jin et al., 2011).  
 
 Recently, TAT has been incorporated into the wheat histone H4 in combination 
with luteinising hormone releasing hormone (LHRH) to produce H4TL, or H4-TAT-
LHRH. The aim of this genetic manipulation was to create an enhanced form of H4 that 
more efficiently crossed the plasma membrane to deliver Apoptin to LHRH receptor-
positive cells which, in the case of this study was the ovarian cancer HO8910 cells 
(Wang and Zhang, 2011). Transfection of these cells with H4-TAT-LHRH resulted in an 
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increase in Apoptin expression at both the mRNA and protein level which coincided 
with reduced growth of HO8910 cells and loss of mitochondrial membrane potential 
(Wang and Zhang, 2011).  
 
 In summary, the data reported in the studies described here suggest a very 
clear potential for Apoptin as a tumour specific anti-cancer therapeutic. In addition, 
Apoptin possesses some unique characteristics that, if developed further, could make it 
an important therapeutic in situations where conventional therapies have failed. 
Moreover, observations presented here indicate that Apoptin, as a combination therapy 
with conventional chemotherapeutics, may offer an effective strategy for cancer 
treatment.  
 
1.3.5.6 Human gyrovirus (HGyV) and its Apoptin homologous protein  
 
 As mentioned previously, when CAV was discovered it was the first known 
gyrovirus, however, recent work has identified a virus originating in humans from this 
family, a virus called human gyrovirus (HGyV). The interesting characteristic of this 
virus is that it produces a protein with sequence homology to VP3/Apoptin that is 
produced by CAV (Sauvage et al., 2011).  
 
 Work produced by our lab further investigated the potential of this protein in 
human cancers. Results indicated that HGyV-Apoptin behaved in a very similar manner 
in both normal and tumour cells as CAV-Apoptin. For example, in normal 1BR3 
fibroblasts, HGyV-Apoptin was found to localise in the cytoplasm and in Saos-2 tumour 
cells and 1BR3 SV40 Large T transformed (1BR3LT) cells, HGyV-Apoptin localised to 
the nucleus, where induction of apoptosis was evident (Bullenkamp et al., 2012). These 
results were shown to compare favourably with CAV-Apoptin, which produced similar 
results, suggesting that HGyV-Apoptin may possess anti-cancer properties in line with 
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1.4  Kinases 
 
 Many, if not all cellular processes require enzymatic catalysis of one kind or 
another, for example, the cleavage of one molecule into another form, the modification 
of a molecule that facilitates its function, or the complete breakdown of a molecule into 
its constituent parts. Each of these processes requires some form of enzyme activity 
and the most important aspect of enzyme activity is specificity. The importance of this 
specificity is that it ensures that processes that occur in the body are performed 
correctly and are well regulated.  
 
 Proteases are a form of enzyme and their role is to facilitate proteolysis, the 
hydrolysation of protein peptide bonds, which also occurs during apoptosis but, in 
addition is involved in the digestion of food and the blood-clotting cascade.           
Caspases are a subdivision of proteases, called cysteine proteases that catalyse the 
cleavage of proteins into new products usually activating them in the process, leading 
to the caspase cascade which is seen during apoptosis.  
 
 Another group of enzymes, known as the transferases, is responsible for 
catalysing the transfer of functional groups from one molecule to another. In biological 
systems, the two main groups of transferases are polymerases and kinases. 
Polymerases are facilitators of DNA and RNA polymerisation by transcription and 
replication of new DNA or RNA from an existing template using nucleotides to catalyse 
synthesis of polynucleotide strands.  
 
 Kinases are a group of enzymes that are involved in many regulatory biological 
processes, relaying signals from outside the cell to cause downstream events, such as 
cell metabolism, migration or proliferation. Kinases comprise 1.8% of the human 
proteome, using ATP to catalyse the transfer of γ-phosphate of ATP to serine, 
threonine or tyrosine residues (Manning et al., 2002). Modification of protein residues 
by kinase interaction results in conformational, structural and functional changes, 
activating or inactivating the target substrate (Figure 1.3). This can then lead to the 
activation of signalling pathways and a cascade of kinase activity and protein 
phosphorylation resulting in a variety of cellular functions, from proliferation and cell 
survival, to cell cycle arrest and apoptosis.  
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 Unregulated activity of certain kinases is the cause of many cancers, and this 
link has been proven by the successful use of kinase inhibitors in the treatment of 







Figure 1.3 Diagram describing the mechanism of kinase mediated phosphorylation of a substrate. 
A kinase interacts with its substrate by catalysing the transfer of a phosphate group from ATP to the 
side chains of the substrates residues. This results in a conformational change and subsequent 
functional changes from an inactive form into an active form of the substrate. This figure was modified 
from another study (Kosior et al., 2011). 
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1.4.1 Kinase inhibitors and their involvement in cancer therapy  
 
 As mentioned previously, a large number of studies on the subject of kinase 
activity and cancer have been published and kinase inhibitors, for example, are already 
commercially available as anti-cancer therapy options. 
 
 Imatinib is a tyrosine kinase inhibitor which was found to selectively inhibit the 
platelet-derived growth factor (PDGF) receptor, c-kit (Tuveson et al., 2001), BCR-Abl, 
c-Abl and Abl-related gene (Arg) at concentrations below the μM level (Buchdunger et 
al., 1996). Imatinib targets cancer by inhibiting the tyrosine kinase activity of these 
kinases which are upregulated in certain cancers. Imatinib is used primarily to treat 
chronic myelogenous leukaemia (CML) because the cause of over 95% of these 
tumours is fusion of the BCR and Abl genes resulting in a constitutively active kinase 
known as BCR-Abl (Advani and Pendergast, 2002; Cortez et al., 1995). The specific 
targeting and inhibition of BCR-Abl by Imatinib results in a 95% haematologic response 
with minor side effects (O'Dwyer et al., 2003).  
 
 Another kinase inhibitor, lapatinib, is used in the treatment of breast cancer and 
targets the kinase domain of epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER2). In studies, Lapatinib was shown to block 
the downstream signalling of the Akt and mitogen-activated protein kinase (MAPK) in 
human tumour xenografts (using HN5 cells in nude mice) (Xia et al., 2002) and SKBR3 
breast cancer cells (Nahta et al., 2007). Other EGFR inhibitors include cetuximab (a 
monoclonal antibody that blocks the EGFR receptor), which is used to treat metastatic 
colorectal cancer and head and neck cancer, gefitinib and erlotinib, small molecule 
inhibitors that are used to treat non-small-cell lung cancer (Morphy, 2010).  
 
 SRC kinase is involved in multiple processes relevant to both prostate and 
breast cancers including bone activity, tumour growth, hormone receptor 
signalling/resistance and metastasis (Saad, 2009). Inhibition of SRC kinase activity 
with dasatinib in mice resulted in reduced prostate tumour growth in bone (Yano et al., 
2008) and significantly prevented the formation of osteolytic metastases (Zhang et al., 
2009). In human trials, dasatinib was shown to reduce the levels of urinary N-
telopeptide, a marker of adverse outcomes in men with prostate cancer bone 
metastases, in 80% of patients treated (Yu et al., 2009).  
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 The mammalian target of rapamycin (mTOR) kinase is a key element of 
intracellular signal transduction, responsible for the regulation of cell growth and 
proliferation (Grzybowska-Izydorczyk and Smolewski, 2012). Rapamycin was first 
described as an anti-fungal agent but later became known for its immunosuppressant 
properties. Subsequent studies found that rapamycin had an anti-cancer activity 
against a large variety of cell lines derived from malignant tumours (Kelly et al., 2011). 
Investigation into rapamycin’s molecular mechanisms found that although rapamycin 
does not directly interact with mTOR, it does bind to the FK506-binding protein (FKBP-
12) to form a complex that inhibits mTOR activity by binding to mTORC1 (Siekierka et 
al., 1989). Deforolimus, an analogue of rapamycin, is an inhibitor of mTOR which has 
been evaluated in a clinical setting. It was delivered via intravenous infusion daily for 5 
days in a phase I clinical trial in solid tumours and haematological malignancies, 
positive responses were seen in patients with a variety of tumour types (Mita et al., 
2008).  
 
    The PIM family of kinases has recently been shown to possess oncogenic 
and survival promoting properties (Nawijn et al., 2011; Shah et al., 2008). Inhibitors of 
this family of kinases, specific inhibition of PIM1 in particular, have been shown to 
induce apoptosis in human and mouse tumour cells in preclinical models (Hu et al., 
2009). Other PIM1 inhibitors, such as ETP-45299 and SGI-1776, have been shown to 
inhibit cell proliferation and migration and influence apoptosis in tumours by 
resensitising them to conventional therapeutic treatments (Blanco-Aparicio et al., 2011; 
Chen et al., 2011c; Mahalingam et al., 2011; Mumenthaler et al., 2009).  
 
 Ruxolitinib, a janus kinase (JAK) inhibitor, has recently been approved for the 
treatment of myeloproliferative neoplasms (Mesa, 2010). The effect this inhibitor has is 
to selectively inhibit JAK1 and JAK2 kinases, whose role in certain myeloid and 
lymphoid cancers is to transduce extracellular signals to the nucleus via STAT (signal 
transducer and activator of transcription) proteins contributing to cell proliferation and 
differentiation (Eghtedar et al., 2012). Ruxolitinib inhibits JAK signalling via the 
cytokines that support transformed cells, arresting growth factor signalling by inhibiting 
downstream STAT phosphorylation. A phase II clinical study found that out of 18 
patients with postmyeloproliferative neoplasm acute myeloid leukemia, 3 showed a 
significant response and 3 achieved complete remission, suggesting that ruxolitinib has 
a modest anti-leukaemic activity as a single agent (Eghtedar et al., 2012).     
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 Rapidly accelerated fibrosarcoma (RAF) serine/threonine kinases are important 
signalling integrators comprised of 3 homologues, A-RAF, B-RAF and C-RAF (Bonner 
et al., 1984; Huleihel et al., 1986; Ikawa et al., 1988). Since the discovery of these 
kinases, the B-RAF gene was found to be mutated in a variety of different cancers 
leading to constitutive activation of the B-RAF kinase (Davies et al., 2002). Half of all 
melanomas exhibit this mutation and it is also found in a number of other cancers 
including colorectal and head and neck cancer (Pollock and Meltzer, 2002; 
Rajagopalan et al., 2002; Weber et al., 2003). An inhibitor of B-RAF, Vemurafenib, has 
successfully completed phase III clinical trials treating melanoma patients with a 
confirmed overall response rate greater than 50% and a median progression-free 
survival of 7 months. (Chapman et al., 2011).             
 
1.4.2 Kinases with potential involvement in Apoptin phosphorylation 
 
 Phosphorylation is an important mechanism for the tumour specific function of 
Apoptin (Rohn et al., 2002). Studies have shown there are a number of potential 
Apoptin kinases that have been extensively investigated. This section will review the 
serine/threonine kinases PKC and PKG.  
 
1.4.2.1 Protein kinase C (PKC) 
 
 The serine/threonine protein kinase C (PKC) family of kinases were first 
identified in the early 1980s as the intracellular receptors for the tumour promoting 
phorbol esters (Castagna et al., 1982; Kikkawa et al., 1983). Currently, there are 12 
known isoforms of PKC, the classical, the novel and the atypical isoforms (Mackay and 
Twelves, 2007). The classical isoforms include PKCα, PKCβ1, PKCβ2 and PKCγ, the 
novel isoforms are comprised of PKCδ, PKCε, PKCη, PKCμ and PKCθ, finally, the 
atypical isoforms are formed of PKCζ and PKCι/λ (Redig and Platanias, 2007).  
 
 All of the PKC isoforms share a common structure; a cell membrane targeting 
N-terminal regulatory domain linked by a flexible hinge region to the C-terminal 
catalytic domain (Newton, 2003; Parker and Murray-Rust, 2004) (Figure 1.4). The 
classical PKC isoforms regulatory domains, C1 and C2, are required for binding to the 
lipid second messenger diacylglycerol (DAG), phorbol esters and phosphatidylserine 
(PS) and also to Ca2+. The novel isoforms share the C1 domain, but also contain a 
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novel C2 domain, which means that they are regulated by DAG but not Ca2+. The C1 
domain of the atypical isoforms of PKC, however, does not bind to DAG or Ca2+ 
(Colon-Gonzalez and Kazanietz, 2006). The regulation of the atypical kinases is mainly 
controlled by protein-protein interactions mediated by the Phox/Bem1 domain (PB1) 
and the carboxy-terminal domain. Heat shock protein 90 (Hsp90) and mTORC2 are 
two proteins that have been shown to be involved in this process (Gould et al., 2009; 
Ikenoue et al., 2008).  
 
           
 
  
                                          
 
   
 
    
 
              
 
                         
 















Figure 1.4 Diagram of the structure of PKC isoforms. The C1 domains are highlighted in 
orange, the C2 domains in blue, and the kinase domain in green. Arrows indicate interactions 
with labelled agents. A and H within the kinase domain are the activation loop and 
hydrophobic domain, respectively. DAG = diacylglycerol, PS = phosphatidylserine, ATP = 
adenotriphosphate, and RACK = receptor for activated C kinases. This figure was modified 
from another study (Newton, 2010).  
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 Activation of the PKC isoforms involves recruitment to the plasma membrane. 
This is caused by stimulation of tyrosine kinase receptors and G-protein-coupled 
receptors which activate phospholipase C (PLC). PLC activation results in an increase 
in the level of DAG in the plasma membrane which, subsequently, induces 
relocalisation and activation of the PKC isoforms (Newton, 2003). However, in the case 
of atypical PKC isoforms, their activation is regulated by the phosphorylation of the 
hydrophobic motif by mTORC2 (Pearce et al., 2010). Binding of PKC to the plasma 
membrane causes a conformational change that exposes the binding sites of the 
kinase domain. Subsequent downstream events include the activation of the MEK-ERK 
and PI3K-Akt pathways (Balendran et al., 2000; Cai et al., 1997; Marshall, 1996).  
 
 Isoforms of PKC can localise differently inside the cell in response to apoptotic 
stimuli through intrinsic localisation sequences or specific-scaffolding protein binding 
(DeVries et al., 2002; Milani et al., 2003; Mirandola et al., 2004; Zauli et al., 1996). 
PKCδ, for example, translocates differently to the Golgi or mitochondrion, the nucleus 
or the membrane depending on its binding to ceramide, DAG or RACK (receptor for 
activated C kinases) (Steinberg, 2004), a protein with the ability to bind specific PKC 
isozymes in a manner that relieves their autoinhibition (Ron and Mochly-Rosen, 1995).  
 
 Studies show that the PKC isoforms have contrasting roles in tumour biology, 
with each isoform making a unique contribution to cancer formation and progression. 
For example, PKCε confers a growth advantage in transformed cells (Cacace et al., 
1996), but PKCδ has been shown to possess anti-proliferative properties (Heit et al., 
2001), with several isoforms of PKC having different, tissue-specific roles (Griner and 
Kazanietz, 2007). The variety of pathways activated by PKC isoforms dependent on 
sub-cellular localisation and access to specific substrates during activation explains 
why the PKCs possess such varied and contrasting properties in both normal and 
tumour cells (Wang et al., 1999).  
 
 In breast and colorectal cancers, PKCα has been shown to be over expressed 
and under expressed, respectively (Assert et al., 1999; O'Brian et al., 1989). Effects in 
normal cells have been reported to be anti-proliferative, with the activation of PKCα 
linked to G1 cell cycle arrest associated with ERK activation and induction of p21 and 
p27 (Frey et al., 1997). Studies indicate that modifications of PKCα are linked to 
regulation of cellular differentiation and the proliferation of a variety of cell types, CaCo-
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2 and gastric epithelial cells being two examples (Scaglione-Sewell et al., 1998; Zhu et 
al., 1999).  
 
 PKCβ is separated into two spliced variants coded by the same gene, PKCβ1 
and PKCβ2. These alternatively spliced variants are differentially involved in cell 
growth, apoptosis and transformation (Deacon et al., 1997; Ono et al., 1987; Zhu et al., 
2000). PKCβ1 has been shown to function in the induction of survival in gastric cancer 
in response to chemotherapeutic agents (Jiang et al., 2002; Zhu et al., 2000). PKCβ2, 
by contrast, has been reported to lead to hyperproliferation and even to colon 
carcinogenesis in transgenic mice (Gokmen-Polar et al., 2001; Murray et al., 2002). 
The activation of PKCβ in tumour cells results in activation of Akt and glycogen 
synthase kinase 3β (GSK-3β), which leads to the transcription of vascular endothelial 
growth factor (VEGF), a molecule implicated in carcinoma growth (Graff et al., 2005).  
 
 PKCδ activation can have anti-apoptotic or pro-apoptotic effects (Wert and 
Palfrey, 2000), however, in many cell types, PKCδ is a critical pro-apoptotic kinase 
(Reyland, 2009). In pancreatic cancer, however, PKCδ is commonly overexpressed 
and activated compared to normal pancreatic tissue (El-Rayes et al., 2008). PKCδ has 
also been implicated in breast cancer, for example, oestrogen receptor positive breast 
cancer cell lines highly express PKCδ, while oestrogen receptor negative cell lines 
express reduced levels of PKCδ (Assender et al., 2007). In support of its pro-apoptotic 
properties, PKCδ has also been shown to down-regulate the expression of cyclins 
leading to cell cycle arrest (Black, 2000).  
 
 Follicular lymphoma and pancreatic cancer cells overexpress PKCζ when 
compared to non-malignant cells (Leseux et al., 2008; Peng et al., 2007). PKCε 
expression has been shown to decrease in breast cancer, pancreatic cancer and colon 
cancer in comparison to surrounding normal tissues (Doi et al., 1994; El-Rayes et al., 
2008; Lavie et al., 1998). PKCε is associated with cell cycle arrest as well as 
differentiation, which could explain the reason for its downregulation in tumour cells 
(Nishizuka, 1984).  
 
 Increased expression of PKC or the differential activation of its isoforms has 
been linked to a variety of cancers including, but not limited to, breast, lung, thyroid, 
adenomatous pituitary cancers and leukaemias (Assender et al., 2007; Komada et al., 
1991). As mentioned previously, PKC isoforms play a variety of cell type specific roles 
in the regulation of cell growth, apoptosis, and differentiation. Studies using RNA 
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interference techniques and genetic manipulation in mice of individual isoforms of PKC 
showed that isoforms α, β, λ, ε and ζ preferentially function to promote cell proliferation 
and survival, but PKCδ was found, in many cell types, to be pro-apoptotic (Reyland, 
2009).    
 
 Taken together, the collected studies presented here highlight the observation 
that the expression of PKC isoforms appears to be responsible for the tumour specific 
characteristics observed in certain transformed cells and tissues compared to their 
normal counterparts. 
 
1.4.2.2 Cyclic guanosine monophosphate-dependent protein kinase (PKG) 
 
 Cyclic guanosine 3’, 5’-monophosphate (cGMP) is a ubiquitous second 
messenger that mediates several signal transduction pathways in mammalian cells. It 
is involved in the regulation of various physiological functions including 
neurotransmission and platelet aggregation (Fallahian et al., 2011). cGMP is also 
involved in the modulation of intracellular calcium levels in vascular smooth muscle 
cells (Eigenthaler et al., 1999; Smolenski et al., 1998; Vaandrager and de Jonge, 
1996). cGMP has also been reported to play a role in cellular proliferation, cellular 
differentiation and apoptosis (Loweth et al., 1997; Shimojo et al., 1999). There are 
several intracellular targets of cGMP, specific phosphodiesterases (PDEs), cGMP-
gated cation channels and cyclic guanosine monophosphate-dependent protein kinase 
(PKG) (Hofmann, 2005; Kaupp and Seifert, 2002; Torphy, 1998). 
 
 PKG belongs to the family of serine/threonine kinases and is comprised of three 
distinct isoforms that are transcribed from two genes (Orstavik et al., 1997; Orstavik et 
al., 1996). The PKG-I gene is alternatively spliced to form PKG-Iα and PKG-Iβ which 
are widely distributed but expression varies in different tissues, while PKG-II is more 
restricted to the brain, kidney and intestine.  
 
 PKG-Iα and PKG-Iβ differ only in the N-terminal ~100 amino acids (Francis et 
al., 2005; Francis and Corbin, 1999; Hofmann, 2005; Wernet et al., 1989). PKG-I 
monomers contain a regulatory domain towards the N-terminal portion of the protein 
and a catalytic domain towards the C-terminal portion. Each domain comprises 
subdomains that possess specific functions (Francis et al., 2005; Hofmann, 2005; 
Hofmann et al., 2009; Lincoln and Corbin, 1977; Monken and Gill, 1980). The 
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subdomains of the regulatory domain are the dimerisation and localisation subdomain 
provided by an extended leucine zipper motif, an autoinhibitory subdomain and a 
cGMP binding subdomain comprised of two homologous cGMP binding sites that are 
arranged in tandem. The two cGMP binding sites are called A and B, with A being a 
high affinity/slow dissociation binding site and B being a lower affinity/fast dissociation 
binding site (Kim et al., 2011). The catalytic domain contains two subdomains, a small 
lobe subdomain that binds to ATP and a large lobe subdomain that binds to protein 
substrates (Figure 1.5). The catalytic domain and the cGMP binding subdomains are 
conserved between the PKG-I isoforms (Richie-Jannetta et al., 2006).                
 
    
 

















 Specific substrates of PKG determine its physiological function through diverse 
signalling pathways (Ammendola et al., 2001; Schlossmann and Desch, 2009). Inositol 
triphosphate receptor-associated cGMP-kinase substrate (IRAG) is an endoplasmic 
reticulum-anchored membrane protein and a main signal transducer of PKG activity in 
the cardiovascular system (Schlossmann et al., 2000). PKG-Iβ stably associates with 
IRAG and phosphorylates this substrate at serine 696, this leads to suppression of 




Regulatory domain Catalytic domain
Leucine zipper
Figure 1.5 Diagram of the structure of PKG isoforms. The Leucine zipper dimerisation domain is 
highlighted in orange, the inhibitory subdomain in purple, the two cGMP binding sites: A (high 
affinity/slow dissociation) and B (lower affinity/fast dissociation) are highlighted in blue and the small 
lobe (ATP binding) and large lobe (protein substrate binding) of the catalytic domain are highlighted in 
green. ATP = adenotriphosphate and cGMP = cyclic guanosine monophosphate. This figure was 
modified from another study (Kim et al., 2011).  
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calcium release by the inositol 1,4,5-triphosphate receptor I (IP3RI) in vascular and 
gastrointestinal smooth muscles and in platelets (Ammendola et al., 2001; 
Schlossmann et al., 2000). The phosphorylation of IRAG by PKG acts by inhibiting 
platelet aggregation, and reduced bleeding time reported in IRAG-KO mice suggests 
that this phosphorylation may play a role in blood clotting (Antl et al., 2007). In addition, 
the myosin phosphatase targeting subunit 1 (MYPT1) is phosphorylated by PKG-Iα at 
serine 695 resulting in an increase in phosphatase activity and relaxation in vascular 
smooth muscle cells.  
 
 Regulation of cellular membrane potential is partially governed by the calcium-
activated maxi-K+ channel (BKCa) and in vascular tissues, BKCa regulates basal blood 
pressure (Sausbier et al., 2005). PKG phosphorylates BKCa at serine 1134, and 
interestingly, phosphorylation by PKC at serine 1151 and 154 determines the activation 
of BKCa by PKG (Zhou et al., 2010). Vasodilator-stimulated phosphoprotein (VASP) is 
involved in angiogenesis and the remodelling of the actin cytoskeleton in the 
cardiovascular system (Chen et al., 2008; Chen et al., 2004). PKG-I phosphorylates 
VASP at serine 239 in vascular smooth muscle cells which reduces the binding of 
VASP to actin and negatively affects the cells invasion and contraction of collagen 
matrices (Defawe et al., 2010). PKG also phosphorylates ras homolog gene family, 
member A (RhoA) at serine 188 resulting in inactivation of RhoA signalling which leads 
to the reduction of vascular remodelling and fibrosis in mouse blood vessels (Sawada 
et al., 2009). Other PKG substrates include the cysteine-rich protein 2 (CRP2) which is 
a protein phosphorylated by PKG-I that is involved in the neural processes of encoding 
and processing noxious stimuli in mice (Huber et al., 2000; Schmidtko et al., 2008). 
Phosphodiesterase 5 (PDE5) is another substrate phosphorylated by PKG, at serine 
92, which is involved in the regulation of relaxation/contraction cycles of smooth muscle 
(Rybalkin et al., 2002).  
 
 PKG can be involved in a number of cellular processes depending on the cell 
type and the substrate that it interacts with and much of the above data describes 
kinase function in the cardiovascular environment. In relation to cellular proliferation 
and cancer, studies have shown that PKG-I levels decrease in primary cells as they are 
passaged during tissue culture and expression is lost in many cell lines (Cornwell and 
Lincoln, 1989; Lin et al., 2004b). The loss of PKG-I expression in cells as they become 
more proliferative, in the case of primary cell lines, could potentially indicate that PKG-I 
expression might be lost in the process of tumourigenesis. Many studies support this 
notion, for example, it was reported that PKG expression in normal and preneoplastic 
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ovarian surface epithelium was lost in neoplastic ovarian tumours (Wong et al., 2001). 
In addition, PKG-I expression has been shown to be greatly reduced in colon tumours 
when compared to normal colon epithelium (Hou et al., 2006). cDNA analysis 
discovered that PKG-I mRNA levels were dramatically reduced in several tumour types 
compared to their normal counterpart tissues. This study also showed that 
downregulation of PKG occurred at the transcriptional level in several cancer cell lines 
(Hou et al., 2006). Additionally, a recent study using quantitative real-time PCR (qRT-
PCR) reported that PKG isoforms were downregulated in malignant and benign breast 
tumours when compared to respective normal tissues (Karami-Tehrani et al., 2012). 
Further supporting the notion of PKG loss during transformation, one study has shown 
that PKG expression is significantly reduced upon introduction of the simian virus 40 
large T antigen (SV40LT), responsible for the transformation and immortalisation of 
primary cell lines (Fujii et al., 1995a).  
 
 Activation of PKG occurs when cellular cGMP levels increase in response to 
natriuretic peptides or nitric oxide (NO). Natriuretic peptides bind to membrane-
spanning receptors that possess guanylyl-cyclase activity on the cytoplasmic side of 
the plasma membrane (Silberbach and Roberts, 2001). NO activates soluble guanylyl-
cyclase, this is the more common mechanism by which cGMP levels are elevated 
(Hofmann et al., 2000). PKG has many effects on the expression of genes, and in 
smooth muscle cells (SMC) PKG is involved in the maintenance of differentiated and 
less proliferative populations of cells (Lincoln et al., 2006; Pilz and Broderick, 2005). 
PKG has also been shown to have anti-proliferative effects in cardiomyocytes and 
mesangial cells (Segawa et al., 2001; Shimojo et al., 1999). In addition, PKG 
expression was reported to inhibit the proliferation of gastric cancer cells through 
blocking epithelial growth factor (EGF) triggered MAPK signal transduction (Wu et al., 
2012).  
 
 The widespread expression of PKG suggests that it may have a fundamental 
role in growth regulation, however, a number of studies report contrasting findings. In 
non-tumour cells such as a pancreatic β-cell line and human neutrophils, PKG was 
found to be pro-apoptotic (Brunetti et al., 2002; Loweth et al., 1997). However, in cell 
lines including cultured astrocytes, PC12 cells, adult rat contractile SMC and human 
endothelial cells, PKG was found to prevent apoptosis (Hood and Granger, 1998; Kim 
et al., 1999; Komalavilas et al., 1999; Takuma et al., 2001). More recently, PKG has 
been shown to induce apoptosis in breast cancer cell lines MCF-7 and MDA-MB-468 
(Fallahian et al., 2012). The anti-tumour properties of PKG are also highlighted in its 
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ability to impair the adaptability of colon cancer cells to an anaerobic environment, or 
hypoxia, a vital requirement for rapid tumour growth in the absence of angiogenesis 
(Kwon et al., 2011).  
 
 Several mechanisms have been proposed for the apoptotic function of PKG, 
including upregulation of caspase genes, death receptors, JNK1 activation and 
attenuation of β-catenin (Huang et al., 2001; Soh et al., 2000; Soh et al., 2001; 
Thompson et al., 2000). In addition, another study indicated that the potential role of 
PKG in growth suppression in colon cancer could be through the suppression of the 
activity and reduction in the nuclear expression of oncogenic β-catenin (Whitt et al., 
2012). 
 
 In the colon, growth factors of the Wnt family regulate the renewal of the luminal 
epithelium by the homeostatic control of the proliferation of colon cells. The Wnt family 
ligands work to stabilise the cellular levels of β-catenin in order to avoid uncontrolled 
proliferation. Disruption of the normal function of this pathway is thought to be the key 
step in initiating intestinal tumourigenesis (Giles et al., 2003). At increased protein 
levels, β-catenin interacts with lymphoid enhancer factor (LEF) and T-cell factor (TCF) 
transcription factors and enters the nucleus where it activates the expression of c-Myc, 
cyclin-D1 and c-Jun, cell growth related genes (Behrens, 2000; Lustig and Behrens, 
2003). As cells advance through the luminal epithelium, the β-catenin in the cytoplasm 
associates with the adenomatous polyposis coli (APC) complex which leads to its 
phosphorylation by GSK-3β, causing ubiquitination and proteasomal degradation 
(Behrens, 2000). Many tumours of the colon express truncated forms of APC that do 
not bind to β-catenin, permitting the accumulation of excessive levels in the absence of 
Wnt (Chandra et al., 2012; Hanson and Miller, 2005).  
 
 The importance of β-catenin in intestinal tumourigenesis and the observations 
that PKG can inhibit the expression of β-catenin, indicate that PKG is an important 
factor in suppression of tumour characteristics, and potentially a normal cell specific 
protein kinase. This, in addition to the anti-cancer properties of PKG described here, 
provides evidence that PKG expression could act as a marker for tumour and normal 
cell identification, in specific cell and tissue types.  
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1.5  Objectives of this study 
 
 Cancer is an aggressive disease that affects millions of people worldwide each 
year. A number of genetic and phenotypic changes are associated with the 
advancement of the disease, described as the hallmarks of cancer, which lead to the 
transformation of normal cells into malignant neoplasms. An important prerequisite of 
cancer therapies is a tumour selective property, the ability to preferentially target 
tumour or transformed cells for destruction, thus avoiding potentially dangerous side 
effects. Apoptin, a chicken anaemia virus derived protein, has been proven in many 
separate studies to possess a tumour selective cytotoxic function, highlighting its 
potential as a cancer therapeutic (Backendorf et al., 2008b; Noteborn, 2005; Tavassoli 
et al., 2005). Further investigation of Apoptin function revealed tumour specific 
modifications and localisation essential to its cytotoxic effects. Phosphorylation of 
Apoptin on threonine 108 (T108) was shown to be important for tumour specific 
function, and nuclear localisation in tumour cells was also shown to be a differentiating 
factor in Apoptin expression in normal and transformed cells (Rohn et al., 2002; Zhang 
et al., 2003).  
 
 Investigation into the phosphorylation of Apoptin on the T108 residue has so far 
failed to identify the kinase or kinases responsible. The main objective of this study was 
to further investigate the tumour specific function of Apoptin and attempt to identify 
potential kinases responsible for Apoptin phosphorylation and subsequent cytotoxicity. 
The specific aims of this study were as follows: 
 
• Using the siRNA library targeting 54 serine/threonine kinases, identify specific 
kinases important for Apoptin cytotoxicity.  
• Analyse expression of two candidate Apoptin kinases, PKG-I and PKCβ1, in a 
panel of paired normal and transformed cell lines. 
• Investigate cell sensitivity to Apoptin in a panel of cancer cell lines in relation to 
the expression of PKCβ1 and PKG-I. 
• Using siRNA knockdown and overexpression studies, analyse effects of these 
two kinases on Apoptin function.   
• Investigate whether human gyrovirus Apoptin has similar function to CAV 
Apoptin.  
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 The work presented here demonstrates a novel role for PKG-I and PKCβ1 in 
Apoptin function in normal and transformed cells. Results of the above objectives are 
explained in Chapters 3, 4, 5 and 6. 
47 
  Chapter 2: Materials and Methods 
Chapter 2 
Materials and Methods 
2.1 Materials 
 
Plastics used in tissue culture were purchased from Greiner Bio-One. All 
chemicals used were obtained from Sigma, unless stated otherwise. Solutions and 
buffers were stored at room temperature unless specified. Cell culture media were 
stored at 4oC. 0.2 µm and 0.45 µm filters were purchased from Schleicher & Schuell. 
2.1.1 Solutions, buffers and media 
 
Agarose gel 
A 1% (w/v) agarose solution was made in 100 ml Tris-acetate/EDTA (1× TAE) and 
boiled to dissolve the powder. The solution was cooled to 50ºC and ethidium bromide 
was added to a final concentration of 0.5 µg/ml. An electrophoresis tray was prepared 
by sealing the edges with tape and inserting a comb. The agarose solution was poured 
into the electrophoresis tray and the gel was left to set at room temperature. Prior to 
use, the tape and the comb were removed. 
 
Agarose gel electrophoresis loading buffer (10×) 
• 0.25% Orange G 
• 20% (w/v) Ficoll 400 
• 10 mM Tris pH8.0 
• 10 mM MgCl2 
• Made up in dH2O 
• Stored at 4oC 
 
Ampicillin 
A stock solution of 50 mg/ml was made in dH2O, sterilised by filtering through a 0.2 µm 
filter and stored at -20ºC. A 50 µg/ml working concentration was used. 
 
10% Ammonium persulphate (APS) 
The solution was made in dH2O and stored at 4ºC for two weeks. 
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Annexin V Binding buffer 
• 10 mM HEPES adjusted to pH 7.4 
• 140 mM NaCl 
• 2.5 mM CaCl2 
 
Annexin V – Allophycocyanin Conjugate (Invitrogen) 
The 250μl stock solution was diluted; 1μl of Annexin V in 100μl of Annexin V binding 
buffer. 
 
Blocking buffer for indirect immunofluorescence cytochemistry 
3% (w/v) bovine serum albumin (BSA) in PBS 
 
Blocking buffer for Western blotting 
5 or 10% (w/v) Marvel milk powder in TBST or 3% (w/v) BSA in TBST 
 
Carbenicillin  
Carbenicillin solution (100 mg/ml) was purchased from Bioline and stored at -20ºC. A 
working concentration of 100 µg/ml was used. 
 
Cell culture media 
DMEM: 
• 10% or 15% FCS (tetracycline free FCS for PKG inducible HT29 clones), 50 
µg/ml streptomycin, 100 µg/ml penicillin and 1 mM sodium pyruvate were added 
into 500ml of medium prior to use. 
• Stored at 4ºC 
McCoy’s 5A: 
• 10% FCS, 50 µg/ml streptomycin, 100 µg/ml penicillin and 1 mM sodium 
pyruvate were added into 500ml of medium prior to use. 
• Stored at 4ºC 
Nut mix: 
• 4 mM L-glutamine 
• 25 µg/L hydrocortisone 
• 95% Nut mix medium (Gibco BRL 21331-020) 
• 5% FCS, 50 µg/ml streptomycin, 100 µg/ml penicillin and 1 mM sodium 
pyruvate were supplemented into 500ml of medium prior to use. 
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• Stored at 4ºC 
RPMI: 
• 10% FCS (tetracycline free FCS was used for PKG inducible clones), 50 µg/ml 
streptomycin, 100 µg/ml penicillin and 1 mM sodium pyruvate were 
supplemented into 500ml of medium prior to use. 
• Stored at 4ºC 
M3 Base A: 
• 10% FCS was supplemented into the medium prior to use. 
• Stored at 4ºC 
 
CellTiter-Glo® Reagent (Promega) 
• Purchased from Promega and stored at -20°C long term. For frequent use, 
solution was stored at 4°C for 48 hours with no loss in activity.  
 
Coomassie Brilliant blue staining solution for Western Blotting 
• 0.25% Coomassie Brilliant blue R-250/G-250 
• 45% methanol 
• 44.75% water 
• 10% acetic acid 
 
Coomassie Brilliant blue destain 
• 45% methanol 
• 45% water 
• 10% acetic acid 
 
Coumaric acid 
• 90 mM p-coumaric acid in DMSO (dimethyl sulfoxide) 
• Stored at -20°C 
 
Cycloheximide 
Cycloheximide solution (100 mg/ml) was purchased from Sigma and stored at 4ºC. A 
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Doxycycline 
Freshly prepared 10 mg/ml doxycycline solution was made in dH2O and stored at 4ºC. 
Before adding doxycycline to cultures, it was diluted 1/10 in DMEM and sterilised by 
filtering through a 0.2 µm filter. A working concentration of 2.5 µg/ml was used. 
 
ECL buffer 
• 100 mM Tris-HCl (tris[hydroxymethyl]aminomethane hydrochloride) pH 8.5 
• Stored at 4°C 
 
EDTA solution (pH 8.0) 
A 0.5 M disodium ethylenediaminetetraacetate.2H2O (EDTA) was made in dH2O. The 
pH was adjusted to 8.0 with NaOH. The solution was aliquoted and autoclaved. 
 
Ethidium bromide 
A 10 mg/ml ethidium bromide solution was made in dH2O and stored at 4°C in the 
dark. 
 
Freezing medium for cell culture 
• 10% DMSO 
• 20% FCS 
• 70% DMEM 
• Stored at 4ºC 
 
G418 (Invivogen) 
A stock solution of 100 mg/ml was purchased from Invivogen and stored at -20ºC. A 
working concentration of 500 µg/ml was used. 
 
Hygromycin B (Invivogen) 
Hygromycin B solution (100 mg/ml) was purchased from Invivogen and stored at -20ºC. 
A working concentration of 250 µg/ml was used. 
 
Laemmli Sample Buffer 
• 62 mM Tris base (2-amino-2(hydroxymethyl) propane-1,3,-diol (tris)) pH 6.8 
• 10% glycerol 
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• 2% SDS 
• 5% β-mercaptoethanol 
• The buffer was made up in dH2O and stored at -20ºC. 
Prior to use, the following components were added to 1 ml Laemmli Sample Buffer: 
aprotinin and leupeptin both at a final concentration of 1 µg/ml, phenylmethylsulfonyl 
fluoride (PMSF) at a final concentration of 100 µg/ml and 3 µl of saturated 
bromophenol blue. 
 
Luria-Bertani (LB) agar plates 
• 1.5% (w/v) agar in Luria-Bertani medium 
• Sterilised by autoclaving 
• Cool down to 50ºC 
• Pour plates after the appropriate antibiotic was added to obtain the working 
concentration of 50 µg/ml. 
 
Luria-Bertani (LB) medium  
• 1% NaCl 
• 0.5% Bacto-yeast extract 
• 1% Bacto-tryptone 
• Made up in dH2O and the pH was adjusted to 7.0 with 5 M NaOH 
• Sterilised by autoclaving 
 
Luminol 
• 250 mM luminol in DMSO 
• Stored at -20°C in the dark 
 
Maxi and Midiprep solutions (QIAGEN) 
 
Buffer P1 (Resuspension Buffer) 
• 50 mM Tris-HCl pH 8.0 
• 10 mM EDTA 
• 100 µg/ml RNase A 
• Stored at 4ºC after addition of RNase A. 
Buffer P2 (Lysis Buffer) 
• 200 mM NaOH 
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• 1% SDS 
 
Buffer P3 (Neutralisation Buffer) 
• 3.0 M potassium acetate pH 5.5 
Buffer QBT (Equilibration Buffer) 
• 750 mM NaCl 
• 50 mM MOPS pH 7.0 
• 15% isopropanol 
• 0.15% Triton® X-100 
Buffer QC (Wash Buffer) 
• 1.0 M NaCl 
• 50 mM MOPS pH 7.0  
• 15% isopropanol 
Buffer QF (Elution Buffer) 
• 1.25 M NaCl 
• 50 mM Tris-HCl pH 8.5 
• 15% isopropanol 
 
Miniprep solutions (Promega) 
 
Cell Lysis Solution (CLA) 
• 0.2 M NaOH 
• 1% SDS 
Cells Resuspension Solution (CRA) 
• 5 mM Tris-HCl (pH 7.5) 
• 10 mM EDTA 
• 100 µg/ml RNase A 
Neutralization Solution (NSB) 
• 4.09 M guanidine hydrochloride 
• 0.759 M potassium acetate 
• 2.12 M glacial acetic acid 
Column Wash Solution (CWA) 
• 162.8 mM potassium acetate 
• 22.6 mM Tris-HCl (pH 7.5) 
• 0.109 mM EDTA (pH 8.0) 
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Add 95% ethanol to make a final concentration to be approximately 60% ethanol, 60 
mM potassium actate, 8.3 mM Tris-HCl and 0.04 mM EDTA. 
Mifepristone 
Mifepristone was stored at -20°C and a working concentration of 1-5 nM was prepared 
in DMEM prior to use. 
 
MTT (3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) stock 
5 mg/ml MTT was prepared in PBS and sterilised by filtering through a 0.2 µm filter. 
 
2% paraformaldehyde in PBS 
In order to prepare a 100 ml solution, 2 g paraformaldehyde was dissolved in 50 ml 
PBS, heated to 60ºC and mixed. A few drops of 5 M NaOH were added while mixing 
until the solution became clear, then PBS was added to a final volume of 100 ml. The 
solution was stored at 4ºC. 
 
PBS (Phosphate-Buffered Saline) 
• 140 mM NaCl 
• 2.7 mM KCl 
• 8.0 mM Na2HPO4 
• 1.5 mM KH2PO4 
• Made up in dH2O and sterilised by autoclaving 
 
500× Penicillin/Streptomycin stock solution 
• 1.25 g Streptomycin sulfate 
• 2.5 g Penicillin G 
• Made up in 50 ml dH2O and sterilised by filtering through a 0.2 µm filter 
 
PMSF (Phenylmethylsulfonyl fluoride) 
10 mM PMSF was made up in isopropanol and stored at -20ºC. 
 
Propidium iodide (PI) stock and working solutions 
Stock solution 
• 1 mg/ml PI Stock solution: 1 mg PI was dissolved in 1 ml PBS and sterilised by 
filtering through a 0.2 µm filter. The solution was stored at 2º to 8ºC and 
protected from light for up to 1 month. 
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• 10 mg/ml Ribonuclease A Stock solution: The solution was stored at -20ºC 
 
Working solutions 
• In order to prepare 10 ml of working solution, 400 µl of PI stock solution and 
500 µl of Ribonuclease A stock solution were added in 9100 µl PBS. The 
solution was sterilised by filtering through a 0.2 µm filter.  
 
Puromycin 
Puromycin was purchased from Invivogen and stored at -20°C. A working solution of 
0.2 μg/ml was used.   
 
ReBlot Plus stripping buffer (Millipore) 
Reblot Plus 10x solution was diluted to 1x in dH2O and stored at 4°C and replaced 
after 5 uses, according to the manufacturer’s instructions.  
 
10× Running/Transfer buffer for Western blotting 
• 250 mM Tris base 
• 2.5 M Glycine 
• 1% SDS 
• Made up in dH2O 
 
1× Running buffer for Western blotting 
• 10% 10× Running/Transfer buffer 
• 90% dH2O 
 
10% SDS (sodium dodecyl sulphate) 
A 10% (w/v) solution of SDS was made up in dH2O, heated to 68ºC to dissolve and the 
pH was adjusted to 7.2 with concentrated HCl. 
 
SDS-Polyacrylamide gel 
30% acrylamide mix was purchased from AMRESCO®. TEMED (N,N,N',N',-









 6% 8%  10% 12% 
dH2O 5.3 ml 4.6 ml 4.0 ml 3.3 ml 
30% acrylamide mix 2.0 ml 2.7 ml 3.3 ml 4.0 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
10% SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
10% APS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
TEMED 0.008 ml 0.006 ml 0.004 ml 0.004 ml 
Total 10 ml 10ml 10 ml 10 ml 
 
Stacking gel 
• 2.7 ml dH2O 
• 0.67 ml 30% acrylamide mix 
• 0.5 ml 1.0 M Tris pH 6.8 
• 0.04 ml 10% SDS 
• 0.04 ml 10% APS 
• 0.004 ml TEMED 
 
3 M sodium acetate (NaAc) pH 5.2 
A 3 M solution of sodium acetate (NaAc) was prepared in dH2O and the pH was 




• On-TARGET plus® control siRNA GAPD: Human (Thermo Scientific 
Dharmacon®), Cat# D-001830-01-05 
• The targeting sequence: 5'-GUCAACGGAUUUGGUCGUA-3' 
siRNA against PKG-I 
• On-TARGET plus® SMARTpool PRKG1 (Thermo Scientific Dharmacon®), 
Cat# M-004658-04-0005 
• The targeting sequences: GAACAAAGGCCAUGACAUU, 
GGACAGGACUCAUCAAGCA, GGAUUGACAUGAUAGAAUU, 
CCUAUAACAUCAUAUUGAG  
siRNA against PKCβ1 
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• On-TARGET plus® SMARTpool PRKCB1 (Thermo Scientific Dharmacon®), 
Cat# M-003758-04-0005 




• Human RTF SMARTpool serine threonine kinase siRNA Library (Thermo 
Scientific Dharmacon®), Cat# H-004400 
 
Simply Blue Safe stain (Invitrogen) 
Simply Blue stain was added to gels for at least 1 hour and the gels were subsequently 
rinsed and washed with dH2O, according to the manufacturer’s instructions.  
 
3 M sodium acetate (NaAc) pH 5.2 
A 3 M solution of sodium acetate (NaAc) was prepared in dH2O and the pH was 
adjusted to 5.2 with glacial acetic acid. The solution was aliquoted and autoclaved. 
 
Solubilisation solution for MTT assay 
• 50% dimethylformamide 
• 0.2% glacial acetic acid 
• 20 mM HCl 
• 20% SDS 
• Made up in dH2O 
 
50× TAE (Tris-acetate/EDTA) 
• 242 g Tris base 
• 57.1 ml glacial acetic acid 
• 37.2 g Na2EDTA.2H2O 
• Made up in dH2O to 1 litre and pH was adjusted to 8.5 and autoclaved. 
 
10× TBS (Tris-Buffered Saline) 
• 250 mM Tris base 
• 1.5 M NaCl 
• made up in dH2O, pH was adjusted to 7.4 using concentrated HCl and 
autoclaved. 
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TBST (Tris-Buffered Saline-Tween 20) 
0.05% Tween 20 in 1× TBS 
 
TE (Tris-EDTA) 
• 10 mM Tris-HCl pH 8.0 
• 1 mM EDTA pH 8.0 
• Made up in dH2O 
 
1× Transfer buffer for Western blotting 
• 10% 10× running/transfer buffer 
• 20% methanol 
• 70% dH2O 
 
0.2% Triton X-100 
• 0.1 ml of Triton X-100 
• 49.9 ml of PBS 
• The solution was stored at room temperature 
 
1× Trypsin 
• 10% 10× trypsin (T4549 Sigma) 
• 90% versene 
 
Versene 
• 0.270 mM EDTA pH 8.0 
• Made up in PBS and sterilised by autoclaving 
 
Zeocin 
Was purchased from Invivogen and stored at -20°C. A working concentration of 200 
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2.1.2 Cell lines 
 
1BR3 
• Human normal fibroblasts 
• Provider: Gift from Prof. Alan Lehmann, Sussex Centre for Genome Damage 
and Stability, University of Sussex, UK 
 
1BR3LT 
• Human SV40 large T-antigen transformed fibroblasts 
• Provider: Gift from Prof. Alan Lehmann, Sussex Centre for Genome Damage 
and Stability, University of Sussex, UK 
 
HeLa 
• Human cervical carcinoma transformed with human papilloma virus (HPV) type 
18E6/E7 genes 




• Gift from Prof. Stephen Prime, Department of Oral and Dental Science, 
University of Bristol, UK 
 
Saos-2 
• Human osteosarcoma 
• Provider: American Type Culture Collection 
 
293A 
• Human primary embryonal kidney cells transformed with human adenovirus 
type 5 E1A and E1B, used for adenoviral packaging. Included in Ad-Easy 
adenovirus recombinant production kit (Qbiogene) 
 
AD-293  
• The AD-293 cell line is a derivative of the commonly used HEK293 cell line, 
with improved cell adherence and plaque formation properties. AD-293 cells, 
like HEK293 cells, produce the adenovirus E1 gene in trans, allowing the 
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production of infectious virus particles when cells are transfected with E1-
deleted adenovirus vectors such as the pAdEasy™-1 vector. Standard HEK293 
cells do not adhere well to tissue culture dishes, hindering adherent cell culture 
and plaque assay procedures. AD-293 cells demonstrate improved adherence 
to tissue culture dishes, making AD-293 cell monolayers less susceptible to 
disruption during cell passaging and plaque assays. 
• Provider: Stratagene 
 
HCT116  
• Human colorectal carcinoma  
• Provider: Gift from Prof. Bert Vogelstein, The Howard Hughes Medical Institute 




• PUMA gene knockout in human colorectal carcinoma 
• Provider: Gift from Prof. Bert Vogelstein, The Howard Hughes Medical Institute 
and Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins University, 
Baltimore, MD 
 
HCT116 p53-/-  
• p53 knockout in human colorectal carcinoma 
• Provider: Gift from Prof. Bert Vogelstein, The Howard Hughes Medical Institute 




• p53 Heterozygous knockout in human colorectal carcinoma 
• Provider: Gift from Prof. Bert Vogelstein, The Howard Hughes Medical Institute 
and Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins University, 
Baltimore, MD 
 
HCT116 p300-/-Clone D10 
• p300 knockout clone D10 in human colorectal carcinoma cells   
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• Provider: Gift from Prof. Carlos Caldas, Department of Oncology, Cancer 
Genomics Program, Hutchison/MRC Research Centre, University of 
Cambridge, Cambridge, UK 
 
NCM460 
• Normal derived human colon cell line 




• Human colon adenocarcinoma cell line 
• Provider: Gift from Dr. Darren Browning, Department of Biochemistry and 
Molecular Biology, Molecular Oncology Program, MCG-CC Medical College of 
Georgia, 1120 15th Street, CB2605, Augusta, GA 30809-2100 
 
SW480 mifepristone inducible clone J5B 
• Mifepristone inducible for PKG1α expression colon carcinoma cell line 
• Maintenance of transgenes using 200 μg/ml Hygromycin B and 200 μg/ml 
Zeocin   
• Provider: Gift from Dr. Darren Browning, Department of Biochemistry and 
Molecular Biology, Molecular Oncology Program, MCG-CC Medical College of 
Georgia, 1120 15th Street, CB2605, Augusta, GA 30809-2100 
 
HT29 
• Human colon adenocarcinoma cell line 
• Provider: Gift from Dr. Darren Browning, Department of Biochemistry and 
Molecular Biology, Molecular Oncology Program, MCG-CC Medical College of 
Georgia, 1120 15th Street, CB2605, Augusta, GA 30809-2100 
 
HT29 doxycycline inducible clone 1 beta # 7 
• Doxycycline inducible for PKG1β expression colon carcinoma cell line 
• Maintenance of transgenes using 0.2 μg/ml Puromycin and 200 μg/ml G418   
• Provider: Gift from Dr. Darren Browning, Department of Biochemistry and 
Molecular Biology, Molecular Oncology Program, MCG-CC Medical College of 
Georgia, 1120 15th Street, CB2605, Augusta, GA 30809-2100   
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• Dr. Joop Gäken, Department of Haematological Medicine, King’s College 
London, UK 
 
pcDNA3 Flag-tagged Apoptin 
• Prof. Mathieu H.M. Noteborn, Biological Chemistry, Leiden University, Leiden, 
The Netherlands 
 
pcDNA3 3X Flag-tagged Apoptin 
• Assistant Prof. Jose G. Teodoro, Rosalind and Morris Goodman Cancer Center 
and Department of Biochemistry, Montreal, Quebec, Canada 
 
pcDNA3 3X Flag-tagged Human Gyrovirus Apoptin  
• Dr. Joop Gäken, Department of Haematological Medicine, King’s College London, 
UK 
 
pcDNA3 PKG1α  
• Gift from Dr. Darren Browning, Department of Biochemistry and Molecular 
Biology, Molecular Oncology Program, MCG-CC Medical College of Georgia, 
1120 15th Street, CB2605, Augusta, GA 30809-2100   
 
pCMV-Apoptin 
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pCMV-GFP-Apoptin 




• Dr. Joop Gäken, Department of Haematological Medicine, King’s College London, 
UK 
 
pEGFP-C1 Human Gyrovirus Apoptin  
• Dr. Joop Gäken, Department of Haematological Medicine, King’s College London, 
UK 
 
2.1.4 Adenoviruses and Lentiviruses 
 
Ad-GFP-p53: expressing p53 fused to GFP, obtained from Prof. Bert Vogelstein, The 
Howard Hughes Medical Institute and Sidney Kimmel Comprehensive Cancer Centre, 
Johns Hopkins University, Baltimore, MD 
Ad-GFP: expressing GFP, obtained from Prof. Bert Vogelstein, The Howard Hughes 
Medical Institute and Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins 
University, Baltimore, MD 
Ad-Apoptin: expressing Apoptin, produced by Dr. Patrayu Taebunpakul, Head and 
Neck Oncology Group, King’s College London Dental Institute, UK 
Lenti-GFP: expressing GFP, obtained from Dr. Jie Jiang, Department of 
Haematological Medicine, King’s College London, UK 
Lenti-GFP-Apoptin: expressing Apoptin fused to GFP, obtained from Dr. Jie Jiang, 














• Mouse monoclonal anti-β-actin 
• Provider: Sigma 
• Dilution: 1:5000 (Western Blotting) 
 
Flag 
• Mouse monoclonal anti-Flag 
• Provider: Sigma 




• Rabbit polyclonal anti-GFP 
• Provider: Cell signalling 
• Dilution: 1:1000 (Western Blotting) 
 
M30 cytodeath 
• Mouse monoclonal anti-Cytokeratin 18 neo-epitope M30 
• Provider: Peviva 
• Dilution: 1:200  
 
Non-specific to T108 Apoptin 
• Rabbit polyclonal non-specific to Apoptin T108 raised against the peptide H2N-
SLITTTPSRPRTA-CONH2  
• Provider: Eurogentec 
• Dilution: 1:1000 (Western Blotting) 
 
p53  
• Mouse monoclonal anti-p53 clone  DO-7 
• Provider: Novacastra Laboratories 
• Dilution: 1:1000 (Western Blotting) 
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p73 
• Mouse monoclonal anti-p73 
• Provider: Abcam 
• Dilution: 1:500 (Western Blotting) 
 
PARP p85 
• Rabbit polyclonal anti-PARP p85 fragment clone G734A 
• Provider: Promega 
• Dilution: 1:2000 (Western Blotting) 
 
Phospho-Apoptin T108 
• Rabbit polyclonal anti-phospho-Apoptin T108 raised against the peptide H2N-
SLITTT(PO3H2)PSRPRTA-CONH2 
• Provider: Eurogentec 
• Dilution: 1:1000 (Western Blotting), 1:200 (Immunocytochemistry) 
 
PKCβ1 
• Mouse monoclonal anti-PKCβ1 
• Provider: Santa Cruz  
• Dilution: 1:500 (Western Blotting) 
 
PKCδ-C20 
• Rabbit polyclonal anti-PKCδ C-20 
• Provider: Santa Cruz 
• Dilution: 1:1000 (Western Blotting) 
 
PKG1 
• Rabbit monoclonal anti-PKG1 
• Provider: Cell Signaling 
• Dilution: 1:1000 (Western Blotting) 
 
Tubulin 
• Mouse monoclonal anti-tubulin 
• Provider: Sigma 
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• Goat-anti-rabbit IgG (whole antibody) FITC conjugate 
• Provider: Sigma 
• Dilution: 1:100 (Immunocytochemistry) 
 
FITC 
• Goat-anti-mouse IgG (whole antibody) FITC conjugate 
• Provider: Sigma 
• Dilution: 1:100 (Immunocytochemistry) 
 
Horseradish peroxidase 
• Donkey-anti-rabbit IgG secondary antibody conjugated to horseradish 
peroxidase 
• Provider: Amersham Life Science 
• Dilution: 1:2000 (Western Blotting) 
 
Horseradish peroxidase 
• Goat-anti-mouse IgG secondary antibody conjugated to horseradish peroxidase 
• Provider: Sigma 
• Dilution: 1:4000 (Western Blotting) 
 
Texas-Red 
• Horse-anti-mouse IgG (H+L)-Texas-Red 
• Provider: Vector Laboratories 
• Dilution: 1:100 (Immunocytochemistry) 
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2.2 Methods 
 
2.2.1 Transformation of plasmid DNA into chemically competent E. coli 
 
1 µl of plasmid DNA was added to 45 µl of competent cells. The mixture was 
gently mixed and the cells were incubated 30 minutes on ice, 30 seconds at 42oC and 
again 2 minutes on ice. Then 400 µl of Luria-Bertani-medium (LB-medium) was added 
and the cells were incubated at 37oC for 45 minutes. The mixture was centrifuged 1 
minute at 13000 RPM, 300 µl of supernatant was removed and the pellet was 
resuspended gently in the remaining supernatant. 50 µl of the suspension of cells was 
plated on an LB-agar plate containing the appropriate antibiotic. After 16 hours 
incubation at 37oC, a single clone was used to inoculate LB-medium for mini- or 
midiprep plasmid isolation. 
 
2.2.2 Plasmid purification 
2.2.2.1 Wizard® Plus SV Minipreps DNA Purification System: Promega 
 
Plasmid DNA was purified using DNA purification columns from a midiprep kit 
(Promega) as recommended by the manufacturer. The protocol is based on a modified 
alkaline lysis procedure. 
 
2.2.2.2 Plasmid midi- and maxiprep: QIAGEN plasmid kits 
 
Plasmid DNA was purified using DNA purification columns from a midiprep kit 
(QIAGEN) as recommended by the manufacturer. The protocol is based on a modified 
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2.2.3 Measuring plasmid DNA concentration 
 
The concentration of plasmid DNA was determined using Nanodrop (Labtech 
International Ltd, East Sussex, UK). A pure DNA has an OD260/OD280 ratio of 2.0, 
acceptable range 1.8-2.0. 
 
2.2.4 Glycerol stocks 
 
Glycerol stocks were generated from bacterial cultures containing plasmid 
constructs and vectors. 800 µl bacterial culture, taken from bacterial midi- or 
maxicultures was added to 200 µl autoclaved glycerol (VWR International Ltd, 
Leicestershire, UK). The glycerol stocks were stored at -70°C and were used to re-start 
the growing of bacteria containing plasmid constructs and vectors. Glycerol stocks 
were streaked out on LB plates containing the appropriate antibiotic. 
 
2.2.5 DNA precipitation 
 
DNA was precipitated in an eppendorf tube by addition of 1/10 volume 3.0 M 
sodium acetate (pH 5.2) and then 2 volumes 100% ethanol (Rathburn). The 
precipitation mixture was incubated for 30 minutes at -70°C or overnight at -20°C and 
subsequently centrifuged for 10 minutes at 13000 RPM in a cold centrifuge. The 
supernatant was removed without disturbing the DNA pellet. 70% ethanol was filled to 
the brim of the eppendorf and the tube was centrifuged for 6-7 minutes at 13000 RPM. 
The supernatant was again removed under the tissue culture hood. The pellet was air-
dried and dissolved in the desired volume of TE under the tissue culture hood. 
 
2.2.6 Agarose gel electrophoresis 
 
Agarose gel was prepared by adding 1% (w/v) agarose to 100 ml 1× TAE, 
which was diluted in dH2O from a 50× concentrated stock solution. The agarose was 
dissolved by heating the mixture to boiling. After the agarose solution was cooled down 
to approximately 50°C, ethidium bromide was added to a final concentration of 0.5 
µg/ml. The agarose solution was poured in an electrophoresis tray, of which the edges 
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were sealed with sticking tape. Combs were used to create slots. The gel was allowed 
to set at room temperature. Subsequently, combs and tape were removed. The gel was 
placed in the electrophoresis tank and covered with 1× TAE. DNA samples were 
prepared by addition of 1/10 (v/v) 10× electrophoresis loading buffer. DNA molecular 
weight markers (New England Biolabs) were run in parallel with the DNA samples as a 
reference for DNA fragment sizes and concentrations. The gel was run at 100 V. DNA 
was visualised by placing the gel on a UV transilluminator. Pictures were taken by 
using a gel documentation system (Syngene). 
 
2.2.7 Cell culture 
2.2.7.1 Cell maintenance 
 
Saos-2, HeLa, HCT116 and 293A cell lines were cultured in DMEM 
supplemented with 10% FCS, 50 µg/ml streptomycin, 100 µg/ml penicillin and 1 mM 
sodium pyruvate.  
H357 cell lines were grown in Nut mix supplemented with 5% FCS, 4 mM L-
glutamine, 25 µg/L hydrocortisone, 50 µg/ml streptomycin, 100 µg/ml penicillin and 1 
mM sodium pyruvate. 
1BR3 and 1BR3LT cell lines were grown in DMEM containing 15% FCS, 50 
µg/ml streptomycin, 100 µg/ml penicillin and 1 mM sodium pyruvate. 
HCT116 cell lines were grown in McCoy’s 5A containing 10% FCS, 50 µg/ml 
streptomycin, 100 µg/ml penicillin and 1 mM sodium pyruvate. 
PKG1α inducible SW480 J5B cells were grown in RPMI medium with 10% FCS, 
zeocin 200 μg/ml, hygromycin B 200 μg/ml and induced with 2.5 µg/ml mifepristone for 
24 hours.  
PKG1β inducible HT29 1 beta #7 cells were grown in RPMI medium with 10% 
tetracycline free FCS, puromycin 0.2 μg/ml, G418 200 μg/ml and induced with 2.5 
µg/ml doxycycline for 24 hours.  
NCM356 and NCM460 cells were grown in INCELL propriety medium M3-Base 
A with 10% FCS. 
  Any derivative clones were cultured in the same medium as the parental cell 
line and all cells were grown at 37ºC and 5% CO2. 
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2.2.7.2 Subculturing of cell lines 
 
Cells were subcultured every 3 to 5 days. For a T75 culture flask, cells were 
washed once with 10 ml versene and incubated with 1 ml 1× trypsin at 37ºC for 1-5 
minutes depending on the cell line. Once cells had become rounded, they were 
resuspended in 10 ml of medium containing 10% FCS in order to stop trypsinisation. 
Cells were then diluted as desired and plated in new tissue culture flasks. 
 
2.2.7.3 Cryopreservation and thawing of cell lines 
 
Cells (approximately 5×106 cells in a T75 tissue culture flask) were trypsinised 
as previously described and centrifuged for 5 minutes at 900 RPM. The supernatant 
was removed. The cell pellet was resuspended in 1 ml of appropriate freezing medium 
and transferred to a cryovial. The vial was placed in a -70ºC freezer (Vip series -86ºC, 
Sanyo) in a freezing container (Nalgene Cryoware) filled with isopropanol to moderate 
the cooling to a rate of 1ºC per minute. The cells were left at -70ºC for at least 24 hours 
before transferring to a liquid nitrogen (-196ºC) tank for long term storage. In order to 
thaw cells, a cryovial was removed from liquid nitrogen and quickly thawed at 37ºC. 
Cells were plated in a T75 flask with 10 ml prewarmed medium and left overnight at 
37ºC and 5% CO2. Medium was replaced the following day. 
 
2.2.7.4 Counting cells 
 
Cells in suspension were counted by using a haemocytometer (Weber Scientific 
International). The haemocytometer was assembled by placing a cover glass, provided 
by the manufacturer, on the grids of the counting chambers. When a cover glass is put 
on the slide, each square contains 0.1 µl of solution. Approximately 10 µl of cell 
suspension was pipetted into the counting chamber and the 4 outer squares were 
counted. The concentration of cells/ml was the total number of cells in the 4 squares 
divided by 4 and multiplied by 104. 
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2.2.8 Western blotting 
2.2.8.1 Protein extraction 
 
Medium was removed from the cells and the dish was washed once in cold 
PBS. Cells in a 100-mm dish were lysed by scraping in 400 µl Laemmli sample buffer 
with a sterile disposable cell scraper. Lysates were kept on ice until use or at -20ºC for 
long term storage. Lysates were passed through a 25G needle or homogenised using a 
motor pestle and boiled for 5 minutes before loading on gel. 
 
2.2.8.2 Coomassie brilliant blue staining 
 
5 µl of lysate from each sample was resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). The gel was subsequently incubated with Coomassie 
Brilliant blue stain for a minimum of 4 hours on a rocking table. The gel was destained 
with Coomassie Brilliant blue destain for 24 hours on a rocking table. Coomassie 
Brilliant blue destain was changed every 2-4 hours during destaining. Proteins in the 
gel stain blue and could therefore be visualised in each lane. In order to load an equal 
amount of protein for Western blotting, the intensity of the blue stain in different 
samples was compared to one another. 
 
2.2.8.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Glass plates (included in Bio-Rad Mini-PROTEAN III Module) were first washed 
with water, rinsed with dH2O and cleaned with 70% ethanol. The gel-casting apparatus 
was set up according to the manufacturer’s instructions (Bio-Rad Mini-PROTEAN III, 
165-3301). The resolving polyacrylamide gel solution was prepared and poured. 200 µl 
of ethanol was added to flatten the top surface of the gel. The gel was allowed to set at 
room temperature and the ethanol was removed by washing with dH2O and soaking up 
the remaining liquid with a Whatman filter paper. The stacking gel was prepared, 
poured on top of the resolving gel and the gel comb was inserted. The comb was 
removed once the stacking gel had set and the gel was placed into the electrophoresis 
apparatus. The gel-tank was filled with 1× Running buffer and equal amounts of protein 
were loaded in each well. 4 µl of PageRuler Prestained Protein Ladder (Fermentas 
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Life Sciences) was run simultaneously with the samples to determine protein size. Gel 
electrophoresis was performed for 1.5-2 hours at 80 V. 
 
2.2.8.4 Protein transfer onto nitrocellulose membrane 
 
Proteins were transferred onto a 0.45 µm pore nitrocellulose membrane 
(Schleicher & Schuell, BA85-401191). This procedure was performed in a tray filled 
with 1× Transfer buffer to ensure that no air bubbles were trapped between the gel and 
the membrane. A soft scouring pad was put onto the black side of a transfer cassette, 
followed by two pieces of 3mm filter paper (Whatman, 3030917), the gel, the 
nitrocellulose membrane and again two pieces of filter paper, all cut to the same size 
as the gel (generally 8.5 cm × 5 cm). A soft scouring pad was put on top of all, the 
transfer cassette was closed and placed in the transfer tank (Bio-Rad Mini-PROTEAN 
III) filled to the brim with 1× Transfer buffer. Transfer was performed at either 50 V for 




Blots were blocked for 30 minutes in 10% blocking buffer (Marvel milk powder 
in TBST) or overnight at 4ºC in 5% blocking buffer. Subsequently, blots were incubated 
for 1.5 hours in primary antibody, diluted in 10% blocking buffer, rinsed three times in 
TBST and washed in TBST for 15 minutes once and 5 minutes twice. Then blots were 
incubated for 1 hour in secondary antibody conjugated to horseradish peroxidase 
diluted in 10% blocking buffer. Finally, blots were rinsed three times in TBST and 
washed for 1 hour followed by two washes in TBST for 5 minutes. 
 
 For probing with rabbit non-specific to Apoptin T108 and anti-phospho-Apoptin 
T108 antibodies, blots were blocked for 1.5 hours in 3% BSA in TBST, followed by 
washing in TBST 10 minutes for three times. Blots were then incubated for 1.5 hours in 
either non-specific to Apoptin T108 or rabbit anti-phospho-Apoptin T108 antibody, 
diluted in 3% BSA in TBST, followed by washing in TBST 5 minutes for six times. Then 
the blots were incubated for 1 hour in anti-rabbit secondary antibody conjugated to 
horseradish peroxidase diluted in 3% BSA in TBST. Finally, blots were washed in 
TBST 20-30 minutes for three times. 
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All antibody incubations and wash steps were performed at room temperature 
on a rocking table. For a second probing procedure after ECL visualisation, the blot 
was stripped for 10 minutes in Reblot Plus Strong buffer (Millipore) and rinsed twice for 
5 minutes in blocking solution. 
 
2.2.8.6 Enhanced chemiluminescence 
 
Horseradish peroxidase-conjugated antibody was detected using the enhanced 
chemiluminescence (ECL) method. Prior to use, the reaction solution was prepared by 
mixing 3 µl 30% w/v H2O2, 25 µl coumaric acid and 50 µl luminol to 10 ml ECL buffer. 
The blot was incubated for 1 minute in the reaction solution, drained and then sealed in 
cling film (Saran wrap). A RX autoradiograph (Fuji) was exposed to the nitrocellulose 
membrane for 5 seconds to 20 minutes and subsequently developed.  
 
2.2.9 Transgene expression 
2.2.9.1 Transient expression 
 
Transfection was performed as recommended by the manufacturer (Invitrogen, 
Paisley, UK). For Western blot analysis, cells were plated at a density of 1×105 in a 12-
well tissue culture plate and allowed to attach overnight. 1.6 µg DNA was added to 
OptiMEM to make 100 µl solution and mixed. 4 µl LipofectAMINE 2000 (Invitrogen) 
was added to 100 µl OptiMEM and mixed. The DNA solution was added to the 
lipofectamine solution, gently mixed and incubated at room temperature for 20 minutes 
and the transfection solution was added to the cells. Cells were transfected for 4 hours 
at 37ºC in air with 5% CO2. Transfection solution was then removed, the cells washed 
once with complete medium and cultured in complete medium until analysis. 
 
 For immunofluorescence studies, cells were seeded in Falcon 8-well culture 
slides (Becton Dickinson, Oxford, UK) at a density of 5×104 per well and transfected at 
50-80% confluency. 0.8 μg DNA was added to OptiMEM to make 50 µl solution and 
mixed. 2 µl LipofectAMINE 2000 was added to 50 µl OptiMEM and mixed. The DNA 
solution was added to the lipofectamine solution, gently mixed and incubated at room 
temperature for 20 minutes and the transfection solution was added to the cells. Cells 
were transfected for 5 hours at 37ºC in air with 5% CO2. Transfection solution was then 
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removed, the cells washed once with complete medium and cultured in complete 
medium until fixation and staining. 
 
2.2.9.2 Adenoviral infection 
2.2.9.2.1 Amplification of adenovirus 
 
Amplification of adenovirus was essentially performed as described by Graham 
and Prevec (1991). 293A cells were grown to 90% confluence (in order to obtain 
approximately 1×107 cells) in 100-mm-diameter petri-dishes in DMEM with all the 
supplements. Cells were infected with virus at a multiplicity of infection (MOI) of 1:1 in a 
minimal amount of medium. Supernatant saved from previously infected cells could 
also be used to infect cells. Cells were harvested when a complete cytopathic effect 
(CPE) was visible, with 80-100% of the cells were rounded and 10-20% were floating. 
Cells were lifted from the dish by pipetting gently and collected by centrifuging 10 
minutes at 900 RPM. The supernatant was immediately stored at -70oC for further use. 
The pellet and a few ml of supernatant above the pellet were mixed, snap-frozen in 
cryovials and quickly thawed three times and centrifuged 10 minutes at 13000 RPM at 
4oC. The supernatant containing viruses was carefully removed and either stored at -
70oC until use or used immediately for further infection of 293A cells. 
 
2.2.9.2.2 TCID50 titration of adenovirus by CPE assay 
 
The tissue culture infectious dose50 (TCID50) value is defined from the dilution 
of virus at which there will be a 50% probability of an infectious particle being present. 
293A cells were plated in 96-well plates with 5×104 cells/well in DMEM containing 5% 
FCS. 24 hours later, the cells were infected with adenovirus in log dilutions in a range 
of 1×10-3 – 1×10-10 in DMEM without FCS. Each dilution was added to 10 wells in a 
row. As a control, DMEM without virus was added to the two outer columns of wells. 7 
days after infection, the cells were examined under a light microscope for cytopathic 
effect (CPE). CPE could be detected in a well if the whole cell monolayer or a large 
area of it was lysed. The number of wells showing CPE was scored at each dilution 
from the highest dilution at which all the wells showed CPE downwards. No CPE was 
observed in the control wells. The TCID50 value was calculated using the following 
formula based on the Spearman-Kärber method (Hierholzer and Killington, 1996): 
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Log10TCID50 = Highest dilution giving 100% CPE + 0.25-0.5 (total number of wells with 
CPE/10) 
 
2.2.9.2.3 Adenoviral infection 
 
Cells were plated at a density of 1.9×104 cells in 100 µl per well in 96-well 
plates. After 18-24 hours, adenovirus was diluted in medium and 100 µl was added per 
well in order to infect cells with a MOI of 10 virus particles per cell. Cells were 
incubated at 37°C and 5% CO2 and assayed at 24, 48 or 72 hours after infection. 
 
2.2.10 siRNA and plasmid transfection by Nucleofection 
 
siRNA or plasmid transfection was performed using Amaxa™ Nucleofector™ as 
recommended by the manufacturer (Lonza Biologics, Cambridge, UK). Cells were 
collected by trypsinisation and an aliquot of the cells was counted to determine cell 
density as previously described in Section 2.2.7. The required number of cells was 
centrifuged for 10 minutes at 100 g (IEC Central-4X, Bedfordshire, England). The 
supernatant was removed completely. The cell pellet was resuspended carefully in 100 
μl of Nucleofector® Solution per sample. siRNA (100 nM siRNA control GAPDH or 100 
nM siRNA against the chosen gene) was added in cell suspension. Cell/siRNA 
suspension was transferred into a certified cuvette. The cuvette was inserted into the 
Nucleofector® Cuvette Holder and the selected programme was applied (D-024 for 
Saos-2 cell line, D-032 for HCT116 cell line and U-023 for 1BR3) by pressing the X-
button on the Nucleofector® I Device. Once the programme was completed, the 
cuvette was taken out of the holder and immediately 500 μl of the pre-equilibrated 
culture medium was added to the cuvette and the sample was gently transferred into 
the prepared 12 well plate (final volume 1 ml media per well). At 48 hours of siRNA 
transfection, cells were infected with either Ad-Apoptin or Ad-GFP or left untreated or 
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2.2.11 siRNA library (Dharmacon) 
 
HCT116 cells were seeded and treated as per manufacturer’s instructions. 
Optimisation of reagents and conditions of culture were performed as described, with 
quantification of gene silencing analysed using the Quantigene branched DNA 
(Panomics, Affymetrix, Cat# SA-10001-01, SA-10003-01, SA-24984-08) method. 
Branched DNA assays require the use of DNA as a method of amplifying a signal. 
Probe set oligonucleotides bind a contiguous region of the target RNA and signal 
amplification is performed by sequential hybridisation of branched DNA to the probe 
sets. Addition of a chemilumigenic substrate generates a luminescent signal 
proportional to the amount of target RNA present in the sample. Protocols were 
provided by the manufacturer and followed exactly. Dharmafect transfection reagent 4 
was used with a HCT116 cell seeding density of 5x103 per well in 96-well library plates.   
2.2.12 Immunoprecipitation protocol 
 
 Cells were transiently transfected with indicated plasmids using lipofectamine 
2000 (Invitrogen) and were harvested 48 hours after transfection. Cells were washed 
twice with PBS and lysed on ice in a solution containing 50mM Tris-HCl (pH 8.0), 150 
mM NaCl, 1mM EDTA (pH 8.0), 100 mM NaF, 10% glycerol, 1mM MgCl2 , 1% Triton X-
100 and complete protease inhibitors (Roche). Immunoprecipitations were performed 
by incubating whole-cell extracts with the indicated antibodies prebound to protein A or 
G-Agarose beads (Roche). Then the immunoprecipitates were mixed gently for 2 hours 
at 4°C, washed 4 times in lysis buffer and denatured in Laemmli buffer. 
2.2.13 Indirect immunofluorescence staining 
 
Cells were seeded in Falcon 8-well culture slides at a density of 5×104 cells/well 
(for transfection) or 1.9×104 cells/well (for infection). At 24 or 48 hours post-treatment, 
cells were washed in PBS and directly fixed in 2% paraformaldehyde for 30 minutes, 
washed three times in PBS and permeabilised in 0.2% Triton X-100 for 15 minutes at 
room temperature. After washing the cells three times in PBS, they were blocked for 30 
minutes in 3% bovine serum albumin (BSA) in PBS and then incubated for 1 hour at 
room temperature in primary antibody, diluted in 3% BSA in PBS. The cells were 
washed twice in PBS and incubated for 1 hour at room temperature in secondary 
antibody, diluted in PBS. For detection of GFP, cells were fixed in 2% 
paraformaldehyde for 30 minutes and permeabilised in 0.2% Triton X-100 for 15 
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minutes at room temperature. Subsequently, cells were mounted in Vectashield 
mounting medium (Vector Laboratories, Peterborough, UK) containing 4’, 6-diamidino-
2-phenylindole (DAPI) to stain nuclei. Cells were visualised using an Olympus BX61 
fluorescence microscope. Digital images were taken using Cell^F software (Olympus, 
Japan). 
 
2.2.14 MTT cell proliferation assay 
 
Cells were seeded in 96-well plates at a density of 5×103 cells per well. Cell 
viability was measured at different time points depending on the experiment. The total 
volume per well before adding the MTT solution did not exceed 100 µl. Briefly, 20 µl of 
5 mg/ml MTT in PBS was added to each well. Cells were incubated with the MTT 
compound for 2-4 hours at 37oC and 5% CO2 after which 150 µl of solubilisation 
solution was added to each well. The plates were incubated for a further 16-24 hours 
and the OD595 was measured using a Bio-Rad model 3550 microplate reader. 
 
2.2.15 CellTiter-Glo® viability assay (Promega) 
 
Cells were seeded at 5×103 cells per 100 µl/well in 96-well plates. After 24 
hours, adenovirus was diluted in medium and 100 µl was added per well in order to 
infect cells. Cells were incubated at 37ºC and 5% CO2 and viability was measured at 
24, 48 or 72 hours after infection. Equilibration of the sample plate at room temperature 
for 30 minutes was required, followed by addition of 100μl of premixed CellTiter-Glo® 
reagent. The contents were mixed for 2 minutes and the plate was incubated for 10 
minutes at room temperature. The luminescence was then measured using a glomax 
96-well luminometer (Promega).    
 
2.2.16 Cell cycle analysis by flow cytometry 
 
Cells were plated in 12 well plates and infected with adenovirus at a MOI of 40. 
The samples were collected at 24 and 48 hours post-infection. Cells were fixed in 70% 
ethanol for a minimum of 2 hours at -20 ºC. Before staining with PI, the cells were 
centrifuged for 10 min at 100 g (IEC Centra-4X, Bedfordshire, England), the ethanol 
was decanted and the cell pellet was suspended in PI FACS staining solution. The 
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samples were incubated at 37°C for 30 min then analysed on FACSCanto within 24 
hours. 
 
2.2.17 Cell death analysis by flow cytometry 
 
Cells were plated in 12 well plates and transfected for 24 hours prior to infection 
with adenovirus at a MOI of 40. The samples were collected at 24, 48 and 72 hours 
post-infection. Cells were trypsinised and centrifuged for 10 min at 100 g (IEC Centra-
4X, Bedfordshire, England); pellets were resuspended in 100 μl Annexin V buffer and 
incubated at room temperature for 20 min. At least 10 min prior to analysis, 5 μl of PI 
solution was added to each sample and 100 μl of Annexin V binding buffer was added. 




















2.2.18 Statistical analyses 
 
For statistical analyses, the student t test was carried out. Statistically 
significant difference was defined as P<0.05. 
Figure 2.1 FACS data analysis example graph. Example analysis of FACS cell death data 
where Q1 is necrosis, Q2 is late apoptotis, Q3 is early apotosis and Q4 is live cells. PerCP-Cy5-
5-a indicates levels of PI staining, and APC-A indicates levels of Annexin V staining. Cells 
with high levels of PI were considered to be dead or necrotic, cells with high levels of Annexin 
V were considered to be undergoing early stages of apoptosis and cells showing high levels of 
both dyes were marked as undergoing late apoptosis.   
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Chapter 3 
Identification of the tumour specific Apoptin kinase/s 
3.1 Introduction 
 
There are clear differences in Apoptin subcellular localisation between tumour 
and normal cells. Nuclear aggregation is observed in transformed cells whilst in normal 
cells, the protein is predominantly cytoplasmic (Guelen et al., 2004). The ability of 
Apoptin to translocate to the nucleus is due to the two nuclear localisation signals 
(NLS1 and NLS2) found in its basic structure (Danen-Van Oorschot et al., 1997).  
 
In addition to the bipartite NLS, the 74-121 domain of Apoptin also contains a 
putative nuclear export sequence (NES), which suggests the ability to migrate not only 
to, but also from the nucleus (Poon et al., 2005). The C-terminal part of the protein 
contains a NLS with a phosphorylation site (threonine 108), that enables interaction 
with other proteins and modifications by kinases. This threonine phosphorylation is 
specific to tumour cells (Rohn et al., 2002; Rohn et al., 2005), where the protein 
localises to the nucleus and induces apoptosis. Phosphorylation of this threonine 
residue appears to be important for Apoptin cytotoxicity (Rohn et al., 2005). 
Substitution of threonine residue 108 with glutamic acid removed Apoptin’s tumour 
specificity, causing it to aggregate in the nucleus of normal cells and induce apoptosis 
(Rohn et al., 2002; Zhuang et al., 1995b).   
 
Importantly, phosphorylation of Apoptin on threonine 108 occurs specifically in 
tumours suggesting tumour specific kinase activity is involved in determining apoptotic 
response to the protein. Identification of such Apoptin kinase/s would therefore prove 
useful in developing greater understanding of Apoptin function and the mechanism of 
action, and could also lead to the development of cancer specific therapeutics.      
 
To identify potential serine/threonine kinases for Apoptin phosphorylation, a 
siRNA library screen of 54 targets was used to knockdown kinases from the MAP 
kinase family. Cells were subsequently infected with an Apoptin expressing adenovirus 
and an MTT assay was performed to analyse any effects on Apoptin induced cell 
death.       
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3.2.1 Selection of a suitable cell line for a siRNA library screen for the         
identification of Apoptin kinase/s 
 
The aim of these experiments was to determine variables for a human MAP 
kinase siRNA library, targeting 54 cell cycle checkpoint kinases known to have aberrant 
activity in cancer. This library was to be used in conjunction with Apoptin expression to 
identify which kinases play a role in Apoptin induced cytotoxicity. Specific factors were 
required for successful knockdown of the target genes and subsequent infection with 
Apoptin expressing adenovirus within a limited time span. A short treatment interval 
was important in order to measure the effect on Apoptin induced cytotoxicity, while 
ensuring the optimal knockdown of kinase expression by the siRNAs.  
 
Initial studies investigated the current assays available for detecting changes in 
cellular viability. The MTT assay and Cell titre glo assay (Promega) were used in these 
experiments. The purpose of testing two viability assays was to determine the most 
sensitive measurement of Apoptin induced cell death. This, in combination with the 
siRNA library kinase knockdown, was used to ultimately attempt to detect the kinase/s 
involved in Apoptin cytotoxicity.  
 
As a control, a chemotherapeutic drug (cisplatin) was added to Saos-2 cells and 
the cytotoxicity measured using MTT assay. The results (Figure 3.1) show that cisplatin 
efficiently kills Saos-2 cells when applied at concentrations of 20μg/ml or higher. At 24 
hours, a loss of cellular viability of 40% was observed, and this result was similar using 
both assays (MTT and Cell titre glo). At a time point of 48 hours, the induction of cell 
death was further increased to 70%, again seen with both viability assays. From the 
results of the cisplatin treatment, the study investigated the sensitivity of a variety of 
cell lines towards Apoptin expression using adenoviral vectors. Saos-2 cells were 
tested first (Figure 3.2 and 3.3) and it could be seen that this particular cell line was not 
responsive to cell death induced by Apoptin in a short timeframe. At 72 hours with an 
MOI of 5-10, minimal cell death was observed (15-20%) when compared to the control. 
Another cell line, H357 cells, were infected with adenoviral and lentiviral vectors (Figure 
3.4) and a drop in viability of 5-10% was evident when H357 cells were infected with 
MOI of 10 after 72 hours, with the result being the same in both assays.   
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 As the H357 and Saos-2 cell lines were found to be resistant to Apoptin induced 
cytotoxicity within the required timepoint another cell line, HCT116, was used. The 
results in Figure 3.5 clearly show that, at an MOI of 20, HCT116 cells lost cellular 
viability by 25% after 24 hours post infection. After a longer time point of 48 hours, cell 
death had increased to almost 50%. The results described were similar using both 
viability assays, but cell titre glo detected 15% more killing after 48 hours than MTT. 
These results highlight the HCT116 cell line as a suitable candidate for use with the 
kinase siRNA library. The MTT assay was chosen for the library screen as it gave the 














































Figure 3.1 Comparison of two viability assays. MTT and cell titre glo assays comparing cellular killing of 
Saos-2 cells by varying concentrations of cisplatin. Normalised to control values. Error bars indicate 



































































































































































Figure 3.2 Infection of Saos-2 cells with ad-Apoptin. MTT analysis and cell titre glo results for Saos-2 
cells infected with increasing MOI of adenoviral Apoptin at 72 hours post infection. Normalised to control 














































































































































































Figure 3.3 Infection of Saos-2 cells with ad-Apoptin. MTT analysis and cell 
titre glo results for Saos-2 cells infected with MOI 40 of adenoviral Apoptin at 
72 hours post infection. Normalised to control values. Error bars indicate 





































































































































































Figure 3.4 Infection of H357 cells with adenoviral Apoptin and lentiviral 
Apoptin. MTT analysis and cell titre glo results for H357 cells infected with 
MOI 10 of adenoviral Apoptin and MOI 8 of lentiviral Apoptin at 72 hours 
post infection. Normalised to control values. Error bars indicate standard 
deviation. n=3.  
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Figure 3.5 Infection of HCT116 cells with adenoviral Apoptin. MTT analysis and cell titre glo results for 
HCT116 cells infected with MOI 20 of adenoviral Apoptin at 24 and 48 hours post infection. Normalised to 
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3.2.2 Optimisation of reagents and siRNA controls for the siRNA library using 
HCT 116 cell line 
 
In order to complete the siRNA library protocol, experimental design 
optimisation was required for the desired cell line. The first optimisation protocol 
determined the best transfection reagent and its optimum concentration from a panel of 
4 separate Darmafect (DF) transfection reagents (DF1, DF2, DF3 and DF4) that would 
provide the highest transfection efficiency and the lowest cytotoxicity.  
 
Using MTT assay, cellular viability was measured after 48 hours of treating the 
cells with 4 different transfection reagents at different concentrations. A control siRNA 
for GAPDH was used. To analyse the transfection efficiency and knockdown efficiency 
of the reagents, we used a branched DNA kit (Quantigene) from Panomics, Affymetrix 
that produces a luminescent signal when bound to the target DNA.  
 
As shown in Figure 3.6A, the highest recorded knockdown of GAPDH, also 
induced a high level of cytotoxicity in the cells. In order to compromise the siRNA 
knockdown with the survival of the cells, a concentration providing the highest cellular 
viability and the greatest knockdown of the target gene was required. Analysis of 
Figures 3.6A and 3.6C, determined that 0.025μl of reagent 4 was sufficient to provide 
an efficient level of knockdown with minimal cytotoxicity.       
 
Control siRNA for the siRNA library was chosen by knockdown of three 
separate housekeeping genes as the protocol for optimisation of siRNA library kit 2A 
recommends. Using a 96-well plate of siRNAs, siRNA efficiency was analysed using 
three genes at different cell densities and differing volumes of transfection reagent 4. 
Cells were once again incubated for 48 hours prior to knockdown analysis using the 
previously described Quantigene kit. Results show that at a low cell density and a 
reagent concentration of 0.025μl, GAPDH induced knockdown at the highest efficiency 
with minimal off target effects (Figure 3.7A) when compared to Lamin A/C (Figure 3.7B) 















































Figure 3.6 Optimisation of HCT116 cells with increasing concentrations of 4 different 
transfection reagents. MTT assays of HCT116 cells treated with control GAPDH siRNA (A) 
and negative control scrambled siRNA (B) showing cellular viability after 48 hours (n=1). 
Quantigene analysis of GAPDH knockdown by RNA expression (C). Normalised to control 
values. Error bars indicate standard deviation. DF1, DF2, DF3 and DF4 are the 4 different 
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Figure 3.7 Optimisation of HCT116 cells with control genes. Quantigene analysis showing percentage 
knockdown of HCT116 cells exposed to siRNA against GAPDH (A), Lamin A/C (B) and Cyclophilin B 
(C). Variation in cell density (low cell density 5x103, and high cell density 10x103) and Darmafect reagent 
concentration were employed. Normalised to control values. Error bars indicate standard deviation. DF1, 
DF2, DF3 and DF4 are the different Darmafect transfection reagents used for optimisation.  
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3.2.3 Determination of kinase/s involved in Apoptin cytotoxicity 
 
Once optimisation of the library controls and reagents was completed, the 
siRNA library screen was performed. MTT analysis of HCT116 cells infected with ad-
Apoptin at MOI 20 for 24 hours showed that with the kinases targeted in this library, no 
significant difference in Apoptin cytotoxicity could be determined (Figure 3.8).  Although 
variation is seen across the genes knocked down, no particular gene was found to 





























































Figure 3.8 Percentage cellular viability of HCT116 cell line after knockdown of various kinases. MTT assay showing effect on apoptin cytotoxicity of knockdown of 
the kinases in the siRNA library.  A = the first 27 kinases, B = the second 27 kinases of the library screen. The first 7 bars are controls. Normalised to control value. Error 
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3.2.4 Further investigation of the Apoptin specific kinase 
 
Collaborative studies using a microarray method identified potential Apoptin 
candidate kinases in Multiple Myeloma (MM1) cell lines (Jiang et al., 2010b). A pair of 
Multiple Myeloma cell lines derived from the same cancer has been conditioned to be 
more resistant to Dexamethasone (MM1R) with the other being more sensitive 
(MM1S). These cells have different sensitivity to Apoptin which is inversely proportional 
to their Dexamethasone sensitivity. Microarray analysis found PKCβ1 was amongst the 
most differentially expressed kinase in MM1R compared to MM1S by approximately 7-
fold. In addition, MERTK (a receptor tyrosine kinase) and DGKH (a kinase involved in 
the conversion of diacylglycerol into phosphatidic acid) were also found to be 
overexpressed in MM1R compared to MM1S. This result was then verified by Q-RT-
PCR and the microarray data was confirmed (Figure 3.10) with a 6-fold overexpression 
of PKCβ1 in MM1R. This kinase was further studied, and interaction between Apoptin 
and PKCβ1 was shown by immunoprecipitation studies and increased phosphorylation 
of Apoptin when PKCβ1 was overexpressed (Jiang et al., 2010b). This observation was 
further reinforced by the kinase prediction assay, described below, which identified a 
potential phosphorylation site by PKCβ1 (Figure 3.9) in close proximity to Threonine 
108.  
 
In order to confirm the relevance of potential target kinases in Apoptin 
phosphorylation or to identify other potential candidates, a kinase prediction assay 
(Figure 3.9) was performed using the Apoptin protein sequence that looks at 
phosphorylation sites of a protein and predicts potential kinases that may have target 
motifs in the sequence.  
 
To confirm these findings in different cell lines and to investigate other potential 
kinases, a HCT116 group of 3 knockout cell lines were studied. The HCT116 cells used 
for this study have knocked down expression of p53 and PUMA, a key mediator of p53-
dependent apoptosis. These cell lines have different sensitivities to Apoptin, compared 
to HCT116 wild type (wt), and so were chosen for the microarray analysis. The 
differences in sensitivity are shown in Figure 3.11, where it can be seen that HCT116 
p53-/- are the most sensitive cells to Apoptin induced cytotoxicity, with the PUMA-/- cell 
line displaying the most resistance to Apoptin. However, this is not significantly greater 
than in HCT116 wt. Due to the largest differences in Apoptin cytotoxicity being 
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observed between the PUMA-/- and the p53-/- cell lines, analysis of the microarray data 
was based on this pair. Table 1 shows that of all the genes that were differentially 
expressed between these two cell lines, only 5 kinases were up or down regulated by a 
magnitude of 2 or above. These candidate kinases were further investigated by 
analysing the sequence homology and potential phosphorylation motifs for these 
kinases on the Apoptin sequence (Figure 3.9). The analysis coupled with findings from 
our collaborative work found that the kinases that were flagged by the microarray were 
not relevant to Apoptin phosphorylation in this system. By using the microarray data, it 
was also possible to further analyse the targets knocked down using the siRNA library. 
Figure 3.12 shows that the kinases that were targeted by the library had little or no 
difference in expression between the Apoptin resistant and sensitive cell lines, with a 
maximum change of 2-fold in kinase expression.  
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Figure 3.9 Kinase prediction assay data. Data from the online kinase prediction software detailing 
kinases with potential phosphorylation motifs in the Apoptin sequence.  
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Figure 3.10 Fold expression of the three most differentially expressed kinases in MM1 cells 
validated by Q-RT-PCR. Quantification of Q-RT-PCR data showing the differences in 
expression of PKCβ1, DGKH and MERTK between MM1R and MM1S cells.   
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Table 2 Microarray kinase analysis of HCT116 panel of knockout cell lines 
Kinases 
overexpressed in 










ARAF 4.23 CHPT1 3.02 
NME1 3.27 CAMK2D 2.63 
SYK 3.02 LMTK3 2.37 
CDC7 2.68 PCK2 2.29 
TTK 2.52 TRIB3 2.28 
PLK4 2.31 SGK 2.24 
YES1 2.11 DDR1 2.24 

















Table 3 Microarray kinase analysis of HCT116 panel of knockout cell lines 
Kinases 
overexpressed in 










SYK 2.77 MAP4K1 2.47 
CTBP1 2.60 PRKCZ 2.44 
CSNK2A1 2.38 PCTK3 2.33 
DPAGT1 2.17 RPS6KA2 2.23 
TCEAL8 2.10 CDC2L6 2.21 
DCK 2.10 NME7 2.11 
ANP32C 2.08 ULK1 2.07 
PRKAR1B 2.07 NUAK1 2.03 
MPHOSPH10 2.03 MAST1 2.01 
















Figure 3.11 HCT116 panel of knockouts tested for Apoptin sensitivity. MTT analysis 
showing differing sensitivity to Apoptin after 4 days of three HCT116 cell lines used for the 
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Kinase expression differences in HCT116 wt vs p53 -/-
Figure 3.12 Expression profile of the kinases targeted in the siRNA library. Quantification of the microarray analysis of only the kinases targeted by the siRNA library 
showing minimal differences in expression between the Apoptin sensitive and resistant cell lines. 
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Kinase expression differences in HCT116 PUMA -/- vs wt
Figure 3.13 Expression profile of the kinases targeted in the siRNA library. Quantification of the microarray analysis of only the kinases targeted by the siRNA library 
showing minimal differences in expression between the Apoptin sensitive and resistant cell lines. 
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Kinase expression differences in HCT116 PUMA -/- vs p53 -/-
Figure 3.14 Expression profile of the kinases targeted in the siRNA library. Quantification of the microarray analysis of only the kinases targeted by the siRNA library 
showing minimal differences in expression between the Apoptin sensitive and resistant cell lines. 
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3.3 Discussion and Conclusions 
 
The focus of this work was to determine kinase activity involved in Apoptin 
cytotoxicity specific to tumour cells using different approaches. Initial studies to 
determine the effectiveness of the two cell viability assays showed minimal difference 
in cell death using cisplatin. However, once infection with Apoptin adenoviral vectors 
was studied, variation in the two viability assays was observed. The decision to use 
MTT for the future viability assays was due to lack of consistency when using cell titre 
glo for viral infection. Explanation of the observed variation in measurements could be 
attributed to the differing methods by which the cell titre glo assay records cellular 
viability. This assay determines the number of viable cells in culture based on the 
concentration of ATP, as an indicator of metabolically active cells. MTT also functions 
by a similar method, however, the result is determined by the actual process of 
metabolism as opposed to a by product of metabolism.  
 
Further MTT cellular viability assays showed that from a group of candidate cell 
lines, HCT116 cells were most suitable for the siRNA library screen. Limitations in 
siRNA technology meant that a window of 72 hours was available once the cells were 
treated with siRNA before the effects of the interference were lost. The intention of this 
experiment was to find a cell line that could be infected with Apoptin and show the most 
significant killing compared to controls in a time point of 48 hours. This would ensure 
that silencing of the particular genes of interest was still at the maximum possible level 
during treatment with Apoptin, avoiding false results.  
 
The siRNA library analysis of HCT116 cells infected with Apoptin showed no 
significant effects of kinase knockdown on Apoptin sensitivity by MTT analysis when 
compared to controls for Apoptin mediated cell death. Variation in cellular viability is 
seen amongst the different kinases silenced; however, this variation is attributable to 
the kinase knockdown itself. This library targets the p38 MAPK signalling pathway 
family of kinases which has been implicated in a range of responses from apoptosis to 
cell cycle regulation, differentiation, survival and transformation (Whitmarsh and Davis, 
1996). As it covers a wide range of functions within the cell, knockdown of members of 
this pathway would have effects resulting in observations such as reduced viability, 
seen in Figure 3.8. The decision to use such a library for the present study originated in 
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published work on p38 MAPK signalling and its involvement in cancer (Loesch and 
Chen, 2008; Taylor et al., 2008).  
 
Studies have shown that Apoptin, once in its active form in a transformed cell, 
initiates cell cycle arrest at the G2/M checkpoint, before inducing apoptosis (Teodoro et 
al., 2004a). This G2 arrest could be linked to the MAPK signalling pathway as studies 
have shown that G2 phase arrest requires the phosphorylation of p38 MAPK after 
gamma radiation (Wang et al., 2000) and exposure to ultraviolet light (Bulavin et al., 
2001). Another tumour-specific protein, HAMLET, also induces apoptosis in 
transformed cells and this cytotoxicity has been linked to the MAPK signalling pathway 
(Cuadrado et al., 2007). As an initial library for identifying some targets for further 
study, the MAPK library was considered a good candidate, even though a full human 
kinome library was available. The library including all known human kinases could have 
identified the Apoptin kinase or kinases. However, the high throughput nature of such a 
study would have made a full kinome library open to larger discrepancies and errors. 
The human kinome library covers over 700 targets, as opposed to the 54 available in 
this library, and a large number of these would be irrelevant, as was seen here. Further 
investigation of an Apoptin specific kinase would therefore need to be more specific to 
allow identification of true targets, for example a more in depth focus on a smaller 
number of kinases. 
 
In addition to PKC and PKG being flagged in the kinase prediction software 
(Figure 3.9), a number of other kinases were also predicted to have some association 
with Apoptin. Specifically CDK5 was found at T108, the residue thought to be important 
for Apoptin tumour specificity. However, because this kinase is found mostly active in 
the nervous system and is involved in development of neurons it was dismissed during 
this study to focus on what appeared to be more relevant targets: PKC and PKG 
(Cheung and Ip, 2004; Huang et al., 2010; Zhang et al., 2008). Interestingly, when 
analysing the data for the kinase prediction assay, p38MAPK was flagged as a 
potential kinase with a consensus motif in the Apoptin sequence. The particular motif 
was not the T108 residue and, in addition to the siRNA library data, any potential 
relevance of this kinase and its pathway was ruled out.  
 
The microarray analysis of the Apoptin sensitive and more resistant HCT116 
cell lines, failed to uncover any kinases with a significant difference in expression as 
was found using the multiple myeloma model cell lines (Jiang et al., 2010b). Any 
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kinases that were flagged had no potential known links to Apoptin in terms of potential 
phosphorylation motifs and target interaction. PKCα, for example, was shown not to 
interact with Apoptin in IP studies (Jiang et al., 2010b) whereas PKCβ1 was found to 
be important for Apoptin phosphorylation, but was not flagged in the microarray 
analysis. In addition, neither DGKH nor MERTK were flagged in the microarray 
analysis of HCT116 cells whereas they were significantly differentially expressed along 
with PKCβ1 in the multiple myeloma studies.  
 
Further to analysing the total kinase expression, the siRNA targets were also 
investigated for differential expression between the HCT116 cell lines. Figures 3.12, 
3.13 and 3.14 show the data for this analysis which highlights the lack of significant 
change in expression of these kinases between the cell lines, further suggesting that 
the library was not relevant to this current study.  
 
The results of the microarray in addition to the siRNA library analysis show that 
there is no significant difference in kinase expression between the two cell lines with 
respect to their sensitivity to Apoptin. These particular cell lines have knocked down 
expression of p53 and p53 target, PUMA, which are important in apoptosis. The 
differences seen in Apoptin sensitivity could more likely be attributed to the abrogated 
expression of p53 proteins, and the subsequent effects of that modulation. However, it 
has been shown by many studies (Backendorf et al., 2008a; Schoop et al., 2004; 
Zhuang et al., 1995b) that Apoptin induced apoptosis is a p53 independent mode of 
cell death, as cell lines without p53 are shown to be sensitive to Apoptin, as is shown 
by this study. Cisplatin induced apoptosis, which is shown to be p53 dependent 
(McCurrach et al., 1997; Vasey et al., 1996), is affected by knockdown of p53 in this 
study (Figure 3.9) where p53-/- cells are more resistant to cisplatin’s effects than the wt 
or PUMA-/- cells. Because of these findings it was considered that these cell lines would 
be good candidates for the study of kinase expression related to Apoptin sensitivity.                    
       
As an alternative to the microarray and siRNA library, Figure 3.9, the Apoptin 
kinase prediction assay highlighted a number of potential kinases for investigation, one 
such kinase was PKG. According to the data presented in Figure 3.9, PKG has 
potential phosphorylation sites on Apoptin at different residues to the T108 site. 
Interestingly, studies have suggested an involvement of PKG in the transition from 
normal to transformed cells. More specifically, PKG expression is shown to be lost 
once a cell becomes transformed or tumourigenic (Fujii et al., 1995b; Kwon et al., 
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2008a). Due to the characteristic expression of PKG in Apoptin resistant cell lines, it 
was hypothesised that this kinase could have a function regulating Apoptin induced cell 
death.  
 
In summary, the data presented here describes PKCβ1 and more tentatively, 
PKG as potential interacting kinases that could affect the cytotoxic ability of Apoptin in 
different cell lines. The expression of kinases could be overlooked in this particular 
study as the relevance appears to be minimal. As with many proteins that are shown to 
have similar transcriptional activity, this does not always equate to similar protein 
expression levels, and, with regards to kinases, potential activity. In the multiple 
myeloma model cells; however, PKCβ1 transcriptional activity and protein expression 
level did correlate with the kinase’s potential effect on Apoptin cytotoxicity. However, 
the difference in PKCβ1 expression between Apoptin sensitive and resistant cells was 
significantly different. In the HCT116 study, no such kinase was found to be expressed 
significantly higher in the more sensitive cell lines, indicating that kinase expression 
levels alone may not be sufficient as a marker for Apoptin sensitivity in this particular 
model. Further investigation will include PKCβ1 and PKG and their interaction and 
effect on Apoptin induced cell death. 
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Chapter 4 
Characterisation of PKG and PKC in normal and tumour cells in 
relation to Apoptin sensitivity 
4.1 Introduction 
 
Kinases are a group of enzymes that catalyse many reactions involved in 
cellular signalling by phosphorylating a multitude of targets including structural proteins, 
signalling molecules and other kinases. Previously, it was explained that Apoptin is 
phosphorylated on a threonine residue in transformed cells. This prompted the current 
study to pursue serine/threonine kinases as potential targets for Apoptin 
phosphorylation. One potential serine/threonine kinase implicated by our work is 
PKCβ1 (Jiang et al., 2010b).  
 
Studies from our group showed that PKCβ1 (a classical PKC isoform) was 
implicated in Apoptin induced apoptosis in transformed cell lines, where there was 
clear evidence of interaction with Apoptin (Jiang et al., 2010b). In order to further 
investigate the potential significance of PKCβ1 in Apoptin induced apoptosis, cell 
specific expression and localisation of PKCβ1 was studied with respect to Apoptin 
sensitivity.   
 
Apoptin phosphorylation motif prediction studies highlighted a further 
serine/threonine kinase, PKG, as a potential Apoptin kinase. This kinase family is 
responsible for a wide range of physiological processes including, cell motility, gene 
expression and apoptosis. A recent study has shown that PKG-I is involved in the wnt 
signalling pathway and is a potential regulator of β-Catenin signalling (Kwon et al., 
2010). In other studies PKG-I expression has been shown to be lost in cells that have 
become transformed or tumourigenic (Hou et al., 2006), this phenomenon is also 
observed during the passaging of certain primary cell lines (Lin et al., 2004b). PKG-I is 
noted for its anti-tumour characteristics and the ability to induce growth arrest or 
apoptosis in a variety of tumour cell lines (Chan and Fiscus, 2003; Deguchi et al., 2004; 




  Chapter 4: Results II 
 
Based on our initial findings of the kinase prediction assay for Apoptin and the 
studies described above, we decided to further study PKG-I as a potential negative 
regulator of Apoptin sensitivity. Expression and localisation of PKG-I in tumour and 
normal cells and the effect on Apoptin sensitivity was investigated.      
 
4.2 Results 
4.2 Analysis of expression of PKG-I and PKCβ1 in normal and tumour cell 
lines 
 
 The aim of the following experiments was to determine expression 
characteristics of a selection of matched pairs of normal and tumour cell lines. This was 
done using Western blot analysis to investigate the relative levels of PKG-I and PKCβ1 
proteins.  
4.2.1 Expression of PKG-I and PKCβ1 in Multiple Myeloma cell lines 
 
Using the Multiple Myeloma matched pair cell lines described in Chapter 3, 
expression of PKG-I and PKCβ1 proteins was evaluated. According to Western blot 
analysis (Figure 4.1), which is confirmed by the Q-RT-PCR in Chapter 3, PKCβ1 is at a 
higher level in MM1R cells compared to MM1S. PKG-I expression, in contrast, is 








































































Figure 4.1 PKG-I and PKCβ1 expression in MM1R and MM1S cell lines. 
Determined by Western blot analysis (A) and quantification, using ImageJ 
software, of expression (B). Cells were grown for 72 hours. Blots in (A) are from 
the same blot, but were modified to remove unrelated data. Blots were exposed 
for 1 minute each probe. PKG-I and PKCβ1 were analysed from the same blots 
where PKG-I was probed first. Β-Actin was probed once at the same time as 
PKG-I. ImageJ quantification was performed by measuring the area and density 
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4.2.2 Expression of PKG-I and PKCβ1 in Head and Neck cancer cell lines  
 
 
Head and Neck squamous cell carcinoma (HNSCC) cell lines were also used to 
investigate differences in the expression of PKG-I and PKCβ1 proteins. Four pairs of 
primary and metastatic HNSCC cell lines were used to analyse changes in kinase 
expression in relation to metastatic status. Western blot analysis found that in general, 
the more metastatic of each paired cell line expressed higher levels of PKCβ1, 





















































Figure 4.2 PKG-I and PKCβ1 expression in Head and Neck cancer cell 
lines. Determined by Western blot analysis (A) and quantification, using 
ImageJ software, of expression (B). Pairs of parental and their more 
metastatic tumour cell lines were used, where a = parental and b = 
metastatic. HSC-3 is parental and HSC-3M3 is metastatic. Cells were 
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4.2.3 Expression of PKG-I and PKCβ1 in Colon cell lines 
 
 HCT116 colon carcinoma and NCM460 normal colon cell lines were studied for 
expression of PKG-I and PKCβ1 proteins in relation to their transformed and normal 
cell status. Western blot analysis showed that the HCT116 tumour cell line had 
increased levels of PKCβ1 protein when compared to the normal NCM460 cells (Figure 
4.3) whilst PKG-I expression seemed to be higher in NCM460 cells compared to 































































Figure 4.3 PKG-I and PKCβ1 expression in HCT116 tumour cells and NCM460 
normal cells. Determined by Western blot analysis (A) and quantification, using ImageJ 
software, of expression (B). Cells were grown for 72 hours. The figure in panel A is 
constructed from the same blot, but modified to remove unrelated data. Blots were 
exposed for 1 minute each probe. PKG-I and PKCβ1 were analysed from the same blots 
where PKG-I was probed first. Β-Actin was probed once at the same time as PKG-I. 
ImageJ quantification was performed by measuring the area and density of each band 
and comparing them with the B-Actin control.       
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4.2.4 Expression of PKG-I and PKCβ1 in Colon cell lines 
 
 HCT116 cell lines with loss of p53 or PUMA expression were studied for their 
sensitivity to Apoptin induced cell death, as described in Chapter 3. In order to further 
examine the relationship between the sensitivity of these cells and the expression of 
PKG-I and PKCβ1, Western blot analysis was used (Figure 4.4). The results in Figure 
4.4 show that PKCβ1 is expressed at a higher level in all cell types in this panel 
compared to PKG-I, which has an expression level below the level of detection. 
However, the variation in the expression of PKCβ1 does not appear to correlate with 
Apoptin sensitivity in this panel (Figure 3.11).  
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Figure 4.4 PKG-I and PKCβ1 expression in HCT116 wild type and knockout for p53 
and PUMA cell lines. Determined by Western blot analysis (A) and quantification, using 
ImageJ, of expression (B). Cells were grown for 4 days. The figure in panel A is 
constructed from the same blot, but modified to remove unrelated data. Blots were 
exposed for 1 minute each probe. PKG-I and PKCβ1 were analysed from the same blots 
where PKG-I was probed first. Β-Actin was probed once at the same time as PKG-I. 
ImageJ quantification was performed by measuring the area and density of each band and 
comparing them with the B-Actin control.       
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4.2.5 Expression of PKG-I and PKCβ1 in Primary Fibroblast cell lines 
 
 1BR3 primary fibroblast cell line and its isogenic match the SV40 Large T 
transformed 1BR3 cell line (1BR3LT) were analysed for PKG-I and PKCβ1 protein 
expression using Western blot. PKCβ1 was more highly expressed in 1BR3LT 
compared to 1BR3 in contrast with PKG-I which showed reduced expression in 





















































Figure 4.5 PKG-I and PKCβ1 expression in normal and transformed fibroblasts. 
Determined by Western blot analysis (A) and quantification, using ImageJ software, of 
expression (B). Cells were grown for 72 hours. Blots were exposed for 1 minute each 
probe. PKG-I and PKCβ1 were analysed from the same blots where PKG-I was probed 
first. Β-Actin was probed once at the same time as PKG-I. ImageJ quantification was 
performed by measuring the area and density of each band and comparing them with the 
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4.3 Relative Apoptin sensitivity and relation to expression of PKG-I and 
PKCβ1  
 
 Using a combination of FACS, Western blot and MTT assays, Apoptin 
sensitivity of the paired cell lines was studied and compared with their expression of 
PKG-I and PKCβ1. The objective was to determine whether there is any correlation 
between the expression of these kinases and Apoptin sensitivity in the cell lines tested.  
 
 The first cell lines tested were the multiple myeloma pair, the MM1R and 
MM1S. The relevance of PKCβ1 in Apoptin sensitivity in this model was previously 
confirmed using Q-RT-PCR (see Figure 3.10). Using Western blot analysis (Figure 4.6) 
showed higher PARP cleavage in MM1R compared with MM1S 72 hours after infection 
with a Lentiviral vector expressing Apoptin. This indicated a marked increase in 
apoptosis in MM1R, suggesting greater sensitivity to Apoptin compared to MM1S. 
Interestingly, there was a lower level of Apoptin expression in MM1S cells, possibly 
suggesting increased degradation of Apoptin in this less sensitive cell line. The levels 
of GFP expression were similar in the two cell lines. This result coincides with 
increased expression of PKCβ1 in this cell line, shown in Figure 4.1. PKG-I expression 
in either cell line was found to be very low (Figure 4.1) and did not appear to correlate 
with sensitivity to Apoptin in this model.  
 
 The Head and Neck cancer cell lines showed a variation in Apoptin sensitivity 
between the pairs of cell lines relative to their status as metastatic. Figure 4.7A shows 
Apoptin sensitivity of UMSCC 11a and 11b cells using MTT assay, the metastatic line 
11b was shown to be more sensitive to Apoptin at both MOIs used; however, the 
difference is not statistically significant. The 22a and 22b cell lines (Figure 4.7B) show 
that at an MOI of 30, the metastatic line 22b is more sensitive to Apoptin induced 
cytotoxicity, but at a higher MOI of 40, 22a is shown to be more sensitive. Figure 4.7C 
shows the MTT results for the 74a and 74b cell line pair, these cells show a similar 
response to Apoptin treatment with 74a being slightly more sensitive at MOI 40. These 
results again were not statistically significant. HSC-3 and HSC-3m3 cell lines were 
found to have a more marked difference in Apoptin sensitivity at MOI 40, with HSC-
3m3 showing approximately 15% more killing in Figure 4.7D. Combining this data 
(Figure 4.7) with the expression profile (Figure 4.2), it can be seen that in the HNSCC 
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panel, there is no apparent direct association between PKG-I and PKCβ1 expression 
and Apoptin sensitivity.    
 
 Colon cell lines HCT116 and NCM460 were tested for Apoptin sensitivity using 
FACS analysis (Figure 4.8) and were compared to the expression of PKG-I and PKCβ1 
(Figure 4.3). The results in Figure 4.8 show that HCT116 are 20% more sensitive to 
Apoptin induced cell death compared to the normal NCM460 cell line. Figure 4.3 shows 
that HCT116 has a much higher level of PKCβ1 expression than NCM460, with 
negligible expression of PKG-I. In contrast, NCM460 express PKG-I, but have 
undetectable levels of PKCβ1, suggesting a link between PKG-I and PKCβ1 
expression and Apoptin sensitivity, however, HCT116 were also found to be more 
sensitive to Cisplatin, another apoptosis inducing agent. 
 
Using a normal fibroblast cell line, 1BR3, and its isogenic SV40 Large-T antigen 
transformed clone, 1BR3LT, an interesting correlation was observed between the 
expression of the PKG-I and PKCβ1 kinases and the sensitivity of the cell lines to 
Apoptin induced cell death. A similar relationship was observed to that found in the 
colon cell pair, HCT116 and NCM460, where the 1BR3 normal fibroblast cell line had a 
more pronounced expression of PKG-I compared to the 1BR3LT cell line which had 
undetectable levels of the kinase (Figure 4.5). A similar relationship was also seen with 
the expression of PKCβ1, in the transformed cell line 1BR3LT, PKCβ1 expression was 
significantly higher compared to 1BR3. However, 1BR3 do have detectable levels of 
PKCβ1 expression. Figure 4.9 shows the FACS analysis of Apoptin sensitivity between 
1BR3 and 1BR3LT. The data show 1BR3 cells to be more resistant to Apoptin induced 
cell death when compared to 1BR3LT, but only with less than 10% difference in killing. 
A difference in Cisplatin sensitivity is seen in Figure 4.9, as was observed in the colon 
cell model; however, the difference in the fibroblast pair is more marked.              
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MM1R                                                                MM1S
3 days
6 days
Figure 4.6 Western blot analysis of Apoptin sensitivity in Multiple 
Myeloma cell lines determined by PARP cleavage. Western blot data (A), 
quantification of PARP cleavage (B) and quantification of GFP expression 
(C). C = Control, G20 = Adenoviral GFP MOI 20, A10 and A20 = 
Adenoviral Apoptin MOI 10 and 20, respectively. Cells were grown for 3 and 
6 days as indicated. 
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Figure 4.7 MTT based analysis of Head and Neck cancer panel of cell lines treated 
with Adenoviral delivered Apoptin. 11a and 11b (A), 22a and 22b (B), 74a and 74b (C) 
and HSC-3 and HSC-3m3 (D). Cells were grown for 4 days. Error bars indicate standard 
deviation. n=3. Cell death shown here is from the total population of cells treated; this data 



























































































































































Figure 4.8 FACS analysis of colon cell lines HCT116 and NCM460 
and their sensitivity to Apoptin. Delivered by Adenovirus at MOI 40. 
Cells were treated for 72 hours. Error bars indicate standard deviation. 
n=3. Cell death shown here is from the total population of cells treated; 
this data does not take into account efficiency of adenoviral infection. 
For example, cells were not gated for Apoptin or GFP positive 
expression.     
Figure 4.9 FACS analysis of fibroblast cell lines 1BR3 and 1BR3LT 
and their sensitivity to Apoptin. Delivered by Adenovirus at MOI 40. 
Cells were treated for 72 hours. Error bars indicate standard deviation. 
n=2. Cell death shown here is from the total population of cells treated; 
this data does not take into account efficiency of adenoviral infection. 
For example, cells were not gated for Apoptin or GFP positive 
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4.4 Protein-protein interaction between Apoptin, PKG-I and PKCβ1 
 
 Previous results suggested a potential link between PKG-I and PKCβ1 in 
sensitivity to Apoptin of certain cell lines. This link was further investigated by looking at 
a physical interaction between Apoptin and PKG-I or PKCβ1.  
 
 To investigate protein-protein interaction, HEK293 cells were used due to their 
ease of transfection and apparent resistance to Apoptin induced cell death. These 
characteristics provided a suitable model to test ectopic expression of the kinases of 
interest and Apoptin and any potential interactions. Cells were transfected with differing 
combinations of plasmids encoding Flag-tagged Apoptin, PKG-I and PKCβ1, incubated 
for 72 hours and then collected for Immunoprecipitation (IP) analysis as described in 
Chapter 2.  
 
 The results shown in Figure 4.10 indicated physical interaction between Apoptin 
and PKG-I and between Apoptin and PKCβ1. Figure 4.10A shows that PKG-I and 
Apoptin are physically bound as pulling down with Flag antibody also pulls down PKG-I 
(Figure 4.10A), suggesting a physical interaction between this kinase and Apoptin. 
Although the lane transfected only with PKG-I (Figure 4.10A) also displays a very faint 
band, this is believed to be due to background because the total protein in Figure 
4.10B for PKG-I is similar to the co-transfected band (Figure 4.10B). The interaction 
between PKCβ1 and Apoptin was also investigated in Figure 4.10C and D. The 
findings suggest that PKCβ1 also binds to Apoptin (Figure 4.10C). Furthermore, 
PKCβ1 and PKG-I appeared to physically interact with each other (Figure 4.10C). 
Collectively, the results suggest that both PKCβ1 and PKG-I physically bind to Apoptin. 
This result suggests that Apoptin, PKG-I and PKCβ1 may form a complex in the cell 
and physically interact with one another. This result is interesting as it provides a 














Figure 4.10 Immunoprecipitation studies in HEK293 cells transfected with a number of 
different plasmids. In A, all lanes were immunoprecipitated with Flag antibody. In B, 
PKCβ1, PKG-I + PKCβ1 and Flag-Apoptin + PKG-I + PKCβ1 (red) were 
immunoprecipitated with PKG-I antibody, pbabepuro and Flag-Apoptin + PKCβ1 were 
immunoprecipitated with Flag antibody. Cells were incubated for 72 hours to be consistent 
with previous experiments. HEK293 are not sensitive to Apoptin induced cytotoxicity. Blots 
were exposed for 1 minute each probe. PKG-I and PKCβ1 were analysed from the same blots 
where PKG-I was probed first. Β-Actin and P-Apoptin were probed once at the same time as 
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4.5 Discussion and Conclusions 
 
 Apoptin expression induces cell death in transformed, but not normal cells. A 
number of different processes occur in transformed cells compared to normal cells and 
these differences need to be studied in order to further understand the function of 
Apoptin. For example, Apoptin in tumour cells is localised to the nucleus, but in normal 
cells this nuclear localisation is much less efficient (Danen-Van Oorschot et al., 2003; 
Guelen et al., 2004). Other studies have also highlighted the importance of 
phosphorylation of Apoptin for its nuclear localisation and subsequent cytotoxicity 
(Noteborn, 2009; Tavassoli et al., 2005).  
 
As was discussed in Chapter 3, a tumour specific kinase or kinases could be 
responsible for the phosphorylation of Apoptin and its resulting toxicity in transformed 
cells. Previous work highlighted PKCβ1 and potentially PKG-I as kinases involved in 
Apoptin cytotoxicity, the focus of the work described here was to further investigate 
these target kinases. 
 
 The MM1R and MM1S pair had been used in our published work (Jiang et al., 
2010b) and it was important to understand whether or not the kinase expression 
hypothesis applied to a proven model of variable Apoptin sensitivity. What we found 
was that PKCβ1 was expressed at a higher level in MM1R than MM1S, as was shown 
in Chapter 3. In contrast, PKG-I expression was detected at low levels in both cell lines, 
however, the Apoptin resistant MM1R cells expressed PKG-I at a higher level than the 
MM1S cells. This result disagreed with the hypothesis and suggested that in the MM 
pair PKG-I expression was not relevant to Apoptin sensitivity.    
 
To determine the correlation between the expression of these kinases and 
Apoptin sensitivity, the cells were infected with Lentiviral vectors encoding GFP-
Apoptin. Sensitivity was investigated by Western blot using PARP cleavage as an 
indicator of Apoptosis. The results clearly showed that MM1R cells were more sensitive 
to Apoptin than MM1S, and this result correlated with a higher expression of PKCβ1. 
An interesting observation in MM1S cells was that Apoptin expression was reduced 
compared to MM1R, suggesting that Apoptin was possibly degraded in the less 
sensitive cell line as GFP expression was similar between the cell lines, the effect of 
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Apoptin degradation has recently been shown in normal cells in response to Apoptin 
treatment (Lanz et al., 2012).  
 
 The next panel of cell lines investigated was the Head and Neck cancer cell 
lines. PKG-I was found to be expressed in a similar manner to PKCβ1, with the more 
metastatic lines showing increased levels of both kinases. The results revealed that 
although there was variation in sensitivity to cell death in the panel of cell lines, there 
was no clear trend to link Apoptin sensitivity to PKG-I and PKCβ1 (Table 3); this was 




Table 4 Kinase expression ratio between primary and metastatic cells in HNSCC panel in 
relation to Apoptin sensitivity 
 11a 11b 22a 22b 74a 74b HSC-3 
HSC-
3M3 
PKG-I 0.42 0.58 0.36 0.64 0.45 0.55 0.34 0.66 
PKCβ1 0.38 0.62 0.33 0.67 0.52 0.48 0.36 0.64 




 PKG-I expression has been shown to be lost in cells as they become 
transformed or tumourigenic (Hou et al., 2006), using a pair of normal and transformed 
colon cell lines, expression of PKG-I and the relationship to Apoptin sensitivity was 
investigated. HCT116 cells expressed higher levels of PKCβ1 protein than NCM460 
and had completely undetectable levels of PKG-I protein expression. In contrast, 
NCM460 expressed PKG-I protein at higher levels than HCT116, but no detectable 
expression of PKCβ1. Cell death analysis shows that HCT116 are more sensitive to 
Apoptin induced cell death than NCM460. This result supports the hypothesis that 
PKCβ1 expression is linked to Apoptin sensitivity and PKG-I expression is linked to 
Apoptin resistance in a colon cancer model.  
 
A HCT116 panel of cell lines including wild type, p53 and PUMA knockout were 
tested for their sensitivity to Apoptin (Chapter 3). This panel was also tested for kinase 
expression to investigate the differences in Apoptin sensitivity in relation to PKCβ1 and 
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PKG-I protein levels. The results found that these cell lines had increasing levels of 
PKCβ1 expression from wild type to the PUMA-/- cell line. While there was variation in 
Apoptin sensitivity, all cell lines were sensitive to Apoptin and the expression of PKCβ1 
did not appear to correlate with this sensitivity. PKG-I expression was very low in this 
panel, perhaps contributing to the Apoptin sensitivity of these cells. The difference in 
sensitivity is shown to be independent of kinase expression, and could be attributable 
to the p53 and PUMA status of these cell lines. 
 
The primary fibroblast cell line 1BR3, and its SV40 Large T transformed clone 
1BR3LT, were used as another model of normal and transformed cell lines to test 
Apoptin sensitivity and its relationship with kinase expression. As was seen in the colon 
model, kinase expression was similar; the normal cell line had increased expression of 
PKG-I and the transformed cell line had increased expression of PKCβ1. Apoptin 
sensitivity was investigated by FACS analysis similar to the colon model and although 
the difference in cell death was not as great as in the colon model, it was observed that 
the 1BR3LT cells were slightly more sensitive to Apoptin induced cell death than 1BR3. 
The observed low levels of killing in the SV40 transformed 1BR3 cell line when 
exposed to Apoptin suggest that this model is not very effective in studying Apoptin 
sensitivity. Cisplatin, however, was again found to have different killing ability between 
normal and transformed cells, which could suggest that PKCβ1 and PKG-I expression 
are involved in cell death as opposed to Apoptin induced cell death in particular. 
Further investigation is required to distinguish between these alternative 
interpretations. In addition, it is important to note that all FACS data is based on total 
populations and does not account for low virus infectability. For example, the reason for 
the low toxicity seen in these cells could be lower viral infection efficiency rather than 
resistance to Apoptin as shown in Figure 4.11. Cells that are expressing Apoptin are 
exhibiting early signs of apoptosis; however, these cells are only a small percentage of 
the total population.    
 
Results show that Apoptin and PKG-I physically bind to one another, evidence 
of interaction within the cell. In addition, PKCβ1 is shown to bind to Apoptin, which also 
indicates an interaction between the protein and this kinase. However, the interactions 
of the other proteins analysed are less convincing. The results indicate that both 
PKCβ1 and PKG-I bind to each other and also form a complex with Apoptin when all 
are present within the cell, but the existence of bands in the control lanes of each IP 
experiment casts doubt on the potential significance of this finding. These could 
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perhaps be dismissed as background, but further investigation would be required to 
prove the presented hypothesis, for example, repeat experiments using different 
complimentary antibodies. These results suggest that there could be a potential 
physical link between Apoptin and PKCβ1 and PKG-I kinases, however this link is 
tentative at best. Direct physical interaction does not exclusively determine functional 
activity and so the ambiguity of these results does not necessarily negate the 
involvement of PKCβ1 and PKG-I in Apoptin cytotoxic function.  Further, the results 
here describe interactions of exogenously overexpressed kinases with Apoptin; a 
further examination would benefit from the investigation of endogenously expressed 
PKCβ1 and PKG-I in a model that more closely resembles cancer.  
 
In summary, the data presented here describes a potential link between Apoptin 
sensitivity in colon and, less convincingly, fibroblast cell lines and the expression of 
PKCβ1 and PKG-I. Other cell lines such as MM1 and Head and Neck cancer were 
found to express these kinases in varying amounts, however, in the case of Head and 
Neck cancer cell lines the expression did not appear to correlate with Apoptin 
sensitivity. HCT116 and NCM460 were found to have varying sensitivity to Apoptin that 
correlated with their expression of PKCβ1 and PKG-I, this was seen to a lesser extent 
in 1BR3 and 1BR3LT, the fibroblast cell lines.  
 
In order to further this study, the interaction between Apoptin and the target 
kinases will be tested further by modifying PKCβ1 and PKG-I expression and 
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Figure 4.11 Fluorescence imaging examples of Apoptin infection efficiency and resulting 
apoptotic effect in 1BR3LT and HCT116. 60x magnification (Scale bar: 25μm) fluorescence 
image (A) of 1BR3LT cells infected with Lenti-GFP-Apoptin and stained with DAPI for 
imaging nuclei. Apoptin infected cells are visible with changed nuclear morphology associated 
with apoptosis. 10 x magnification (Scale bar: 125μm) fluorescence and brightfield image (B) 
of HCT116 cells infected with Lenti-GFP-Apoptin showing the infection efficiency generally 
seen. Of note is the morphology of the cells expressing Apoptin, they are no longer fully 
adhered to the plate and are beginning to round up, an early sign of cell death. Cells were grown 
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Chapter 5 




Apoptin phosphorylation in tumour cells has been shown to be important in its 
cytotoxic effect (Rohn et al., 2002). However, specific kinase/s responsible for Apoptin 
phosphorylation have yet to be discovered. Cyclic guanosine monophosphate 
dependent protein kinase I (PKG-I) and Protein kinase C beta 1 (PKCβ1) have been 
implicated in Apoptin cytotoxicity in this study (see Chapter 4) and in previous studies 
from this lab (Jiang et al., 2010a).  
 
Using two pairs of PKG-I inducible cell lines in combination with overexpression 
and knockdown studies; the effect of PKG-I expression on Apoptin phosphorylation and 
cytotoxicity was investigated. The objective of the studies described in this chapter was 
to investigate the effects of these kinases, through their modulation, on Apoptin 
cytotoxicity and phosphorylation. This was a logical extension of our previous studies 
described in Chapter 4 which had highlighted the potential relationship between PKCβ1 
and PKG-I expression and Apoptin sensitivity.  
 
The aim of this study was to confirm these data by knocking down or 
overexpressing these kinases in normal and tumour cells. In addition, the aim was to 
recreate a normal expression pattern in tumour cells and a transformed expression 
pattern in normal cells in order to investigate the effects on Apoptin cytotoxicity and to 
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5.2 Results 
5.2.1 Inducible expression of PKG-I and its effect on Apoptin 
phosphorylation   
 
 Cell lines SW620 and HT29 and their PKG-I inducible pairs, were treated with 
Apoptin with or without the presence of their inducible drugs, mifepristone and 
doxycycline, respectively. Phosphorylation of Apoptin was detected using an antibody 
specific to T108 phosphorylation and compared to total Apoptin levels using an 
antibody able to detect Apoptin independently of its phosphorylation status. Using 
Western blot analysis, levels of phosphorylated Apoptin were compared with total 
Apoptin levels between induced and non-induced cell lines and the parental cells given 
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Figure 5.1 Western blot analysis of PKG-I expression compared to 
phosphorylated Apoptin in SW620 and J5B. Cell lines treated with 
mifepristone and infected with MOI 4 of Lentiviral GFP-Apoptin. Cells were 
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Figure 5.1 shows changes in the expression of PKG-I in the inducible cell line 
J5B in comparison to the J5B uninduced and parental cell line SW620. Each cell line 
was treated with mifepristone as control and infected with Lentiviral GFP-Apoptin. In 
Figure 5.1 and 5.2A, expression of PKG-I was induced by mifepristone in J5B; this 
effect is not seen in SW620 which showed no detectable levels of PKG-I.  However, 
un-induced J5B also expressed a basal level of PKG-I which could be due to the 
leaking of the inducible plasmid. In SW620 cells, Apoptin is phosphorylated, with 
mifepristone treated cells showing an increase in total Apoptin expression and 
phosphorylated Apoptin expression when the data was quantified (Figure 5.1 and 
5.2C). In contrast, J5B cells show no detectable expression of phosphorylated Apoptin 
when induced by mifepristone and when the cells are untreated (Figure 5.1 and 5.2B); 
however, the total Apoptin detected was lower than in the SW620 cells. This data 
indicates that the presence of PKG-I in this cell line affects the expression of Apoptin, 
decreasing the total level and thereby reducing phosphorylation to undetectable levels 
in J5B (Figure 5.2B) when compared to the parental SW620 (Figure 5.2C).  
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Figure 5.2 PKG-I expression and Apoptin phosphorylation data quantified for 
SW620 and J5B. Cells using imageJ software. Quantification from Western blot data 
in Figure 5.1. 
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 HT29 cells and their doxycycline inducible clones, 1beta#7, were used as a 
second cell line pair to confirm the previous result with SW620 and J5B, and to 
investigate if the result was specific only to SW620. As with the SW620 experiment, 
HT29 cells and their inducible clones were treated with doxycycline before being 
infected with Lentiviral GFP-Apoptin. Western blot analysis in Figure 5.3 shows a 
similar pattern to that seen in Figure 5.1, PKG-I expression correlates with reduced 
phosphorylation of Apoptin. Figure 5.3 indicates that the basal level, likely due to 
leaking of the inducible system, of PKG-I in the 1beta#7 clone is higher than HT29 as 
detected by Western blot. Induction of PKG-I expression by doxycycline treatment 
increased expression of PKG-I in the control and Lentiviral GFP-Apoptin treated 
1beta#7 cells, however an increase in expression was not detected in all doxycycline 
treated variables (Figure 5.4A). This is a marked difference to the J5B system where 
induced expression was a lot higher than basal levels of PKG-I (Figure 5.2A). The 
presence of PKG-I expression, however, did correlate with a reduction of Apoptin 
phosphorylation detected by Western blot (Figure 5.3 and 5.4B and C) and compared 
to the HT29 parental cells that do not express PKG-I. However, as with the J5B 
Figure 5.3 Western blot analysis of PKG-I expression compared to 
phosphorylated Apoptin in HT29 and 1 beta#7. Cell lines treated with 
doxycycline and infected with MOI 4 Lentiviral GFP-Apoptin. Cells were grown for 
4 days. C=Control, P=Polybrene treated, G=Lenti-GFP, A=Lenti-GFP-Apoptin, 
Cis= Cisplatin. 
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system, total Apoptin expression was also reduced in the PKG-I expressing cell line, 
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Figure 5.4 PKG-I expression and Apoptin phosphorylation data quantified for 
HT29 and 1beta#7. Analysed using imageJ software. Quantification from Western blot 
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5.2.2 Inducible expression of PKG-I and its effect on Apoptin induced 
cytotoxicity   
 
 In the previous results section in the HT29 inducible clone 1beta#7, Apoptin 
seemed less phosphorylated than the parental HT29 cells. To determine the potential 
role of this phosphorylation in cytotoxicity a similar experiment was performed and 
analysed using FACS to investigate cell death. Cells were treated with doxycycline and 
then infected with Adenoviral vectors expressing Apoptin or control GFP at MOI 40. 
The cells were treated for 72 hours and collected for FACS analysis.  
  
 Data in Figure 5.5A indicate that HT29 cells are sensitive to Apoptin induced 
cell death with a reduction in live cells of approximately 15%; doxycycline treatment 
had no impact on Apoptin sensitivity in this cell line. Interestingly, cisplatin treatment 
was also affected by doxycycline treatment in this cell line, reducing the toxicity of the 
drug by approximately 15%. Treating the 1beta#7 inducible cells with doxycycline had 
a similar effect on cisplatin toxicity, with the treated cells showing a reduced sensitivity 
to the drug (Figure 5.5B). Doxycycline treatment reduced the number of live cells in 
1beta#7 and also in the control and Ad-GFP, suggesting a mild toxicity associated with 
induction of PKG-I in this clone (Figure 5.5B). However, doxycycline treatment of 
1beta#7 cells as shown in Figure 5.5B suggests that Ad-Apoptin sensitivity was 
completely inhibited upon induction of PKG-I expression when compared to the non-
treated cells (Figure 5.5B).  
 
 Comparing both cell lines with doxycycline treatment, as shown in Figure 5.5C, 
suggests that only Ad-Apoptin expression in 1beta#7 cells treated with doxycycline 
exhibits increased resistance to the protein.    
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Figure 5.5 FACS analysis for HT29 and 1beta#7 cells treated with 
doxycycline inducing agent and infected with Adenoviral vectors for 
Apoptin and GFP. Cells were grown for 72 hours. Error bars indicate 
standard deviation. n=3. Cell death shown here is from the total population of 
cells treated; this data does not take into account efficiency of adenoviral 
infection. For example, cells were not gated for Apoptin or GFP positive. 
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5.2.3 Effects of PKCβ1 and PKG-I modulation on Apoptin phosphorylation 
and sensitivity in colon cancer  
 
 Previous results with inducible clones showed that modulation of PKG-I 
expression affects Apoptin sensitivity and expression. To further investigate the 
potential role of PKG-I, and also PKCβ1, in Apoptin function HCT116 and NCM460 
colon cell lines were used.  
 
As was described in Chapter 4, HCT116 and NCM460 are tumour and normal 
colon cell lines respectively. Each cell line expressed PKCβ1 and PKG-I kinase with a 
pattern that correlates with Apoptin sensitivity; HCT116 are sensitive to Apoptin and 
have high levels of PKCβ1 and low levels of PKG-I (Figure 4.3 and 4.8). In NCM460 
the inverse is seen, resistance to Apoptin with low levels of PKCβ1 and high relative 
levels of PKG-I. To further investigate the importance of these associations, 
overexpression and siRNA knockdown studies were used. 
 
Figure 5.6 shows the effect of knockdown and overexpression studies in 
NCM460 cells. The data suggest that PKCβ1 was overexpressed and resulted in an 
increase in the level of Apoptin phosphorylation when compared to the control cells 
(Figure 5.6B). Although there appears to be overexpression of PKCβ1, the bands are 
not clearly defined, so the result is not entirely conclusive. Interestingly, in the PKCβ1 
over-expressing cells, PKG-I expression was reduced compared to both control as well 
as the PKG-I siRNA treated cells. Treatment of cells with siRNA targeting PKG-I, was 
shown to reduce PKG-I expression when compared to the control siRNA, although 
PKG-I knockdown was inefficient in the Ad-GFP infected cells. Ad-Apoptin 
phosphorylation was also marginally increased in the siPKG-I treated cells. 
Interestingly, the siControl expresses a higher level of phosphorylated Apoptin than 
both the control and PKCβ1 overexpressing samples, suggesting that the levels of 
phosphorylated Apoptin can vary between experiments. Additionally, it should be noted 
that although phosphorylation levels of Apoptin were well detected, the expression of 
total Apoptin was very low with a high level of background (Figure 5.6A).       
 
Using HCT116 cells, PKCβ1 was knocked down and PKG-I was overexpressed 
to determine changes in the phosphorylation of Apoptin (Figure 5.7). As shown in 
Figure 5.7A, overexpression of PKG-I resulted in a decreased level of PKCβ1 and, 
against expectations; these cells expressed a higher level of phosphorylated Apoptin 
134 
 
  Chapter 5: Results III 
 
compared to control (Figure 5.7B). However, the control sample expressed total 
Apoptin at a much lower level than the PKG-I overexpressing sample. PKCβ1 
knockdown by siRNA in HCT116 cells decreased the level of expression of PKCβ1 by 
approximately half compared to the control siRNA, however this resulted in no effect on 
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Figure 5.6 Western blot analysis of PKCβ1, PKG-I and Apoptin expression in NCM460. 
Displaying overexpression of PKCβ1 using plasmid transfection and knockdown of PKG-I using 
siRNA and the effect on Apoptin phosphorylation. Western blot data (A) and quantification 
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Figure 5.7 Western blot analysis of PKCβ1, PKG-I and Apoptin expression in HCT116. 
Displaying overexpression of PKG-I using plasmid transfection and knockdown of PKCβ1 
using siRNA and the effect on Apoptin phosphorylation. Western blot data (A) and 
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 Using FACS analysis, cells were treated with siRNA or transfected with 
plasmids for expression of PKCβ1 or PKG-I exogenously, and then infected with 
Adenoviral vectors expressing either Apoptin or GFP as a control. The results of these 
experiments as shown in Figure 5.8A, suggested that for NCM460 cells overexpression 
of PKCβ1 made these cells more sensitive to Apoptin induced cell death with a 
reduction in viable cells of approximately 30%. PKG-I siRNA treatment resulted in a 
20% loss of cell viability  with Apoptin treatment as compared to a 10% loss of viability  
in cells treated with siRNA control. Cisplatin treatment showed a similar loss of live 
cells across each variable, with Control cells displaying the smallest loss in viable cells.  
 
 For HCT116 cells, the FACS data, shown in Figure 5.8B, revealed that upon 
infection with Ad-Apoptin, empty vector transfected cells lost viability of 40%. When 
cells overexpressed PKG-I, the loss of viability was reduced to 20%, although this was 
not a reduction in cell death when compared to untreated control cells. Knockdown of 
PKCβ1 was shown to reduce Apoptin induced cell death when compared to all controls 
except the siRNA control, where the difference was minimal. Cisplatin treatment, again, 
showed a similar loss of cell viability as described for NCM460 cells (Figure 5.8B). 
 
 Collectively these functional studies suggest that interference with PKG-I and 
PKCβ1 expression appears to correlate with Apoptin sensitivity in the normal NCM460 
colon cells, but this correlation does not seem to extend to the transformed HCT116 
colon cells. Normal cells expressing PKG-I at high levels and expressing low levels of 
PKCβ1 are less sensitive to Apoptin induced cell death compared to tumour cells 
expressing high levels of PKCβ1 and lower relative levels of PKG-I; however this 
observation, described in Chapter 4 is based on endogenously expressed levels of 
each kinase. Exogenous overexpression of PKG-I in HCT116 cells may not have the 
same effect as the endogenous expression associated with the normal NCM460 colon 
cells.    
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Figure 5.8 FACS analysis of colon cell lines NCM460 and HCT116 and their sensitivity 
to Apoptin. Delivered by Adenovirus at MOI 40 after knockdown or overexpression of 
PKCβ1 and PKG-I. NCM460 (A) and HCT116 (B). Cells were treated for 72 hours. Error 
bars indicate standard deviation. Data from at least 2 separate experiments. Cell death shown 
here is from the total population of cells treated; this data does not take into account 
efficiency of adenoviral infection. For example, cells were not gated for Apoptin or GFP 
positive expression.             
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5.2.4 Effects of PKCβ1 and PKG-I modulation on Apoptin phosphorylation 
and sensitivity in a transformed fibroblast model 
 
 1BR3 and their transformed isogenic match 1BR3LT were previously shown to 
differentially express both PKCβ1 and PKG-I (Figure 4.5) and this correlated with 
differences in Apoptin sensitivity (Figure 4.9). Although these differences were not as 
marked as those seen with the colon model, it was important to examine whether the 
fibroblast cell model displayed similar characteristics in relation to the expression of 
these kinases. To investigate these differences and their potential effects on Apoptin 
function, siRNA and overexpression studies were performed and the effects were 
examined using Western blot and FACS analysis.  
 
 Overexpression of PKCβ1 in 1BR3 cells was shown to be successful and 
produced a marked increase in the expression of this kinase. Overexpression of 
PKCβ1 resulted in a substantial decrease in PKG-I expression compared to control 
(Figure 5.9) as previously observed with the colon cell lines (Figure 5.6). Knockdown of 
PKG-I, however, did not appear to have any effect on PKCβ1 expression as detected 
by Western blot analysis (Figure 5.9A and B). 1BR3 cells that overexpressed PKCβ1 
had a reduced level of Apoptin phosphorylation and an overall reduction in the level of 
total Apoptin expression in contrast with the proposed hypothesis (Figure 5.9B). 
Further, knockdown of PKG-I had no effect on the level of Apoptin phosphorylation 
when compared to the siRNA control treated cells, but an increased expression of total 
Apoptin was observed, also against expectation (Figure 5.9B). 
 
 1BR3LT cells were studied in a similar way, with overexpression of PKG-I and 
siRNA targeted knockdown of PKCβ1 (Figure 5.10). The results show that 
overexpression of PKG-I induced a marked decrease in the expression of PKCβ1 to a 
much higher extent than that achieved by PKCβ1 siRNA (Figure 5.10A and B). siRNA 
knockdown in 1BR3LT did not successfully reduce the expression of PKCβ1 when 
compared to the siRNA control (Figure 5.10B). Quantification analysis showed that 
overexpression of PKG-I resulted in reduced Apoptin phosphorylation compared to the 
control, however, total Apoptin levels were undetectable (Figure 5.10B). In the siPKCβ1 
treated cells Apoptin phosphorylation was essentially unchanged compared to the 
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Figure 5.9 Western blot analysis of PKCβ1, PKG-I and Apoptin expression in 1BR3. 
Analysis of 1BR3 after overexpression of PKCβ1 using plasmid transfection and knockdown of 
PKG-I using siRNA and the effect on Apoptin phosphorylation. Western blot data (A) and 
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Figure 5.10 Western blot analysis of PKCβ1, PKG-I and Apoptin expression in 1BR3LT. 
Analysis of 1BR3LT after overexpression of PKG-I using plasmid transfection and knockdown of 
PKCβ1 using siRNA and the effect on Apoptin phosphorylation. Western blot data (A) and 
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 To further investigate the role of PKCβ1 and PKG-I in Apoptin function, 
sensitivity to Apoptin induced cytotoxicity was investigated in relation to kinase 
expression by FACS analysis.  
 
 The results in Figure 5.11A show that PKCβ1 overexpression had no effect on 
Apoptin induced cell death when compared to the controls; the cells responded in a 
similar way to the empty vector control transfected cells, with no increase in cell death 
upon Apoptin treatment. In the cisplatin treated cells, the PKCβ1 expressing cells again 
showed no variation in cell death compared to empty vector control, however, a 
reduction of 30% in cell viability was observed as compared to non-transfected controls 
(Figure 5.11A). Knockdown by siRNA of PKG-I resulted in a significant increase in the 
percentage of cell death in Apoptin treated cells of approximately 10% compared to the 
siRNA PKG-I untreated cells (Figure 5.11A). Cisplatin treatment induced an increased 
cell death compared to siRNA control and untreated control cells; however, this cell 
death was comparable to empty vector and PKCβ1 transfected cell lines (Figure 
5.11A).         
 
 1BR3LT, the transformed isogenic match of 1BR3 cells, were used to test the 
sensitivity of Apoptin in relation to the expression of these kinases and compare to their 
matched normal cells described above. Figure 5.11B shows that upon the induction of 
PKG-I overexpression, 1BR3LT cells became more sensitive to Apoptin induced 
cytotoxicity, with a small reduction in cell viability of 5% compared to the control. 
Cisplatin treatment showed no change in cell death compared to both the control and 
empty vector control. Knockdown of PKCβ1 results showed that siRNA knockdown was 
not successful in 1BR3LT (Figure 5.10). As a result of this, no change in Apoptin 
sensitivity was observed (Figure 5.11B).   
 
 In the normal versus transformed fibroblast model, PKG-I expression appears 
to have some effect on Apoptin sensitivity, but there is no observable effect of PKCβ1 
expression on Apoptin function.   
























Figure 5.11 FACS analysis of fibroblast cell lines 1BR3 and 1BR3LT and their 
sensitivity to Apoptin. Delivered by Adenovirus at MOI 40 after knockdown or 
overexpression of PKCβ1 and PKG-I. 1BR3 (A) and 1BR3LT (B). Cells were treated for 72 
hours. Error bars indicate standard deviation. Data from at least 2 separate experiments. Cell 
death shown here is from the total population of cells treated; this data does not take into 
account efficiency of adenoviral infection. For example, cells were not gated for Apoptin or 
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5.2.5 Effects of PKCβ1 and PKG-I modulation on Apoptin cellular localisation 
 
In the previous sections PKCβ1 and PKG-I expression was found to correlate 
with the phosphorylation and cytotoxic effects of Apoptin. The tumour specific nature of 
Apoptin has been linked to many specific characteristics and behaviours in normal and 
transformed cells, one of which being subcellular localisation (Guelen et al., 2004). To 
determine whether modulation of the kinases described in this study affected Apoptin 
localisation in addition to its phosphorylation and cytotoxicity, immunofluorescence 
studies were performed.  
 
Using HCT116, NCM460 and 1BR3 cell lines, a combination of siRNA and 
plasmid overexpression techniques were used as described in previous sections, 
followed by infection with Adenovirus to express Apoptin or GFP control and then the 
cellular localisation was analysed.  
 
HCT116 cells were transfected with siRNA targeted to PKCβ1 and changes in 
Apoptin localisation were observed as described in Figure 5.12A. The results showed 
that when PKCβ1 expression is reduced, HCT116 cells displayed healthier looking 
nuclei in Apoptin expressing cells compared to siRNA control cells (Figure 5.12A). 
There is also a reduction in the number of cells expressing Apoptin after treatment with 
siRNA against PKCβ1 in Figure 5.12A. 
 
NCM460 cells were also transfected with siRNA, but this time targeted to PKG-
I. In those cells treated with PKG-I siRNA, Apoptin appeared to localise at a higher 
level in the nucleus compared to the siRNA control, with aggregates of Apoptin within 
the nucleus of these cells (Figure 5.12B). This correlated with increased Apoptin 
sensitivity results in NCM460 upon knockdown of PKG-I as was shown in Figure 5.8A. 
NCM460 cells were also transfected to overexpress PKCβ1 to determine the effects on 
localisation of Apoptin, as there was a significant change in Apoptin sensitivity as 
shown in Figure 5.8A. The results in Figure 5.12B showed that overexpression of 
PKCβ1 in NCM460 cells and subsequent Apoptin infection induced a noticeable 
increase in the level of Apoptin nuclear aggregates as compared to the empty vector 
control. This aggregation produced an expression pattern indicative of PML body 
145 
 
  Chapter 5: Results III 
 
localisation which, interestingly, is associated with the binding and localisation of 
Apoptin in tumour cells (Poon et al., 2005).     
 
1BR3 cells were transfected in a similar way to NCM460 with knockdown of 
PKG-I by siRNA and overexpression of PKCβ1 using plasmid transfection. Results in 
Figure 5.12C show that when PKCβ1 is overexpressed in 1BR3 cells, Apoptin localises 
more in the nucleus compared with cells transfected with the empty vector control, 
however, there is still cytoplasmic localisation seen in these cells. This could potentially 
be responsible for the lack of sensitivity to Apoptin induced cytotoxicity seen in Figure 
5.11A. In contrast, knockdown of PKG-I in 1BR3 cells was shown to increase Apoptin 
sensitivity (Figure 5.11A). Figure 5.12A shows that siRNA knockdown of PKG-I in 
1BR3 cells induced a dramatic change in Apoptin localisation compared to siRNA 
control. Control cells display characteristic cytoplasmic localisation of Apoptin, but once 
PKG-I expression is abrogated Apoptin localises to the nucleus with little or no Apoptin 
detected in the cytoplasm.  
 
The above results suggest that PKCβ1 and, more importantly, PKG-I 
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Figure 5.12 Immunofluorescence images of HCT116, NCM460 and 1BR3 
cells showing Apoptin localisation. Immunofluorescence images of HCT116 
(A), NCM460 (B) and 1BR3 (C) cells infected with Adenoviral Apoptin after 
overexpression or knockdown of PKCβ1 or PKG-I. Apoptin was visualised 
with FITC conjugated antibodies, and PKCβ1 or PKG-I were visualised with 
Texas Red conjugated antibodies. Nuclei visualised with DAPI staining. 60x 
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Figure 5.13 Quantification of cellular localisation of Apoptin in 
HCT116 (A), NCM460 (B) and 1BR3 (C) cells. Quantification of 
nuclear and cytosolic localisation of Adenoviral Apoptin taken by 
manually counting Apoptin expressing cells from the experiment shown 
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5.3 Discussion and Conclusions 
 
Based on the observations made in Chapter 4, the aims of this section were to 
modify expression of PKCβ1 and PKG-I and further investigate the effects of these 
changes on the function of Apoptin in paired normal and transformed cell lines. 
 
SW620 and their inducible clone, J5B, were tested for inducible PKG-I 
expression and the effect on Apoptin phosphorylation. Interestingly, PKG-I expressing 
clones, with or without induction were shown to express Apoptin with no detectable 
phosphorylation (Figure 5.1 and 5.3), however, total Apoptin expression was also 
reduced. This result suggests that PKG-I expression may in some way interfere with 
Apoptin phosphorylation in these cell lines, but could also affect the total expression of 
Apoptin. Abrogated phosphorylation was also seen in the non-induced clones; 
however, these cells did express some PKG-I that was at a much higher level than that 
seen in the parental cell lines. This is likely to be due to the leakiness of the inducible 
system used (Figure 5.2 and 5.4).  
 
Further investigation of the effects of PKG-I expression in the HT29 paired cell 
lines revealed that the abrogation of Apoptin phosphorylation in the inducible clones 
also coincided with an increased resistance to Apoptin induced cell death (Figure 5.5B 
and C). The use of the PKG-I inducible system in this study revealed that there was a 
correlation between PKG-I expression and Apoptin expression in this model.  
 
The results in Chapter 4 showed a correlation between Apoptin sensitivity and 
expression of both PKG-I and PKCβ1 in the colon cell model. Thus supporting the 
notion that normal cells express higher levels of PKG-I (Karami-Tehrani et al., 2012) 
and lower levels of PKCβ1 compared to tumour cells. This was confirmed to be the 
case in NCM460 and HCT116 cells, Figure 4.3 and 4.8, by further investigation during 
this study showing that the silencing of PKG-I by siRNA transfection can result in 
significant increased Apoptin sensitivity in NCM460 cells compared to siControl cells 
(Figure 5.8A). However, overexpression of PKG-I in HCT116 cells was less conclusive 
(Figure 5.8B), suggesting that PKG-I endogenous expression is more significant than 
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NCM460 cells became more sensitive to Apoptin induced apoptosis upon 
overexpression of PKCβ1 (Figure 5.8A) accompanied by an increase in Apoptin 
phosphorylation levels (Figure 5.6). Together this data further supports our previous 
findings that this kinase might be involved in Apoptin phosphorylation and its toxic 
effects. As previously reported, PKCβ1 phosphorylates Apoptin and induces cell death 
in cells expressing high levels of PKCβ1 (Jiang et al., 2010a). In HCT116 cells, the 
effects of PKCβ1 on Apoptin function were less conclusive. PKCβ1 siRNA silencing 
studies revealed an increased sensitivity to Apoptin by only 5% (Figure 5.8B), however, 
the siRNA was not very effective and PKCβ1 expression was still detected (Figure 5.7). 
Although the knockdown was successful in reducing the level of expressed PKCβ1 
protein, this was likely not enough to significantly negate the effect this kinase has on 
Apoptin function in HCT116 cells.         
 
In the 1BR3 model, PKG-I expression was shown to have an effect on the 
sensitivity of each cell line to Apoptin induced cytotoxicity. For example, 1BR3 cells 
transfected with siRNA targeting PKG-I were found to be more sensitive to Apoptin. 
Interestingly, overexpression of PKG-I in the transformed 1BR3LT cell line increased 
the sensitivity to Apoptin induced cell death. However, studies have shown that the 
overexpression of PKG in some transformed cell lines can induce apoptosis (Fallahian 
et al., 2012; Fallahian et al., 2011), possibly explaining the effect seen in 1BR3LT. 
SV40LT transformation of cell lines has also been shown to reduce expression of PKG; 
this could explain the reduction in PKG expression seen in 1BR3LT cells. This loss of 
PKG expression may be required for transformation through this mechanism and 
reintroduction of PKG through overexpression could, perhaps induce growth arrest and 
apoptosis (Fujii et al., 1995b).  
 
Overexpression of PKCβ1 in 1BR3 cells was successful, but no effect on 
Apoptin sensitivity was observed; 1BR3 cells have a basal level of PKCβ1 and an 
increase in expression may not have an increased effect over this basal activity. In 
1BR3LT knockdown experiments for PKCβ1, reduction of expression of PKCβ1 was 
limited and an overall effect on Apoptin sensitivity was un-noticeable, phosphorylation 
was also unaffected. From the results obtained here, it can be concluded that PKG-I 
has some influence on both Apoptin phosphorylation and cytotoxicity in all the cell lines 
studied. However, PKCβ1 can only be linked to Apoptin phosphorylation and toxicity in 
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Further to these findings it is interesting to note that, in all cell lines tested, 
overexpressing either PKG-I or PKCβ1 resulted in reduced expression of PKCβ1 or 
PKG-I, respectively, suggesting a link between the two kinases as has been proposed 
in previous studies (Hou et al., 2003; Zhu et al., 2009), for example one kinase may 
regulate the function and/or the level of the other.     
 
In order to fully investigate the effects of PKG-I and PKCβ1 expression on 
Apoptin and its function, immunofluorescent localisation studies were performed. 
HCT116 cells were transfected with siRNA targeting PKCβ1 as previously described, 
and the cellular localisation of Adenovirus delivered Apoptin was analysed. The data 
showed that although knockdown did not have a major effect on Apoptin sensitivity, 
compared to the siRNA control there was a reduction in the number of cells expressing 
Apoptin in the nucleus, however, this coincided with a reduction in total Apoptin 
expression (Figure 5.12A).   
 
NCM460 cells overexpressing PKCβ1 showed that Apoptin localisation was 
clearly affected. Every cell analysed presented a changed distribution of Apoptin 
(Figure 5.12B), indicating that overexpressing PKCβ1 in this cell line causes Apoptin to 
localise to the nucleus, and subsequently induces cell death. A similar effect is seen 
upon the knockdown of PKG-I which resulted in Apoptin aggregating in the nucleus of 
the cell and the appearance of abnormal nuclei. Interestingly, in both cases Apoptin 
expression increased in the nucleus but there was still evidence of cytosolic 
expression, suggesting that the nuclear export of Apoptin was still functioning, although 
not as effectively (Figure 5.13B).   
 
Similarly, the overexpression of PKCβ1 in 1BR3 resulted in Apoptin moving 
from the cytoplasm into the nucleus of the cells. Cells with successful knockdown of 
PKG-I exhibited complete nuclear localisation of Apoptin with evidence of nuclear 
aggregation (Figure 5.13C). This distribution could explain why PKG-I knockdown is 
important in increasing Apoptin sensitivity in 1BR3 cells. 
 
In conclusion, the data described here suggest a novel role for PKG-I and 
PKCβ1 in the regulation of Apoptin phosphorylation, localisation and induction of cell 
death in colon cells. PKG-I abrogates Apoptin expression and interrupts its nuclear 
shuttling in the cell, which may subsequently lead to resistance to Apoptin induced 
apoptosis, possibly through the regulation of PKCβ1 (Figure 5.14).                       
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Figure 5.14 Schematic diagram describing a model of regulation by PKG-I of 
both Apoptin and PKCβ1. PKCβ1 phosphorylates Apoptin leading to apoptosis. 
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Chapter 6 
Characterisation of a novel Gyrovirus product Human Apoptin 
6.1 Introduction 
 
Chicken Anaemia Virus (CAV), first reported in 1979 in Japan, was the first 
gyrovirus to be discovered and studied extensively (Yuasa et al., 1979). In the years 
since that first discovery, 3 other gyroviruses have been reported, the Avian gyrovirus 2 
(Rijsewijk et al., 2011), Human gyrovirus (Sauvage et al., 2011) and Human gyrovirus 3 
(Phan et al., 2012).  
 
Of interest to this study was the Human gyrovirus reported by Sauvage in 2011, 
this virus was shown to produce a protein that was similar in structure to Apoptin 
derived from CAV (Sauvage et al., 2011). It was then hypothesised that if this protein 
shared some sequence structure with Apoptin, then it could potentially share its tumour 
cytotoxicity and, possibly, be tumour specific. Intriguingly, this virus was discovered in 
Human tissue (Sauvage et al., 2011), and it could be assumed that the Human 
gyrovirus protein (referred to as Human gyrovirus Apoptin) could have a higher 




6.2 Analysis of Human gyrovirus Apoptin expression in relation to CAV 
Apoptin 
 
To test the hypothesis that Human gyrovirus Apoptin behaves in a similar way 
to CAV Apoptin, Apoptin and Human gyrovirus Apoptin were compared in normal and 
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6.2.1 Generation of Human gyrovirus Apoptin 
 
 In order to begin the investigation of Human gyrovirus Apoptin, the protein 
needed to be generated from the sequence homology data reported (Sauvage et al., 
2011). Alignment of CAV with HGyV revealed that there was a relatively low sequence 
identity overall, however, in the region of nucleotides 100-700, 70% identity was 
observed with a similar sequence organisation of the encoded proteins and the 
promoter region. The protein HGyV Apoptin was found to be comprised of 125 amino 
acids compared to 121 for CAV Apoptin with a low overall sequence similarity. In spite 
of this, HGyV Apoptin was shown to share the nuclear localisation signal, the nuclear 
export signal and phosphorylation sites with CAV Apoptin (Bullenkamp et al., 2012).  
 
 Synthetic HGyV Apoptin fused to GFP was generated by our group using 
primers overlapping by 15 bases. The resulting product was PCR amplified and the 
PCR product was cloned using TOPO TA (Invitrogen). The inserts were sequence 
verified and a correct HGyV-Apoptin gene (HGyV-AP) was removed from the TOPO 
vector and cloned in-frame with GFP into the mammalian expression vector pEGFP-C1 
(Clontech) (Bullenkamp et al., 2012).     
 
   
6.2.2 Expression of Human gyrovirus Apoptin and CAV Apoptin in colon 
cancer cells 
 
 Using the HCT116 colon cancer cell line, described in Chapter 2, expression of 
CAV Apoptin and Human gyrovirus (HGyV) Apoptin was studied. Cells were 
transfected with CAV Apoptin and HGyV Apoptin by Lipofectamine, described in 
Chapter 2. Western blot analysis was used to investigate the expression and molecular 
weight of HGyV Apoptin and compare the results to CAV Apoptin. 
 
 In agreement with the sequence, Western blot analysis showed HGyV Apoptin 
to be slightly larger than CAV Apoptin at 45kDa when fused to GFP, compared to 




























6.2.3 Cellular distribution of CAV Apoptin and Human Apoptin in normal and 
transformed fibroblasts 
 
Apoptin is a tumour specific protein and presents a distinct difference in 
localisation in normal and transformed cells. Human Apoptin has been reported to 
possess sequence similarity to CAV Apoptin and, as shown in Figure 6.1, the MW of 
the two proteins is very close. In order to investigate if these structural similarities 
extend to protein function, cellular distribution of the two proteins was compared by 
fluorescence microscopy.  
 
Using primary fibroblasts, 1BR3, and their transformed isogenic match, 
1BR3LT, expression and localisation of CAV and HGyV Apoptin was investigated by 
fluorescence imaging. Localisation analysis shows that the two proteins distribute in a 




































Figure 6.1 Expression of Human Apoptin in HCT116 cells. HCT116 cell line transfected 
with plasmids encoding GFP, CAV-Ap, GFP tagged CAV Apoptin and GFP-tagged Human 
Apoptin. Expression and molecular weight shown by Western blot analysis. Cells were grown 
for 72 hours.    
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GFP-tagged proteins localise in the cytoplasm and seem not to translocate into the 
nucleus. In addition, both GFP-tagged Apoptin proteins appear to cluster to form large 
aggregates in the cytoplasm of the normal cells which has been reported to be a 
precursor step in the degradation and removal of Apoptin in normal cell lines (Zhang et 
al., 2003). However, in transformed cells, a marked difference is observed with both 
CAV Apoptin and Human Apoptin localising to the nucleus of the cells (Figure 6.2) 
 
 
















6.2.4 Cytotoxicity of Human Apoptin in comparison to CAV Apoptin 
 
 The results shown in Figure 6.2 indicate that HGyV Apoptin had very similar 
characteristics to CAV Apoptin when studying localisation in normal and transformed 
cell lines. To determine whether this specific localisation would result in transformed 
cell specific cytotoxicity, apoptosis was quantified by counting apoptotic nuclei in 1BR3 
and 1BR3LT expressing HGyV Apoptin and CAV Apoptin. 
 
 Figure 6.3 shows that 1BR3 cells are resistant to CAV Apoptin, with no 
evidence of increase in killing but, HGyV Apoptin treatment induced 10% of cells to 
undergo apoptosis. However, in 1BR3LT (Figure 6.3), approximately 90% showed 
Figure 6.2 Fluorescence images of localisation of Apoptin and Human Apoptin 
constructs in fibroblast cells. Fluorescence imaging of 1BR3 and 1BR3LT transfected with 
GFP-tagged Apoptin constructs using Nucleofection. Slides were fixed and stained for DAPI. 
Cells were grown for 72 hours. 60x magnification. Scale bar: 25μm. 
1BR3LT 1BR3
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killing with CAV Apoptin treatment decreasing slightly to approximately 80% killing 





















 Further apoptosis analysis was performed to confirm this data using FACS 
analysis, which is less subjective, to investigate the effects of CAV Apoptin and HGyV 
Apoptin in these cell lines. As shown in Figure 6.4, 1BR3 cells treated with both viral 
proteins did not show a discernible change in cellular viability. Meanwhile, in 1BR3LT 
both CAV Apoptin and HGyV Apoptin significantly reduced cell survival, with CAV 
Apoptin killing approximately 18% of cells and HGyV Apoptin approximately 25% of 
cells. The reason for the discrepancies in the data between Figure 6.3 and 6.4 is 
because the results recorded in Figure 6.3 are representative of only the GFP positive 
cells, in Figure 6.4 all cells are recorded irrespective of GFP expression. This suggests 





Figure 6.3 Quantification of cell death in fibroblast cells treated with 
Apoptin and Human Apoptin. Quantification of apoptotic cells by counting 
fragmented nuclei in 1BR3 and 1BR3LT cell lines transfected with Apoptin 
constructs. Error bars indicate standard deviation. Cells were grown for 72 hours. 

















































6.3 Discussion and Conclusions 
 
 The discovery of a new protein with sequence homology to Apoptin is very 
exciting, and to find such a protein derived from a virus that was identified in human 
tissue makes the discovery even more intriguing. The purpose of this study was to 
compare the properties of HGyV Apoptin and CAV Apoptin to determine tumour 
specificity and potential cytotoxic efficacy in human cells.  
 
 Using a combination of techniques, HGyV Apoptin and CAV Apoptin were 
compared for their molecular weight, cellular distribution, cytotoxic effect and 
transformed cell specificity. Western blot analysis comparing protein size between CAV 
and HGyV Apoptin found that the two proteins were comparable in size (Figure 6.1). 
Figure 6.4 FACS analysis of cell survival in fibroblast cell lines treated with 
Apoptin constructs. Error bars indicate standard deviation. Cells were grown for 
72 hours. n=3. Cell death shown here is from the total population of cells treated; 
this data does not take into account efficiency of adenoviral infection. For 
example, cells were not gated for Apoptin or GFP positive expression.             
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This result was expected as sequence analysis of HGyV Apoptin shows similarities to 
CAV Apoptin (Sauvage et al., 2011).  
 
 Further investigation in normal 1BR3 and transformed 1BR3LT cell lines 
showed that the cellular distribution of HGyV Apoptin was very similar to CAV Apoptin, 
and in particular, the tumour specific localisation of CAV Apoptin was also shown using 
HGyV Apoptin (Figure 6.2). This specific localisation also related to increased toxicity 
and transformed cells expressing either form of Apoptin in the nucleus were found to 
be more apoptotic (Figure 6.3), suggesting that HGyV Apoptin has similar function to 
CAV Apoptin that have been previously reported (Danen-Van Oorschot et al., 2003; 
Tavassoli et al., 2005). This result provides evidence that HGyV Apoptin behaves in a 
similar way in normal and transformed cells as CAV Apoptin in these types of cells.   
 
 FACS analysis (Figure 6.4) confirmed the previous results and shows that 
HGyV Apoptin induces tumour specific apoptosis and is less toxic to normal cells, as 
shown with CAV Apoptin (Tavassoli et al., 2005). 
 
 Taken together, these data show that Human gyroviral Apoptin has a similar 
tumour specific cellular distribution pattern to CAV Apoptin, and the similarities extend 
to apoptotic potential in tumour cells. Human gyrovirus has yet to be linked to human 
disease, as was the case with CAV in chickens, so further study would be required to 
understand any potentially damaging properties the virus may have.  
 
 As has been shown using CAV Apoptin, kinase interaction in HGyV Apoptin is 
another important area of investigation, similar apoptotic and localisation properties 
may convey similar phosphorylation characteristics. Using kinases of interest from CAV 
Apoptin studies (Jiang et al., 2010a; Maddika et al., 2005; Maddika et al., 2009) it 
would be important to investigate the same kinases with HGyV Apoptin, potentially 
revealing tumour specific kinases linked to the apoptotic ability of each protein.  
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Chapter 7 




The tumour specific characteristics of Apoptin have been shown to be linked to 
phosphorylation at a specific residue, T108. However, the specific kinase responsible 
for this phosphorylation in tumour cells is currently unknown. The aim of this study was 
to investigate potential kinases involved in Apoptin’s T108 phosphorylation and 
subsequent apoptosis induction in tumour cells. The data presented in this study 
describes a tentative link between PKCβ1 and PKG-I expression and Apoptin function. 
 
 The two kinases of interest, PKG-I and PKCβ1, are expressed at differing levels 
correlating with the transformed status of a cell. For example, a transformed cell line 
expresses higher relative levels of PKCβ1 and lower relative levels of PKG-I, an 
observation that is reversed in normal cell lines. This trend is interesting because it is a 
clear differentiator between normal and transformed cells, at least those cell line 
models used in this study. In addition, Apoptin behaves in drastically different ways 
depending on the transformed status of the expressing cell.  
  
 Taking these observations together, a hypothesis was formed describing a 
potential link between the expression pattern of PKG-I and PKCβ1 and the function of 
Apoptin. The following pages describe the evidence for and the criticisms against such 
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7.2 Relevance of the k inase siRNA library  
 
 Apoptin cytotoxicity has been shown to be linked to the phosphorylation status 
of the protein (Danen-Van Oorschot et al., 1997; Rohn et al., 2002), however, a kinase 
responsible has yet to be determined. The phosphorylation site of noted importance is 
threonine 108 (T108), requiring a serine/threonine kinase to phosphorylate its residue.   
 
The siRNA library generated results that suggest that the kinases targeted were 
not relevant to Apoptin induced cell death (Figure 3.8). The siRNA library used targeted 
the p38 MAPK signalling pathway family of kinases which has been implicated in a 
range of responses from apoptosis to cell cycle checkpointing, differentiation, survival 
and transformation (Whitmarsh and Davis, 1996). This pathway encompasses a wide 
range of functions within the cell, so knockdown of members of this pathway would 
have non-specific effects resulting in observations such as reduced viability, seen in 
Figure 3.8. Further investigation of an Apoptin specific kinase would therefore need to 
be more specific and controlled to allow identification of true targets. 
 
In conclusion, this particular section of the work succeeded in eliminating the 54 
serine/threonine kinases targeted by this library from future investigation of the Apoptin 
tumour specific kinase. 
 
7.3 PKC and PKG expression correlates w ith Apoptin sensit ivity 
 
 Data previously reported from this laboratory had shown that PKC isoforms 
were involved in the sensitivity of multiple myeloma (MM) cell lines to Apoptin and 
played a role in its function through phosphorylation (Jiang et al., 2010a). In particular, 
PKCβ1 phosphorylated Apoptin and, in return, was phosphorylated by Apoptin, 
resulting in Apoptin induced cell death in MM cells (Jiang et al., 2010a). This study also 
revealed that PKCβ1 expression was increased in Apoptin-sensitive, more malignant 
cells, suggesting that there could be a potential role for this kinase in Apoptin’s tumour 
specificity.  
 
 In contrast, studies have shown that PKG expression is increased in normal 
cells and appears to be lost once cells become transformed (Hou et al., 2006). In 
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addition, in silico kinase prediction found that PKG was a potential kinase that interacts 
with Apoptin (Figure 3.9). 
 
 Normal and tumour cells were investigated for the expression pattern of these 
two kinases supporting the above findings. Apoptin sensitive tumour and transformed 
cells express high relative levels of PKCβ1 and much lower relative levels of PKG-I. 
Normal cells were found to possess much higher relative levels of PKG-I and a 
reduction in PKCβ1 expression levels, supporting evidence that suggests that PKCβ1 
may have a tumour-specific role in Apoptin function. Initial results support the 
hypothesis that PKG-I expression could play an opposing role in Apoptin function, and 
may be involved in the protection of normal cells from Apoptin induced cytotoxicity.  
 
7.4 PKC and PKG expression has limited effects on Apoptin function 
 
 IP studies reveal that there is some physical interaction between PKG-I, PKCβ1 
and Apoptin; however these findings are not conclusive evidence for a functional effect 
of such an interaction. Additionally, the IP studies conducted here used exogenously 
expressed proteins and therefore were not completely indicative of the environment 
within the cell line models used. Although some physical interaction is evident, it would 
have been very interesting to have tested the functional effects of these interactions by 
investigating the phosphorylation status of Apoptin pulled down by PKG-I, PKCβ1 and 
the two kinases together. It can be concluded that there is a trend that shows that 
physical interaction may occur between Apoptin and the two kinases of interest; 
however, owing to the inconclusive nature of the data and the technical issues 
presented, no definitive statement can be made in support of the hypothesis. Further 
work would be required to confirm or deny the existence of functional effects on 
Apoptin by PKG-I and PKCβ1 physical interaction.  
 
The modification of kinase expression produced a variety of effects on Apoptin 
function in individual cell lines. For example, cells that were once resistant to Apoptin 
induced cytotoxicity (normal cells) became marginally more sensitive after 
overexpression of PKCβ1 or knockdown PKG-I expression. In the case of transformed 
cells, results were less convincing; knockdown of PKCβ1 was not successful enough to 
produce a significant change in kinase expression. Future work would require a more 
efficient method of silencing PKCβ1 expression, such as the method used in our 
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previous study in order to conclusively investigate the effect of PKCβ1 expression on 
Apoptin induced cytotoxicity (Jiang et al., 2010a). At the time of this study, however, 
this method was proving to be inconsistent. PKG-I overexpression was successful, but 
caused little effect in transformed cells aside from inducing some toxicity which has 
been observed in other studies (Fallahian et al., 2012; Fallahian et al., 2011). The data 
here suggests that for Apoptin cytotoxicity, the kinases PKG-I and PKCβ1 may be 
important in normal cells, however, based on cytotoxicity alone, this correlation is not 
observed in transformed cells. Additionally there was little correlation between kinase 
expression and phosphorylation of Apoptin in the cell lines tested, where a decrease in 
phosphorylation of Apoptin was most often accompanied by a decrease in total Apoptin 
expression, or vice versa, suggesting that kinase expression more likely affects the 
expression or stability of Apoptin. This could be further investigated by studying the 
stability and degradation of Apoptin by proteasomal inhibition experiments in 
combination with the kinase overexpression and knockdown techniques used here.  
 
Apoptin localisation experiments performed here show that PKG-I and PKCβ1 
kinase expression have some effect on the cellular distribution of the Apoptin protein. 
In normal cells the greatest effect on localisation is observed with a clear change from 
cytoplasmic to nuclear expression when PKCβ1 levels are higher and PKG-I levels are 
lower than basal. This set of observations does suggest that these kinases and their 
expression have some effect on Apoptin localisation; however, these experiments do 
not reveal the nature with which this distribution is affected. Further study using 
truncated and mutated variants of Apoptin would help to ascertain the mechanisms by 
which Apoptin localisation is affected. In transformed cells, the knockdown of PKCβ1, 
which has previously been shown to be ineffective, results in a reduced number of cells 
expressing Apoptin. These cells however still express Apoptin in the nucleus, 
suggesting that in this case the expression of Apoptin was reduced by kinase 
expression or siRNA treatment rather than there being any effects on Apoptin function 
and cellular distribution.                     
 
7.5 Human Apoptin, a promising tumour k illing protein 
 
 A new gyrovirus, recently discovered in human skin, was shown to produce a 
protein with sequence homology to Apoptin, referred to here as HGyV Apoptin 
(Sauvage et al., 2011). Using a combination of techniques it was shown that HGyV and 
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CAV Apoptin share tumour selective characteristics, in particular, cellular localisation 
and cytotoxicity. This set of data shows that HGyV Apoptin has a tumour specific 
cytotoxic potential comparable to CAV Apoptin, suggesting that with further 
investigation HGyV Apoptin could also be a potential targeted cancer therapy. It would 
also be very interesting to test the kinases studied here in the context of HGyV Apoptin. 
This kind of study could not only help to reveal the specific functional effects that 
PKCβ1 and PKG-I have on HGyV Apoptin, but could also provide further information 




To summarise, the data presented here, although inconclusive, does indicate 
that Apoptin function is affected by the expression of the protein kinases PKG-I and 
PKCβ1. Differential expression of these kinases has been shown to correlate with the 
transformed phenotype of the cell lines studied and it is widely accepted that Apoptin 
behaves differently in normal and transformed cell lines. The aim of this work was to 
determine whether kinase expression had any involvement in Apoptin function or 
whether differential kinase expression was just a consequence of the transformed 
phenotype and had no bearing on the mechanism of Apoptin cytotoxicity.  
 
Cytotoxicity assays found that there was a trend towards PKG-I expression and 
Apoptin resistance and PKCβ1 expression and Apoptin sensitivity, suggesting that cells 
with an expression pattern fitting the observations made here could have a predictable 
response to Apoptin treatment. For example, those cells with a higher relative PKG-I 
expression level and reduced PKCβ1 expression could be predicted to be resistant to 
Apoptin. As this study did not conclusively show that the kinase expression directly 
affected Apoptin function it can only be concluded that modification of PKG-I and 
PKCβ1 expression creates an environment within the cell that causes changes in 
Apoptin behaviour. The effects on the cell could be to induce a more or less 
transformed phenotype which would in turn change the function of Apoptin and give 
rise to the observations seen here. Interestingly, changes in the kinase expression in 
the cells studied induced a change in the response to cisplatin treatment. This is an 
indication that PKG-I and PKCβ1 kinase expression may affect sensitivity to apoptosis 
inducing agents rather than Apoptin specifically. Cisplatin is a tumour specific drug so 
this finding also supports phenotypic change (cells becoming more or less transformed) 
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as a consequence of kinase expression modification. Phosphorylation experiments 
were inconclusive and so a connection with kinase expression was not clearly shown. 
The effects of kinase expression appeared to be to inhibit or increase the expression of 
Apoptin. Localisation results also show that Apoptin expression and distribution is in 
some way affected by the expression of PKG-I and PKCβ1, however, this again could 
be explained by a change in the phenotype of the cells rather than specific interaction 
or direct effects of kinase expression on Apoptin function. Increased nuclear 
expression of Apoptin is associated with increased PKCβ1 and decreased PKG-I 
expression. However, as mentioned previously, these results do not clearly show that 
this is a direct consequence of the kinases themselves and their interaction with 
Apoptin or phenotypic changes induced by kinase expression which result in differing 
distributions of the Apoptin protein. 
 
The results presented in this study are useful because they highlight the 
different functions of Apoptin depending on the transformed nature of a cell. Apoptin is 
cytotoxic in many transformed cell types and relatively harmless in normal counterpart 
cells, and the mechanisms by which this specificity is determined are still largely 
unknown. Phosphorylation is thought to be a key step in specificity and this study 
shows that there is some evidence for phosphorylation determined by PKG-I and 
PKCβ1. Apoptin localisation is also important, and again, a link between the kinases 
studied and Apoptin localisation is shown.  
 
A trend towards Apoptin function and PKG-I and PKCβ1 expression could be 
implied from this research, and previous work has already shown a link between 
PKCβ1 and Apoptin function (Jiang et al., 2010a). Further, the evidence presented 
here for the regulation of PKCβ1 expression by PKG-I is intriguing, rather than a direct 
effect of PKG-I on Apoptin, this kinase could in fact reduce the expression of PKCβ1 
thus impairing the function of Apoptin.  
 
On reflection, although the work presented is not entirely conclusive, the 
evidence does suggest that there is a link between the expression of PKG-I and 
PKCβ1 and the function of Apoptin. Whether this link is a result of direct interaction, 
such as phosphorylation or physical modification, or even the changes in the cell 
associated with kinase expression, is not clear, however, this study highlights a novel 
approach to the investigation of Apoptin function and a new avenue for further study of 
this complex protein.             
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Additionally, the novel discovery of HGyV Apoptin, and the potential discoveries 
that could be made through further investigation of this viral protein in concert with CAV 
Apoptin, could prove very exciting for the field of targeted cancer therapies.        
 
7.7 Future Perspectives 
 
 Cancer is still a major killer in the Western world and many therapeutic 
strategies have been developed to target the specific biological differences inherent in 
cancers derived from different tissues. However, there is still hope for the management 
of this disease. Many properties of transformed cells are shared between different 
cancers, even if the specific causes are different. For example, the Hallmarks of 
cancer, described in Chapter 1, highlights common characteristics observed in all 
forms of cancer, from increased, uncontrolled proliferation to evasion of the body’s own 
methods of cell growth control. In addition, all cancer cells overexpress and 
underexpress certain proteins and kinases compared to their normal counterparts, and 
the results reported here suggest that Apoptin may exploit these differences in a variety 
of tumour cells, being specific to cancer rather than being specific to certain types of 
cancer.  
 
 In the future, the advantages of an agent, such as Apoptin, that could be used 
to treat a variety of tumour types, would be a major aid in the management of cancer, 
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